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It has long been axiomatic that a protein’s structure determines
its function. Intrinsically disordered proteins (IDPs) and
disordered protein regions (IDRs) defy this structure−function
paradigm. They do not exhibit stable secondary and/or tertiary
structures and exist as dynamic ensembles of interconverting
conformers with preferred, nonrandom orientations.1−4 The
concept of IDPs and IDRs as functional biological units was
initially met with skepticism. For a long time, disorder,
intuitively implying chaos, had no place in our perception of
orchestrated molecular events controlling cell biology.
Over the past years, however, this notion has changed. Aided
by findings that structural disorder constitutes an ubiquitous
and abundant biological phenomenon in organisms of all
phyla,5−7 and that it is often synonymous with function,8−11
disorder has become an integral part of modern protein
biochemistry. Disorder thrives in eukaryotic signaling path-
ways12 and functions as a prominent player in many regulatory
processes.13−15 Disordered proteins and protein regions
determine the underlying causes of many neurodegenerative
disorders and constitute the main components of amyloid
fibrils.16 They further contribute to many forms of cancer,
diabetes and to cardiovascular and metabolic diseases.17,18
Research into disordered proteins produced significant
findings and established important new concepts. On the
structural side, novel experimental and computational ap-
proaches identified and described disordered protein ensem-
bles3,19,20 and led to terms such as secondary structure
propensities, residual structural features, and transient long-
range contacts.1,21 The discovery of coupled folding-and-
binding reactions defined the paradigm of disorder-to-order
transitions22 and high-resolution insights into the architectures
of amyloid fibrils were obtained.23,24 On the biological side, we
learned about the unexpected intracellular stability of
disordered proteins, their roles in integrating post-translational
protein modifications in cell signaling and about their functions
in regulatory processes ranging from transcription to cell fate
decisions.15,25,26 One open question remaining to be addressed
is how these in vitro structural insights relate to biological in
vivo effects. How do complex intracellular environments
modulate the in vivo properties of disordered proteins and
what are the implications for their biological functions (Figure
1)?27−29
Here, we attempt to answer these questions by reviewing the
physical and biological properties of intracellular environments
in relation to structural and functional parameters of disordered
proteins. Specifically, we discuss how IDPs may experience in
vivo environments differently to ordered proteins. To this end,
we provide a description of the compositional and physical
parameters of the cellular milieu and their effects on ordered
and disordered proteins (section 2). We evaluate how
biological processes may act differently on ordered and
disordered proteins (section 3) and discuss how combined
physical and biological contributions modulate the intracellular
aggregation behavior of IDPs (section 4). Finally, we review
theoretical and experimental approaches to study the structural
and functional properties of disordered proteins in cells
(section 5).
2. PHYSICOCHEMICAL PROPERTIES OF THE
INTRACELLULAR ENVIRONMENT
To understand how proteins function inside cells, one needs to
consider the particular physical properties of the intracellular
environment and how they shape the cellular behaviors of
ordered and intrinsically disordered proteins. In the following
paragraphs, we discuss the composition of the prokaryotic and
Figure 1. Intracellular complexity. (A) Left: Cryo-electron tomog-
raphy slice of a mammalian cell. Middle: Close-up view of cellular
structures colored according to their identities: Right: Three-
dimensional surface representation of the same region. Yellow,
endoplasmic reticulum; orange, free ribosomes; green, mitochondria;
blue, dense core vesicles; red, clathrin-positive compartments and
vesicles; purple, clathrin-negative compartments and vesicles. Re-
printed with permission from ref 27. Copyright 2012 Public Library of
Science. (B) Tomography image of the interior of a Dictyostelium cell
with actin filaments shown in orange and ribosomes in blue. Reprinted
with permission from ref 29. Copyright 2012 Rockefeller University
Press. (C) Schematic representation of the E. coli cytosol. Ribosomes
and tRNA are shown in pink, chaperones in green and red, disordered
proteins in orange, and all other proteins in dark blue. Reprinted with
permission from ref 28. Copyrigth 2011 Elsevier.
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eukaryotic cytoplasm in terms of average ion and metabolite
concentrations, dielectric properties, macromolecular crowding
and how these parameters affect intracellular viscosity,
rotational and translational diffusion, and macromolecular
association events.
2.1. Composition of the Cytoplasm
We begin by reviewing cytosolic ion and metabolite
compositions and concentrations, and delineate their effects
on cellular dielectric constants, pH and viscosity. We do so by
making use of the CyberCell database from David Wishart’s
laboratory30 (http://ccdb.wishartlab.com/CCDB/) and of
BioNumbers, and references therein, from the Systems Biology
Department at Harvard Medical School (www.bionumbers.
hms.harvard.edu).
2.1.1. Inorganic Ions. The total concentration of
cytoplasmic inorganic ions in E. coli is ∼300 mM according
to the CyberCell database. The concentration of K+, by far the
most abundant inorganic ion, varies drastically with osmotic
conditions.31 200 mM is reported to be physiologically
relevant32 and CyberCell notes a concentration range of
200−250 mM. (For the remainder of this paragraph,
concentrations reported by CyberCell, where available, are
given in brackets when following concentrations provided by
other sources). In separate studies of E. coli grown in
McIlvaine’s medium,33 glucose,34 or LB,35 for example, the
concentrations of K+ were determined to be ∼250 (free),
∼180−200, and ∼100 mM, respectively. Similarly, large
variations in the total concentration of Mg2+ have been
reported, with estimates ranging from 2035 to 100 mM,36
although the amount of free Mg2+ is estimated to be much
smaller in comparison at 1−2 mM.37,38 Estimates for other
common inorganic ions include Na+ at ∼5 mM,34 Ca2+ at ∼0.1




3−) at 6 and 5 mM,30
respectively. Although variations between tissues exist, average
concentrations of inorganic ions in E. coli, yeast and mammalian
cells are in the same range.30,34,35,38−41 For example, differences
have been reported for some specialized tissues/organs such as
resting frog muscle with 141 mM for K+, 9.0 mM for Na+, 2.2
mM for Cl−, and 1.4 mM for total inorganic phosphate, while
the concentrations of free Ca2+ and Mg2+ were reported as 52
nM and 0.8 mM, respectively.42
Bacteria can store metal ions at concentrations much higher
than those in the growth medium. The concentrations of
several transition metals have indeed been measured, with Fe
and Zn at 0.1 mM35,43 [18 and 4 mM, respectively],30 and Cu,
Mn, Mo, and Se at ∼10 μM35,43 [4 mM for Cu, Mn, and
Mo].30 In eukaryotic cells, intracellular concentrations of metal
ions are more difficult to determine accurately, because large
variations between different organelles exist (Figure 2A).44 In
HeLa cells for example, the concentration of free Zn2+ in
mitochondria is in the pM range but nM in the cytoplasm.45 In
addition, many proteins bind metals, and their abundance and
localization leads to dynamic changes in metal content.46−48
Specialization and metabolic activities further modulate intra-
cellular metal concentrations. The total iron load in red blood
cells is ∼20 mM for example, while it is 1 mM in
neurons.47,49,50 Despite these differences, global intracellular
concentrations of free metals are similar in prokaryotic and
eukaryotic cells.51 Concentrations of free Fe2+/Fe3+, Zn2+ and
Cu+/Cu2+ are usually low because of their poor solubility at
neutral pH and strong affinities toward intracellular metal-
binding proteins.
Changes in intracellular ion levels can have pronounced
effects on the conformational properties of disordered proteins
as seen in the enhanced aggregation of α-synuclein at high salt
concentrations.52 Because charged amino acids are selectively
enriched in IDPs53 and play important roles in compaction,54,55
their capacities to mediate, as well as to shield electrostatic
interactions depend on their charge states and counterion
coordination.56 In addition, many metal-binding proteins
contain extended disordered regions (∼30−50 residues),57
and metal binding can affect their mean net charge to a degree
that they become ordered. Zn2+ coordination by the disordered
N-terminal domain of HIV-1 integrase, for example, results in
α-helix formation.58 For several other IDPs such effects are
more subtle. Zn2+ binding to ProThymosin α (ProTα)
increases transient helicity from <1% to 12%59,60 and induces
partial folding of its C-terminal Glu-rich region.60 Metal
binding can also promote oligomerization. In the case of
HIV-1 integrase, the Zn2+-bound protein tetramerizes readily.58
Deletion of the disordered C-terminal 27 residues of the
scavenger protein cardiac calsequestrin results in the loss of
Ca2+-dependent tetramerization.61 Growing evidence suggests
that changes in metal homeostasis and altered IDP-metal
interactions contribute to the pathogeneses of several neuro-
degenerative disorders.62−64 Indeed, many amyloidogenic IDPs
Figure 2. Intracellular composition. (A) Localization of various
elements in a mammalian PC12 cell (exposed to MnCl2). Reprinted
with permission from ref 44. Copyright 2009 Royal Society Publishing.
(B) Average pH values of organelles and compartments in mammalian
cells. Adapted with permission from ref 92. Copyright 2010 Nature
Publishing Group.
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such as α-synuclein, tau or amyloid beta (Aβ) peptides directly
bind metals, and metal interactions modulate their in vitro
aggregation behaviors (see section 4).
2.1.2. Metabolites. Recent advances in metabolomics
technologies have allowed the concentrations of large numbers
of metabolites to be measured in E. coli.65 In glucose-fed,
exponentially growing E. coli cells the combined concentrations
of metabolites have been estimated to be ∼300 mM, with
glutamate (Glu−) being the most abundant metabolite by far
(96 mM), followed by glutathione, fructose-1,6-bisphophate
and adenosine triphosphate (ATP) at 17 mM, 15 mM and 9.6
mM, respectively.65 However, these concentrations depend on
the culture medium. By changing the carbon source from
glucose to glycerol or acetate, intracellular Glu− levels change
from 96 to 149 to 45 mM, respectively. Similarly, intracellular
glutathione concentrations change from 17 to 18 to 8 mM;
Fructose-1,6-bisphophate from 15 to 6 to <0.15 mM; ATP
from 9.6 to 9.0 to 4.1 mM.65 Significant variations in
intracellular Glu− levels due to changes in glucose levels in
the growth media or due to changes in osmotic conditions have
also been seen in other studies.33,66 When E. coli cells were
grown in McIlvaine’s medium at pH 6 and harvested at
midexponential phase, the total concentration of all amino acids
was determined to be ∼90 mM, of which Glu− comprises ∼60
mM.33 In the presence of 200 mM glucose, Glu− concentration
increase to ∼117 mM. At 400 mM glucose, it is ∼160 mM. By
contrast, CyberCell lists the combined E. coli concentrations of
all “small organic molecules” as 40−50 mM (undefined growth-
medium and -stage), concentrations of free amino acids total
∼15 mM, and ATP is indicated between 1.3 and 7.0 mM,
depending on growth conditions and sugar sources.30
In eukaryotes, metabolite concentrations are subject both to
variations between subcellular organelles, and to variations
between cell and tissue types. In the yeast S. cerevisiae, total
cellular concentrations of glutamate, glutathione, and ATP are
∼75, ∼15, and ∼2.5 mM, respectively.39,67,68 In human cells,
according to the human metabolome database, HCO3
− is the
most abundant metabolite at ∼11 mM, followed by 2,3-
diphosphoglyceric acid at 4.0−5.0 mM, glutathione at ∼2−5
mM, L-malic acid at ∼3−4 mM, ATP at ∼1−2 mM, and Glu−
at ∼1−2 mM.69 Again, these concentrations are subject to cell-
and tissue-type variations. One example is frog muscle, where
phosphocreatine is the most abundant metabolite (∼50 mM),
followed by carnosine, total free amino acids, creatine and total
ATP at respective concentrations of 19.5 mM, 11.7 mM, 11.0
mM, and 6.2 mM.42
Not measured in the above studies are the important
polyamine metabolites putrescine, spermidine, and spermine.70
These polycations, found in all eukaryotes and most
prokaryotes, and have roles in cell growth and proliferation.71,72
Decreased levels are associated with aging and increased levels
are associated with cancer.72 Putrescine and spermidine are
generally found at high concentrations in Gram-negative
bacteria such as E. coli, where spermine is absent. Studies in
E. coli reported concentrations of ∼20−30 mM for putrescine
and ∼6−7 mM for spermidine.73 Levels of putrescine and
spermidine in mammalian cells are significantly lower.
Spermidine was measured in bovine lymphocytes and rat
liver cells at ∼1 mM.74 For spermine, the concentrations are ∼2
and ∼1 mM, respectively. Relative to these two, putrescine is
present at ∼5-fold lower levels in rat liver and human
promyelocytic leukemia HL-60 cells.70,71
Polyamines have been found to accelerate the in vitro
aggregation and fibrillation of α-synuclein, an IDP implicated in
Parkinson’s disease (PD), in vitro.75 The extent of these effects
increases with polyamine charge, length and concentration,
suggesting that they can also occur in vivo.75 Other metabolites
such as glycerol, trehalose and zwitterions such as trimethyl-
amine-N-oxide, proline, betaine, and ectoine, stabilize proteins
at intracellular concentrations between 100 and 300 mM.76
These compounds may represent a special class of metabolites,
because they also function as powerful stabilizing agents in
vitro. Nevertheless, these data indicate that metabolite
concentrations in the range of ∼300 mM are sufficient to
alter the properties of individual proteins. While it is unlikely
that metabolites generally induce folding of disordered proteins
in cellular environments, they may modify the structural
features of some of them.
2.1.3. Dielectric Properties. Ions and charged metabolites
contribute to the dielectric properties of the intracellular
environment. The static dielectric constant of pure water is 78.4
at 25 °C,77 but dissolved ions can decrease this value
substantially due to the tendency of water molecules to align
with local electric fields caused by nearby ions.78 This effect is
concentration-dependent, but linear in the dilute regime, i.e., at
ion concentrations below ∼2 M. Based on measurements by
Hasted et al., we estimate that in physiological solutions the
dielectric constant of water would be reduced by only ∼2 units
(i.e., to ∼76) primarily because of K+; given the complexity of
the intracellular environment it is questionable whether this
estimate is accurate. In addition to affecting the dielectric
behavior of the water component of a solution, charged ions
and metabolites also contribute to a solution’s conductivity. On
the other hand, many metabolites, such as free amino acids,
carry neutral net charges and, therefore, do not contribute to
conductivity but the overall dieletric properties of the
environment.79−81 Free amino acids increase the dielectric
constant by molar increments of 20−30 M−1. For example, at
its physiological concentration of 0.8 mM in E. coli (CCDB),
alanine is expected to increase the dielectric constant of the
cytosol by a very modest ∼0.02 units.
The dielectric properties of many cell types have been
investigated, including E. coli,82−84 murine lymphocytes and
erythrocytes,85 murine erythroleukemia cells,86 and human
breast- and colon-cancer cells,87,88 as well as red blood cells.87 It
is difficult to draw firm conclusions from these studies because
the reported values for the dielectric constants of the cytoplasm
range from ∼50−150, while those of membranes range from
∼2−15.88 For eukaryotic systems, a further complication is the
possibility of significant variations between organelles. Wang et
al. have recently reported the use of a surface plasmon
resonance (SPR)-based electrochemical impedance microscope
(EIM) that enables intracellular resistance levels to be
measured at submicrometer resolution;89 in combination with
sophisticated mathematical modeling, these measurements
could be used to calculate intraorganelle, approximative
conductivities and dielectric constants. The authors obtained
indicative values for intracellular dielectric constants in the
range of ∼30 and ∼60.89 Dielectric constants of 15 and 60 were
recently determined for the cytoplasm and cell nucleus of
mammalian CHO cells, respectively.90
Variations in permittivity modify the strength of charge−
charge interactions. Hence, intracellular dielectric constants can
impact the conformational properties of disordered proteins,
whose shapes are modulated by intramolecular charge−charge
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interactions.53−55 Intracellular electric susceptibility depends on
ion and metabolite concentrations, and it is difficult to separate
the effects of these two parameters. Having shown that different
subcellular compartments exhibit different dielectric properties,
it is moreover possible that ion and metabolite effects scale
differently in different intracellular microenvironments (see
section 2.4). In turn, this complexity may lead to spatially
modulated effects on IDP structure and function.
2.1.4. pH. As a rule of thumb, the pH of the cytoplasm is
7.2,91 and it is critical to maintain this value for any given
organism.92 Phosphate or bicarbonate ions and other weak
acids and bases within the cell provide the intracellular
buffering capacity, to which the side-chains and free amino-
and carboxy-termini of amino acids and proteins contribute less
than 1%.93,94 Indeed, only histidine (pKa ∼6.04) and other
imidazoles affect buffering near neutral pH.94 The pKa’s of
other amino acids are either too far from neutral92 or, as in the
case of cysteine (pKa 8.3) have chemistries that are too complex
to contribute to buffering.94
At optimal growth conditions, E. coli maintains an intra-
cellular pH of 7.4−7.8, provided that the pH of the external
environment is between 5.5 and 9.0.95−98 Using fluorescence
imaging, approximate pH values of HeLa cytoplasm,
mitochondria, endoplasmic reticulum, and Golgi were
determined to be 7.4, 8.0, 7.5, and 6.6, respectively.99 In a
recent review, the pH values of various eukaryotic compart-
ments and organelles were reported to be 7.2 for the cytosol,
7.2 for the nucleus (due to permeability), 7.2 for the
endoplasmic reticulum, 6.7 for cis-Golgi cisterns and 6.0 at
trans-Golgi networks, 8.0 in mitochondria, 7.0 in peroxisomes,
5.5 in secretory granules, 6.3 in early endosomes, 6.5 in
recycling endosomes, 5.5 in late endosomes, and 4.7 in
lysosomes (Figure 2B).92
How do changes in intracellular pH affect disordered
proteins? Ordered proteins are sensitive to pH, and unfolding
is common at pH values <3.100 By contrast, disordered proteins
withstand “denaturing” pH titrations, as judged by circular
dichroism (CD), fluorescence- and NMR-spectroscopy, and
resistance to pH changes serves as a common indicator for
native “unfoldedness”.101 Some IDPs adopt more ordered
structures in response to “drastic” pH changes. Examples
include the gain of α-helical content in histones at pH 10,102
increased helicity of the calpastatin domain I at pH levels below
4,103 and an increase in transient helicity of ProTα at pH 2
(from <1% to 10.7%).104 Below pH 5.5, α-synuclein displays
higher levels of compaction105 brought about by the
neutralization of its acidic C-terminal residues and the
concomitant abolishment of intramolecular contacts with
positively charged amino acids at its N-terminus.106,107 Low
pH also favors α-synuclein aggregation.105 However, given that
most of these pH conditions are not compatible with
physiological environments, it is questionable whether these
results are biologically meaningful.
2.2. Viscosity
Intracellular viscosity is a bulk phenomenon that is manifested
at multiple scales. Because large pools of molecules, macro-
molecules, and macromolecular assemblies are present in the
cytoplasm, ranging from water to metabolites, from soluble
monomeric proteins to the cytoskeleton, from isolated lipids
and fatty acids to membranes and organelles, objects of
different sizes, shapes and chemistries contribute to what we
perceive as effective intracellular viscosity. Each of these
components evokes different dissipative forces that oppose
motions and affect different molecules to different degrees.
Here, we limit our discussion to “solvent viscosity”, i.e., to local
viscosity effects that act on the subnanometer scale.
Concerning water motions on the pico- (ps) to nano- (ns)
second time scale, corresponding to the subnanometer (nm)
length scale, ∼85% of all intracellular water displays transla-
tional (macroscopic) and rotational (microscopic) dynamics
that are indistinguishable from pure water, both in prokaryotic
and eukaryotic cells.108,109 This amount of bulk water is not
coordinated in the first hydration shell of cellular macro-
molecules and only marginally affects the rotational dynamic
properties of small fluorescent dyes.110 Moreover, ∼90% of the
water molecules in the hydration layer of proteins, and other
macromolecules, display an average 2-fold reduction in dynamic
properties compared to bulk water,108,109 although 10-fold
reductions may occur at macromolecule-to-solvent ratios above
30−50% (v/v), according to in vitro measurements.111
Therefore, and despite the astonishingly large intracellular
concentrations of small solutes (see above), these molecules
contribute little to intracellular viscosity. This observation is
consistent with the measured effects of ions and metabolites,
such as amino acids on water viscosity in vitro. With the
exception of K+, other ions and amino acids generally increase
viscosity by 5−15% at concentrations typical of intracellular
conditions.112,113 As we outline next, macroscopic intracellular
viscosity is primarily governed by the pool of much larger
macromolecules, which collectively give rise to yet another
important phenomenon in cellular biophysics: macromolecular
crowding.
2.3. Macromolecular Crowding
A general property of the intracellular space is its high net
content of large biological macromolecules. The typical E. coli
cell contains ∼25% protein by volume, of which ∼10% are
cytoskeletal filaments and ∼90% are soluble globular proteins,
along with substantial amounts of RNA, DNA, and biopolymers
such as lipids and glycans. In the E. coli cytoplasm, this
corresponds to 200−320 g/L of protein (∼4 mM), 75−120 g/
L of RNA, and 11−18 g/L of DNA.66,114 In mammalian cells,
protein concentrations ranging from 50 to 250 g/L and nucleic
acid concentrations of 20−50 g/L have been determined, which
vary with cell types.115−117 Thus, macromolecules occupy 10−
40% of any cell volume and make this space unavailable to
other macromolecules. The resulting macromolecular crowding
effect has several consequences.
It was realized early on that steric repulsion between
individual molecules in highly volume-occupied solutions such
as the cytoplasm decreases the volume available to other
molecules. The resulting “excluded volume effect” stipulates
that the effective concentration of a test solute is determined by
the number of molecules of that solute per unit of available
volume, rather than the total volume (Figure 3A). Therefore,
the thermodynamic activity of a given solute in a crowded
environment does not depend on its nominal concentration but
on its effective concentration, which depends on the available
volume.118,119 The thermodynamic activity of the test species
might thus exceed its nominal concentration by several orders
of magnitude, especially in cases of severe crowding. The term
macromolecular crowding was coined in 1981 to connote the
influence of mutual volume exclusion on the thermodynamic,
kinetic and structural properties of macromolecules in crowded
media.120 While the original use of term denoted effects of inert
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repulsive forces, it has since been updated to also include weak
attractive interactions.121 In the first part of our discussion, we
describe “classical” macromolecular crowding effects that result
from steric repulsion and volume exclusion. In the second part,
we outline additional attractive effects that contribute to
crowding in cells.
2.3.1. Macromolecular Crowding and Steric Repul-
sion. In a simplified model of macromolecular crowding,
intracellular background molecules are considered inert hard-
spheres that exert steric repulsions on other molecules and
thereby increase the total free energy of the system. In turn, the
system shifts equilibria toward states that maximize the
available volume. One predicted outcome is that macro-
molecular crowding promotes protein compaction (Figure 3B),
which may stabilize globular proteins (Figure 3C), or promote
protein−protein associations (Figure 3D), which may, in turn,
lead to conformational collapse and aggregation (see section
4).122−124 Mimicking crowding with high-pressure experiments
for example, showed that poly alanine helices are more compact
under such conditions.125 Macromolecular crowding can also
increase protein hydration.126 Surface hydration generally
favors protein folding by promoting the formation of
hydrophobic cores, but also because water is a poor solvent
for the polypeptide backbone.56,127 However, at high
concentrations of macromolecules (>100 g/L), weak inter-
actions between the crowding molecules induce cluster
formation128 and crowder-solute interactions, which can
destabilize globular proteins.124,129,130 Accordingly, in vivo
studies of protein folding reported weak modulatory effects.
Macromolecular crowding within the E. coli cytoplasm was
found to not be sufficient to fold the slightly (1 kcal/mol)
destabilized B1 domain of streptococcal protein L.131 In
mammalian cells, the melting temperature of folded phospho-
glycerate kinase (PGK) increases by ∼3 K compared to isolated
in vitro conditions,132 whereas that of the surface antigen VlsE
decreases by ∼4 K.133 These effects are cell type-specific and
vary in different organelles,134,135 and at different stages of the
cell cycle,136 which is largely due to modulations of intracellular
crowding, and changes of specific and unspecfic interactions
(see section 2.3.4).
How does intracellular macromolecular crowding affect the
conformational properties of disordered proteins? IDPs are
more flexible and less compact than ordered proteins;137,138
therefore, they may experience exacerbated crowding effects
and respond with even greater degrees of compactions. Indeed,
IDP compaction was reported for the disordered carboxyami-
dated ribonuclease T1 (TCAM) in the presence of 400 g/L of
dextran139 and for the C-terminal domain of histone H1 in the
presence of PEG and Ficoll.140 Similarly, the disordered FlgM
protein displays structural alterations toward more folded
conformations in intact E. coli cells and in glucose, BSA and
ovalbumin-crowded solutions (see section 5.2). Urea denatu-
rated CRABP, which normally folds into a β-rich structure, was
also found to be more compact in the presence of Ficoll.141
Higher concentrations and larger sizes of PEG molecules lead
to greater intramolecular FRET efficiencies, and enhanced
compaction of N- and C-terminal fragments of human
prothymosin-α, the binding domain of the activator for thyroid
hormones and retinoid receptors (ACTR) and the N-terminal
domain of HIV-1 integrase.142 By contrast, other disordered
proteins, including the c-Fos transactivation domain, the p27
(Kip1, Cdkn1b) kinase-inhibition domain, the acidic extrac-
ellular α-casein, the basic cytoplasmic protein MAP2c, the
nuclear kinase inhibitor p21 (Cdkn1a), the highly acidic protein
ProTα, the basic protein TC-1, the repeat-in-toxin (RTX)
motif (which folds upon binding to Ca2+), as well as the
bacteriophage λ N protein failed to show compaction under
similarly crowded in vitro conditions.143−147 In-cell IDP
compaction or folding was not reported for α-synuclein or
human tau.148−151 Together, these results show that cellular
and in vitro crowding contributions on protein compaction do
not follow the uniform trend predicted by “classical” theory and
that intracellular “soft” interactions, often of unspecific nature,
may indeed determine the net effects observed in intact cells
(Figure 4B).136,147
2.3.2. Macromolecular Crowding and Viscosity. At
identical (w/v) concentrations, macromolecular crowders cause
greater macroscopic viscosity than small solutes. For example,
PEG solutions are more viscous than ethylene glycol solutions.
At a given concentration of PEG, viscosity further increases
with increasing chain length.152,153 Similar observations were
Figure 3. Excluded volume effects. (A) Schematic representation of
excluded volume effects for disordered and folded proteins. (B) Left:
IDP free energy as a function of compaction in noncrowded (black
line) and crowded environments (blue line). Right: Representation of
stabilizing or destabilizing effects via soft interactions (green lines).
(C) Free energy of ubiquitin denaturation as a function of temperature
in buffer pH 5.4 (black), 100 g/L Ficoll (blue), 100 g/L BSA (green),
and 100 g/L lysozyme (pink). Solid lines are fits based on
experimental measurements, dashed lines are extrapolations for
different temperatures. Adapted with permission from ref 124.
Copyright 2012 American Chemical Society. (D) Dimerization
equilibrium constants for different dimer shapes (constant volumes)
as a function of volume fraction ϕ of hard-sphere crowders. Adapted
with permission from ref 123. Copyright 2008 Annual Reviews.
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made for dextran154 and other crowding agents.155−158 To
explore these viscosity anomalies, Lu et al. employed a
theoretical capture-flow model, in which macromolecules
exhibit size-dependent characteristics, i.e., capture capacities
and weak interactions with other molecules that they drag
along. These particles exert draining forces on noncaptured
molecules, which result in passive flows. The combination of
these effects determines the overall macroscopic viscosity.159
This description provides a valuable dynamic and scale-
dependent view: Shape, size, and surface properties of crowders
and solute molecules mutually influence each other by exerting
dragging and draining forces.
As we discussed above, and consistent with the model by Lu
et al., neither metabolites nor macromolecules alter the
viscosity of bulk intracellular water on the nm scale.108,109 At
this level, macromolecular crowding only influences water
molecules in the first hydration layer. Because these properties
are similarly displayed in pure protein-buffer solutions,
additional contributions may affect the viscosity of intracellular
water at larger time- and length-scales. Indeed, when intra-
cellular water dynamics are measured by magnetic resonance
imaging (MRI), i.e., in the ∼10−100 ms range or at 1−10 μm,
water diffusion coefficients in intra- and extra-cellular brain
sections are found to be reduced by factors of 2 to 10, which
could reflect different spatial or compositional cell organizations
or time-averages of movements of water molecules in and out
of hydration layers.160 In general, however, these results
indicate that intracellular solvent viscosity displays the same
features as viscosity in aqueous protein solutions at the nm
scale: unperturbed properties of bulk water, with increased
solvent viscosity and reduced dynamics of hydration shell
water.
Moving to larger objects, such as proteins, it is beneficial to
also discuss viscosity effects with respect to different time- and
length-scales. At the ns time scale, i.e., in the Å range, crowding
induces local nanoviscosity via hydrodynamic interactions, not
hard-sphere repulsions. Movements of solute molecules induce
water flows, which, in turn, reduce the self-diffusion of other
solute molecules (Figure 4A).161 In crowded environments, a
transition from nano- to microviscosity is observed. Below the
nm scale, normal diffusion is guided by Brownian motion and
results in particle mean square displacements that increase
linearly with time, while diffusion coefficients decrease with
hydrodynamic forces. Above the nm scale, overall increases in
apparent microviscosity are felt by solute particles. At this
point, intermolecular hard-sphere repulsions between crowders
and solute particles impair diffusion. The extent to which
microviscosity is experienced by a particle depends on its
radius, and the crowding agents’ dimensions and concen-
trations.157,162−169 Holyst et al. rationalized this effect in an
advanced manner: (i) When a particle is much larger than the
crowding agent, it experiences microviscosity, which increases
exponentially with the concentration of the crowding agent. (ii)
When a particle is much smaller than the crowding agent it
experiences nanoviscosity, which corresponds to the viscosity of
bulk water. (iii) Between these extremes, viscosity increases for
particles that are larger than the average distance between the
individual crowding molecules. This correlation length scales
inversely with the concentration of the crowding agent. Using
this formalism, the authors fitted data from previous studies of
intracellular tracer molecules of different sizes and types
(protein, DNA, dextran) and deduced average correlation
lengths of ∼0.5 and ∼5 nm for prokaryotic and eukaryotic cells,
respectively (Figure 4B).157,170
The hydrodynamic radii of most disordered proteins are in
the range of these correlation lengths. 140 residue α-synuclein
has a radius of ∼4 nm,171 whereas tau (441 residues) has a
radius of ∼6 nm.172 According to the correlation length model,
and provided that intracellular crowding does not significantly
change the hydrodynamic radii of these IDPs, both proteins
experience an intracellular microviscosity inside E. coli and
mammalian cells that is 8- and 3-times greater than in buffer,
respectively. Because both radii are representative for many
disordered proteins, these approximate values are likely to be
generally valid.173,174 Accordingly, IDPs succumb to an effective
intracellular nanoviscosity that is ∼2-fold greater than in dilute
solution, whereas microviscosity is ∼5-fold greater, on average.
Holyst et al. conceptualized these differences in apparent
viscosities by modeling proteins as spheres that move through a
solution of polymers. These spheres create a solvent layer
depleted in polymers due to macromolecular repulsion or low
polymer entropy at the protein−solvent interface. The protein
moves within the depletion layer according to its nanoviscosity,
whereas the solvent layer diffuses independently and according
to the microviscosity of the system (Figure 4C).168,175 This
model conceptualizes many of the measured intracellular
viscosity effects and also accounts for differences in diffusion
Figure 4. Macromolecular crowding and viscosity. (A) Schematic
representation of water flows (black arrows) in response to protein
movements (blue spheres and arrows). Forces resulting from water−
protein friction are shown as red arrows. Translational diffusion is
slowed down by hydrodynamic interactions with water flows caused by
protein movements. (B) Different viscosity regimes experienced by
probes of radii (rp) in the cytosol of E. coli and HeLa cells (red curves).
Average size range of proteins is indicated in blue. Adapted with
permission from references 157 and 170. Copyright 2011 American
Chemical Society and Copyright 2012 Oxford University Press,
respectively (C) Protein motions in crowded environments. Proteins
experience Brownian motion in the depletion layer of apparent
nanoviscosity (ηnano) (blue). The depletion layer moves according to
the microviscosity (ηmicro) (gray) of its surrounding. (D) Particle mean
square displacements (MSD) in different diffusion regimes as a
function of time. Anomalous subdiffusion occurs at the transition
between fast nano- (Dnano) and slow microdiffusion (Dmicro). Adapted
with permission from ref 169. Copyright 2013 IOP Publishing.
Chemical Reviews Review
dx.doi.org/10.1021/cr400695p | Chem. Rev. 2014, 114, 6661−67146667
behaviors in cells (although intracellular viscosity and diffusion
are strongly related, we treat cellular diffusion processes
separately in the next paragraph). This model also offers a
compelling explanation for why rotational diffusion, governed
by nanoviscosity, is less affected than translational diffusion,
which is primarily influenced by microviscosity (see
below).155,176
2.3.3. Macromolecular Crowding and Diffusion.
Macromolecular crowding-induced nano- and microviscosity
affect intracellular protein diffusion. In general, we distinguish
between two main types of diffusion: Rotational diffusion, as a
property that is felt at the subnano- to nanometer scale and that
denotes the localized reorientations of solute molecules
according to their internal mobilities. Translational diffusion,
on the other hand, is felt at length scales above 10 nm and
describes movements of solutes from one point in space to
another.
2.3.3.1. Rotational Diffusion. In E. coli, rotational diffusion
was found to be 2−3 times slower than in pure water.177 For
eukaryotic intracellular compartments, the measured rotational
correlation times in the cytoplasm are 10−20% larger than in
dilute solution, 10−30% larger in mitochondria and 100%
larger in the endoplasmic reticulum.178−180 These values
directly reflect the local cellular viscosity on the subnano to
nanometer scale, which influences the rotational correlation
times of proteins, but also their internal motions. In the case of
disordered proteins, backbone motions are difficult to dissect
from rotational diffusion properties, because both occur on the
same ns time scale. It is therefore advantageous to describe the
dynamic properties of IDPs in a residue-resolved manner. In
the absence of protein−protein interactions or global
conformational rearrangements, IDPs display residue-specific
correlation times that are directly proportional to the
nanoviscosity of their environment, i.e., their internal dynamics
scale inversely with nanoviscosity.181 Hence, disordered
proteins may exhibit intracellular correlation times that
correspond to low nanoviscosity environments (∼2-fold greater
than in buffer), whereas their translational diffusion properties
may be slowed 5-fold or more (see section 2.3.3.2). However,
these numbers need to be considered with caution as they
reflect ideal dynamic behaviors in the absence of intracellular,
intermolecular interactions and proteins tend to constantly
engage in short-lived, weak interactions with other intracellular
biomolecules.121 As we discuss in section 2.3.4, Li et al. showed
that, in E. coli, these interactions slowed the rotational diffusion
properties of the small folded protein G B1 domain (GB1) and
ubiquitin (Ub) by as much as viscosity increases of 5 and 22 cP,
respectively.177 Given the average solvent viscosity of the E. coli
cytoplasm (∼3 cP), this is in good agreement with the 8-fold
increase in the rotational correlation time of GB1 that Wang et
al. measured by in-cell NMR spectroscopy.182
Do transient intracellular interactions affect ordered and
disordered proteins differently? In folded proteins, weak
interactions often target localized structural entities such as
hydrophobic or charged surface patches.182,183 In disordered
proteins, transient contacts may predominantly occur at
clustered charged or hydrophobic residues or at regions of
transient secondary structure functioning as promiscuous
binding interfaces (see section 3.7). Hence, weak IDP
interactions may result in more discontinuous viscosity effects
that target individual protein segments differently. In-cell NMR
data on human tau, α-synuclein and other disordered proteins
support this notion (see section 5.2).149,151,184,185
2.3.3.2. Translational Diffusion. Translational diffusion is
defined as the mean-square displacement of a given particle
with time (t), and according to Fick’s law, the diffusion
coefficient (D) denotes the velocity with which a solvent unit
cross section (μm2) is transversed in time (s−1). In a
homogeneous solvent, where the solute size is comparable to
or greater than that of the solvent, translational diffusion is
primarily determined by the solute’s size and shape. We refer to
this type of diffusion as normal diffusion, which is primarily
governed by Brownian motion (i.e., Brownian diffusion). In
inhomogeneous environments or where the solute is smaller
than the solvent or where large fractions of the volume are
occupied by other solutes (i.e., macromolecular crowding),
translational diffusion can become complex and exhibit
characteristics of anomalous diffusion (non Brownian diffu-
sion). While normal diffusion scales linearly with time,
anomalous diffusion does not. To describe non-Brownian
diffusion, a tα term is introduced. α values between zero and
one denote subdiffusion. α values greater than one denote
superdiffusion.
A central assumption in describing normal diffusion is that
the solute moves within a continuous hydrodynamic fluid,
which is not the case in cells. Cellular interiors harbor vast
amounts of metabolites and macromolecules, exhibit finite
dimensions, spatial restrictions, confinements and intricate
networks of organelles, vesicles and the cytoskeleton. Given
that macromolecular crowding increases viscosity at different
length scales, it is clear that normal diffusion is restricted in cells
and that intracellular diffusion displays anomalous character-
istics.168,169 In the following paragraph, we discuss exper-
imentally determined diffusion behaviors of proteins on the
micrometer scale in prokaryotic and eukaryotic cells. Methods
to measure these properties are mostly based on fluorescence
imaging in combination with single-particle tracking. We
discuss these techniques in section 5.3.
As indicated above, prokaryotes exhibit much higher
intracellular concentrations of metabolites and biological
macromolecules than eukaryotes. At physiological osmotic
concentrations (∼0.44 Osm), bacteria contain ∼200 g/L of
protein. When shifted to 1.02 Osm, protein levels reach ∼320
g/L, which corresponds to a concentration typically observed in
protein crystals. Translational diffusion of GFP [∼27 kDa,
hydrodynamic radius (RH) 2.82 nm] in E. coli is ∼10 times
slower (Dcyt = 3−8 μm2/s) than in water (D = 87 μm2/s).164
These diffusion properties are contrasted by the 3- to 9-fold
higher intracellular diffusion coefficients inside Dictyostelium
discoideum (Dcyt 24 μm
2/s) and in mammalian NIH-3T3
fibroblasts (Dcyt = 27 μm
2/s), which reinforces the notion that
macromolecular crowding in mammalian cells exerts weaker
effects on intracellular diffusion than in bacteria. Moreover, the
intracellular translational diffusion coefficients of Ficoll and
dextran scale similarly with size in mammalian cells and in pure
water, up to molecular weights of ∼500 kDa (radius of gyration
∼17.5 nm) and their magnitudes are only ∼4 times
smaller.163,186 The average hydrodynamic radii of disordered
proteins (4−6 nm) are slightly larger than those of similarly
sized, ordered proteins, which suggests that the reductions in
intracellular GFP diffusion similarly apply to IDPs. Thus,
translational protein diffusion in E. coli and mammalian cells is
∼8- and ∼3-times slower than in pure water in the supra-
nanometer range (see section 2.3.2).
When bacteria are exposed to external osmotic upshifts, the
passive loss of intracellular water (up to 70%) increases the
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molar concentrations of intracellular macromolecules. Under
such conditions, most intracellular water is coordinated within
the first hydration layer of the “suspended” biomolecules. At
1.02 Osm, corresponding to 400 mM of external NaCl, the
intracellular diffusion coefficient of GFP is 0.014 μm2/s.164
Under similar osmotic conditions, van den Boogaart et al.
reported a drastic reduction in intracellular GFP diffusion,
which coincides with the formation of noncontinuous pools of
intracellular GFP indicating that active diffusion barriers are
formed.187 Interestingly, no such diffusion barriers or impair-
ments on intracellular diffusion behaviors are detected for low
molecular weight compounds, such as fluorescently labeled
sugars, even at 14.7 Osm (2 M NaCl).164 These results imply
that the bacterial cytoplasm displays sieve-like properties
toward larger molecules that result in strong impairments of
translational diffusion and local entrapments under conditions
of severe macromolecular crowding. These properties, however,
largely depend on the bacterial metabolic state and cytoplasmic
fluidity can be drastically different in active or inactive cells.188
The Stokes−Einstein relationship states that diffusion of a
particle scales inversely with its Stokes radius, also called
hydrodynamic radius (RS or RH), which is determined by its
size and shape. When Mika et al. plotted intracellular diffusion
coefficients of different proteins in E. coli against their
individual molecular weights they found that, while diffusion
scales inversely with size as expected, cytosolic diffusion
coefficients (Dcyt) are generally smaller than predicted by the
Stokes−Einstein equation.164 This disparity increases with
molecular weight, which indicates that larger proteins or
protein complexes diffuse much slower than suggested by their
size. Theoretical and experimental approaches in artificial
crowded in vitro environments recapitulated some of these
properties via excluded volume effects (see section
2.3.2).157,167,168 However, they were unable to explain the
quasi-immobile nature of intracellular particles larger than 50
nm.186,189 Similar observations were made in E. coli for particles
larger than 4.5 nm, which is equivalent to 4 covalently bound
GFP molecules.166 These results suggest that organized
intracellular structures, such as the cytoskeleton, form a
restrictive sieve-like meshwork impeding the diffusion of
macromolecular assemblies above certain sizes. These struc-
tures were estimated to exhibit pores of ∼5 and ∼50 nm
diameters in E. coli and mammalian cells, respectively. In the
case of mammalian cells, this size is above the average RH of
folded and intrinsically disordered proteins in their monomeric
states. However, when one considers the average hydrodynamic
radii of IDP aggregates (∼90 nm for fibrillar tau, for instance),
oligomeric IDP species may exhibit reduced intracellular
diffusion (see section 2.3.2). In fact, IDP aggregates may
constitute barriers to intracellular translational diffusion and
increase intracellular viscosity or exacerbate the effects of
existing sieve-like structures. In the case of α-synuclein for
example, aggregates could hamper vesicle transport in neuronal
cells and contribute to Parkinson’s disease. Similarly, fibrillar
tau tangles may increase the diffusion-limiting effects of the
microtubule network, with which the protein physiologically
interacts, and thereby impair active transport along micro-
tubules.
What are the biological consequences of slowed intracellular
diffusion? Although the crowded cytoplasm of prokaryotic and
eukaryotic cells restricts translational diffusion, most biological
reactions occur faster than diffusion. Mika et al. calculated that
inside E. coli (∼3 μm long) it takes 30 ms for fluorescently
labeled glucose (MW ∼0.3 kDa; D = 50 μm2/s), 0.5 s for GFP
(MW ∼27 kDa; D = 3 μm2/s), 2 s for 4xGFP-tagged β-
galactosidase (MW ∼580 kDa; D = 0.8 μm2/s), and 75 s for
25−50 MDa ribosome-loaded mRNAs (D = 0.02 μm2/s) to
transverse the cytoplasm.164 Given the average doubling time of
E. coli (∼30 min), even the largest macromolecular assemblies
can travel back and forth multiple times during one cell division
cycle. Osmotic stress will increase these times and progressively
affect biological reactions that rely on fast macromolecular
diffusion.
Recent data suggest that even simple organisms such as
bacteria employ forms of spatial organization that anchor large
macromolecular assemblies at defined intracellular positions
(see section 4.2).190,191 This organization may ensure that
biomolecules, such as newly synthesized proteins are
abundantly available in certain intracellular areas to enable
fast interactions en route to supramolecular complex formation.
In turn, such spatial restrictions may promote the establishment
of functional compartments in the absence of organelles. In
higher eukaryotes, translational diffusion in the lumen of
intracellular organelles contributes to many cellular processes.
Diffusion in mitochondria has been studied extensively,
primarily because of the functional importance of this organelle
and its high degree of macromolecular crowding, with protein
concentrations ranging from 270 to 560 g/L.192 These
concentrations prompted researchers to propose that “metab-
olite channeling” along spatially arranged, membrane-bound
enzymes was the only way to ensure efficient mitochondrial
activity.180,193 However, fluorescence studies of GFP targeted
to the mitochondrial matrix established that its diffusion
coefficient in this environment is 20−30 μm2/s, only 3−4 fold
lower than in pure water.180 These measurements revealed that
inside mitochondria effective contributions from macro-
molecular crowding are much smaller than expected based on
absolute protein concentrations. Herrmann et al. later showed
that membrane embedded polypeptides make up the largest
portion of these mitochondrial proteins and do not contribute
significantly to matrix lumen macromolecular crowding.194
When one subtracts the spatial restrictions that the inner
mitochondrial membrane and its invaginations impose on
translational diffusion, the effective viscosity felt by GFP is only
∼2 times higher than in water.195,196 Similarly, GFP diffusion in
the lumen of the endoplasmic reticulum is only 9 to 18 times
slower than in water, including reductions due to membrane
intrusions.179 The viscosity in the nucleus is 1.2 to 1.4 times
greater than in water.197 Together, these results establish that
general intracellular- or organelle-macromolecular crowding
exerts small effects on the diffusion properties of average-sized
proteins at physiological concentrations, irrespective of whether
they are ordered or intrinsically disordered.
2.3.4. Macromolecular Crowding and Weak Interac-
tions. One additional observation from these, and other
experiments concerns the notion that similarly sized, but
chemically distinct particles or proteins, often exhibit marked
differences in their intracellular diffusion behaviors. Extended
DNA fragments for example, diffuse slower in the cytoplasm
and nucleus of HeLa cells than dextran molecules of similar
sizes.189 Clearly, up to now we adopted an overly simplified
view of the cellular interior and neglected possible “biological”
contributions to macromolecular crowding. It is therefore
reasonable that size and shape alone do not determine a
biomolecule’s intracellular diffusion. Especially weak transient
interactions exert a strong influence on rotational and
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translational diffusion processes in cells. We collectively refer to
these contributions as “soft” interactions, also to contrast their
effects with “hard-sphere repulsions” according to classical
macromolecular crowding theory.121 Soft interactions can be
repulsive or attractive, and they can either exacerbate or
counteract hard-sphere effects. Depending on their nature and
magnitudes, soft interactions can enforce or diminish the
previously outlined, purely physical crowding effects on protein
diffusion.
Because “soft” interactions are omnipresent in biological
systems, several studies have aimed at providing concise
descriptions about their origins. Simple examples include
positive or negative electrostatic contributions: Strongly
charged surface properties, especially when they occur in a
highly localized manner, can differentially modulate a protein’s
diffusion behavior in positively or negatively charged environ-
ments.198,199 Similarly, hydrophobic surface patches or
promiscuous binding sites can result in soft interac-
tions.177,182,183,200 In contrast to ordered proteins, IDPs expose
their residues to the solvent and, therefore, have much larger
solvent accessible surface areas. In turn, this increases the
likelihood for multivalent weak interactions, which may lead to
complex subdiffusion.162
2.3.5. Macromolecular Crowding and Intermolecular
Association. So far, we discussed how macromolecular
crowding has the capacity to modulate the structures and
diffusion behaviors of biological macromolecules, as well as how
weak transient interactions can counteract or exacerbate these
effects. In our introduction to classical macromolecular
crowding theory, we also stated that greater effective
concentrations and enhanced thermodynamic activities result
in direct consequence of excluded volumes and crowding. Here,
we outline how these combined crowding and interaction-
effects influence protein−protein association. We separately
discuss the impact of macromolecular crowding on aggregation
in section 4.
2.3.5.1. Contributions to Equilibrium Thermodynamics.
Using the same simplistic thermodynamic rationale employed
to explain protein compaction, i.e., minimizing volume
occupancy; macromolecular crowding can favor protein−
protein association, because it also enables the system to
decrease its volume. However, this statement cannot be
generalized, because some associations result in complexes
with dimensions that are greater than those of the individually
interacting molecules.123 Therefore, macromolecular crowding
can either stabilize or destabilize protein−protein interactions,
depending on the size and shape of the reacting molecules and
the resulting complexes (Figure 3D). Mildly stabilizing (∼2−5
fold) effects were observed in vitro for the formation of
heterodimers between E. coli polymerase III theta-epsilon
subunits in dextran and Ficoll-crowded solutions and for the
interaction of superoxide dismutase and xanthine oxidase in
PEG-, dextran-, and Ficoll-containing environments.201 Desta-
bilizing effects (∼2−4 fold) were noted for the barnase-barstar
interaction in the presence of PEG and for TEM1 and β-
lactamase-BLIP inhibitor in PEG- and dextran-crowded
solutions.201 In agreement with theory, stronger stabilizing
effects were detected for complexes with more than two
subunits.123,201 A 2-fold in vivo affinity increase between the
GTPase Cdc42 and its various effector-proteins was reported in
HeLa cells.201
2.3.5.2. Contributions to Kinetics. Viscosity-dependent
diffusion of reacting molecules determines their interaction
rates. Higher viscosity decreases association rates but also
decreases dissociation rates. Because intracellular viscosity
depends on different macromolecular crowding contributions
and scales differently at different length scales (see sections
2.3.2 and 2.3.3), kinetic effects can have complex behaviors. On
the subnm scale, translational diffusion in cells is much faster
than on the μm scale, where anomalous diffusion prevails.
According to theory, anomalous diffusion produces greater
probabilities for protein−protein interactions in the vicinity of
binding interfaces, i.e., at distances below 10 to 100-times the
radii of interacting molecules.202 In other words, proteins
succumb to macromolecular crowding-induced partial confine-
ment in a concentration-dependent manner. Following this
notion, one concludes that chances for interactions increase
when two proteins are abundant and in close proximity. This
behavior is exacerbated by steric repulsion, but unaffected by
slower translation diffusion. When two proteins are present at
low abundance and separated, their chances to interact
decrease. This opposite behavior is equally affected by
macromolecular crowding, but largely governed by slower
translational diffusion. Such a view is nevertheless biased
toward intracellular association rates and oblivious to
dissociation kinetics. Because specifically interacting proteins
tend to colocalize in cells, these assumptions may not accurately
reflect physiological scenarios, and in vivo association kinetics
may differ only marginally from in vitro rates. Some
experimental results point in this direction. Association rates
of the barnase-barstar interaction are not affected by
polyvinylpyrrolidone (PVP) crowding and reduced 3-fold in
the presence of 300 g/L PEG.201 Similarly, TEM1-BLIP
binding is less than 4-fold slower in PEG-, dextran-, and Ficoll-
solutions, and only 2-fold slower in HeLa cells.201
2.4. Cellular Interfaces and Environments
So far, we discussed the compositional and physical properties
of intracellular environments as continuum parameters.
However, in cells, these properties fluctuate in a spatial and
temporal manner. Subcellular organization directly correlates
with evolutionary advancement, and organismal complexity and
compartmentalization are instrumental in many biological
processes.203−206 In turn, different regions in prokaryotic and
eukaryotic cells exhibit different microenvironments that affect
biomolecules in their vicinity.
Organelles are separated by membranes that function as
physical barriers in preserving environmental properties and
counteracting exchange. Their interiors offer different environ-
mental conditions, which are often determined by their
biomolecular compositions. The cell nucleus for example,
harbors vast amounts of DNA, a negatively charged
polyelectrolyte with an overwhelming charge potential of −2e
per base pair, which imposes considerable electrostatic
constraints on architectural proteins such as histones or
DNA-binding proteins such as transcription factors.207−209
Histones contain extended, disordered “tail” regions that are
highly positively charged. In the context of nucleosomes, the
basic packaging unit of nuclear DNA,210 histone tails experience
electrostatic DNA contributions, that ultimately dictate their
structural and functional behaviors.211 Post-translational
histone modifications alter these electrostatic properties and,
in turn, modulate interactions with DNA. Because these
modifications partially establish the epigenetic histone code,
thereby regulating the transcriptional states of entire genomes,
they provide a compelling example of a context-regulated
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biological activity that relies on structural disorder as the main
determinant for function.212
Enveloped by membranes, organelles offer additional lipid-
solvent interfaces at their interiors and exteriors. Given the
chemical and compositional diversity of biological membranes,
and their differing physical properties including thickness,
fluidity, curvature, lateral pressure, bilayer coupling and surface
charge, they constitute highly specialized environments.213−215
All biological events at membranes occur with strong
electrostatic contributions.216 One classical example of how
structural disorder is functionally linked to these properties is
the electrostatic myristoyl switch.217 Peripheral membrane
proteins such as the myristoylated alanine-rich C kinase
substrate (MARCKS), Src kinase and the transducin αt subunit
contain N-myristoylated glycines, followed by long stretches of
disordered residues with characteristic patterns of basic and
hydrophobic amino acids, so-called basic effector domains.
Membrane attachment is mediated by the respective myristoyl
moieties. However, myristoyl-membrane binding is not strong
enough to firmly anchor these proteins in the lipid bilayer.
Complementary charge interactions between acidic phospho-
lipids and the basic effector domains are required for high
affinity binding. In turn, phosphorylation of conserved serines
within the effector domain of MARCKS, for example, reduces
its net charge and results in membrane dissociation.218 Thus,
synergistic hydrophobic and electrostatic effects, conferred by
disordered protein regions mediate the reversible membrane
interaction.217 In fact, most signal sequences that target
proteins to organelles are intrinsically disordered and exhibit
high contents of hydrophobic and/or positively charged
residues. Therefore, some of the mechanisms of membrane
binding and membrane crossing rely on similar biophysical
principles.219−222
In prokaryotes and eukaryotes, different types of lipids
assemble into functional microdomains termed lipid rafts.223
Lipid rafts harbor specific sets of trans-membrane proteins and
act as platforms for complex biological processes such as signal
transduction, cytoskeletal organization, membrane transport
and pathogen invasion.223−225 Different lipid rafts exhibit
distinct lipid compositions and have characteristic permeabil-
ities, fluidities, and overall electrostatic properties.226,227 In
eukaryotes, they are characterized by high degrees of stiffness,
which results from enrichment in cholesterol and sphingoli-
pids.221,224 Microenvironments around these lipid rafts
exacerbate or reduce electrostatic effects and mediate attractive
or repulsive long-range interactions.228 Because all membranes
exert hydrophobic and electrostatic effects, the latter predom-
inantly through acidic phosphoplipids, disordered proteins with
clustered positively charged residues experience attractive
forces, which can be weak, but biologically meaningful in
mediating membrane interactions, as we have seen above. By
the same token, patches of negatively charged residues in
disordered proteins are electrostatically repulsive, which may
prevent unspecific membrane interactions.
Protein complexes spanning membranes and connecting
cellular compartments, often mediate selective transport and
exchange of biomolecules. To do so, they frequently form
microenvironments of defined physical properties, especially
with regard to permeability. One striking example is the nuclear
pore complex. Bridging the cytoplasm and the nucleus, it
contains an interior microenvironment that is made up entirely
by disordered segments of distinct nucleoporins.229,230 Their
extended, Phe-, Gly-rich (FG) regions form a meshwork of
filaments that functions as a sieve-like hydrogel.231−233
Proteins, and other biomolecules, entering or exiting the
nucleus, have to pass through this microenvironment to reach
their respective destinations.234,235 Interestingly, FG-filaments
form amyloid-like, β-rich structures and thus represent another
cunning example of a functional IDP aggregate (see section
4.2).232
The cytoplasm harbors additional interfaces and micro-
environments. As we discuss in section 2.3.3.2, the cytoskeleton
establishes multiple physical barriers that spatially confine
vesicles, organelles and large cellular machines such as
ribosomes. The segregation of the cytoplasm into nanometer-
sized compartments bounded by cytoskeleton filaments creates
defined pools of biomolecules and metabolites. Building on
early work by McConkey et al.236,237 and others,66,238,239
Spitzer and Poolman developed a comprehensive physicochem-
ical model of the cytoplasm to explain these effects. Although
originally delineated for prokaryotic systems, their concepts can
be extended to eukaryotic cells.204,205,240 The Spitzer and
Poolman model postulates the existence of intracellular
metabolic zones that comprise electrolyte pools and levels of
macromolecular crowding different from other regions, such as
cell membranes and organelles.204 Formation of metabolic
zones largely depends on asymmetric charge distributions,
which are generated by electrostatic surface properties,
especially anionic patches.65,241 Positively charged species are
less abundant and only partially neutralize the entirety of
cellular macro- and microanions.242 In their model, the
cytoplasm is steeped in electrolyte pools that contain unique
temporal compositions of metabolites, ions and freely diffusing
macromolecules.205,240 The boundaries of these pools are
defined by the charged surfaces of macromolecules, which
further provide electrochemical gradients that drive the flow of
charged metabolites. Overall, the surfaces of these structures
remain negatively charged and repel each other, thereby
preventing spontaneous aggregation. Cellular machines such
as ribosomes reside at specific locations in these metabolic
zones, where more or less defined compartments insulate
concurrent biological processes and prevent mutual perturba-
tions.205,237,243
The model by Spitzer and Poolman is a good description of
the heterogeneous cytoplasm. Importantly, it emphasizes the
notion that the physical and compositional characteristics
outlined in this section only describe a basis set of general
parameters influencing the structural and functional properties
of disordered and ordered proteins in cells. To fully grasp in
vivo contributions to cellular structural biology we must take
spatiotemporal variations of these physicochemical parameters
into account.
3. BIOLOGICAL PROPERTIES OF IDPS INSIDE CELLS
Proteomic analyses of numerous organisms show that intrinsic
disorder scales linearly with evolutionary progression and that
disorder contents are larger in proteomes of higher eukaryotes
than in prokaryotes or archaea. Furthermore, proteomes of
multicellular eukaryotic organisms contain larger proportions of
disorder than unicellular ones.5,6 Approximately 30% of all
mammalian proteins are disordered, whereas 75% of all
signaling proteins contain extended disordered regions.
Globular proteins make up the majority of cellular enzymes
and transport proteins, which require stable three-dimensional
structures to execute their respective biological functions.15
Proteins or protein domains that regulate and mediate adaptive
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and malleable biological responses require significant conforma-
tional flexibility and are predominantly disordered (see section
3.6).13,244 Accordingly, disorder is particularly prevalent in
eukaryotic proteins and processes that rely on these functions,
such as cell differentiation, cell−cell communication, cell-cycle
progression, transcriptional regulation, apoptosis, etc..15
Comprehensive functional annotations of disorder can be
found in several reviews.13,245
Given their prominence in many proteomes, the question
arises as to how intracellular levels of disordered proteins, their
intactness, stability and degradation are regulated, especially in
comparison to ordered proteins. IDP homeostasis must be
tightly controlled to avoid incidences of self- and nonself
associations, which can directly result in several pathologies.
Abnormal accumulations of α-synuclein, Huntingtin, tau, or the
Aβ peptides for instance, promote the formation of toxic
amyloid fibrils and oligomeric species implicated in Parkinson’s,
Huntington’s and Alzheimer’s disease, respectively (see section
4).16 Failure of the proteasome to clear aggregated IDPs
additionally contributes to the multifactorial etiology of these
disorders.246−249 Besides neurodegenerative pathologies, mis-
regulation of cellular disordered proteins is strongly associated
with many forms of cancer. Overexpression of Stathmin and
low levels of p27 for example, contribute to the metastatic
phenotypes in human sarcomas.250,251 In the following
paragraphs, we outline how cells regulate the synthesis, cellular
diversity, stability and degradation of intrinsically disordered
proteins.
3.1. Regulation of IDP Synthesis
Protein synthesis is generally controlled on the transcriptional
(DNA), post-transcriptional (RNA), and translational (ribo-
some) levels. Because the primary characteristics of IDPs are
manifested on the protein level, information about the
regulation of their genes and transcripts is sparse. Nevertheless,
insights into these processes exemplify how cellular diversity
and abundance are regulated.
Two independent studies analyzed gene expression and
mRNA levels in higher eukaryotes and compared the relative
abundance of transcripts encoding intrinsically disordered-,
versus ordered proteins.252,253 Results indicated that, on
average, genes encoding disordered proteins are more
intricately regulated than genes encoding folded proteins,
while the mRNA levels of IDP genes are lower than those of
ordered proteins. IDP transcripts were grouped into five
categories based on their expression levels and protein
abundance.253 Highly expressed mRNAs encode ribosomal
proteins or disordered housekeeping proteins such as splicing
factors and architectural chromatin components, protease
inhibitors, or regulators of enzymatic activities. Intermediately
expressed IDP transcripts encode general transcription factors,
tissue specific regulators such as receptor ligands, or transcrip-
tional cofactors. Low abundance mRNAs encode disordered
proteins involved in organ development and differentiation.253
In another study in E. coli, the authors found a weak, positive
correlation between intrinsic disorder, mRNA expression levels
and predicted protein abundance.254 Although bacteria have
fewer disordered proteins in their proteomes (∼5%) than
higher eukaryotes (∼30-50%), their prominence in copius
cellular factors such as ribosomal proteins, transcriptional
regulators and chaperones253 renders IDP mRNAs more
abundant than transcripts of folded proteins. The Babu group
also investigated the synthesis and degradation rates of IDP
transcripts and compared them to the rates of ordered proteins
(Table 1).252 They found that the number of transcription
factors regulating IDP gene expression is roughly the same as
for folded proteins, and so are their transcriptional rates. Also,
that the half-lives of mRNAs encoding highly disordered
proteins are shorter compared to ordered proteins.252,253 These
results indicated that IDP transcript abundance is primarily
regulated by degradation. To validate this assumption, the
authors analyzed the lengths of mRNA poly-A tails, which
govern intracellular lifetimes and degradation rates.252 They
found that IDP transcripts contain shorter poly-A tails than
ordered proteins. When the occurrence of Pumilio repeat
(PUF)-binding sites on both transcript types was analyzed,
PUF proteins bind and down-regulate mRNAs either by
signaling degradation or via translational repression by 3′ UTR
binding,255,256 more sites were found in IDP mRNAs than in
transcripts encoding ordered proteins.252 In agreement with
these observations, the Jones group showed that human IDP
mRNAs display a higher abundance of predicted miRNA
binding sites and faster degradation rates than transcripts
encoding ordered proteins.253 However, these values are
statistical averages and their distributions are broad.
3.2. Cellular IDP Diversity
Several biological processes can regulate the cellular diversity of
disordered proteins. In this section, we discuss the evolvability
of IDPs and their greater resistance to mutational damage, as
well as how alternative mRNA splicing generates functionally
distinct proteins. Furthermore, we provide examples of
proteolytic processing reactions that specifically target dis-
ordered proteins and describe how they extend IDP diversity in
vivo.
3.2.1. Evolutionary Selection. Disordered proteins exhibit
greater capacity for mutational evolvability and resistance to
mutational damage. Evolutionary rates of ordered proteins are
determined by their requirements to preserve structural
integrity, which is not the case for disordered proteins.
Therefore, IDPs should evolve faster than folded proteins. To
investigate this notion, Dunker and Lin compared the genetic
distances of ordered and disordered protein regions within 26








transcription factors/gene 2.0 2.0
transcriptional rate (mRNAs/hour) 2.2 1.8
transcript abundance (copies per cell) 0.9 0.8
transcript half-life (min.) 23.0 19.0
transcript degradation (% with short polyA
tails)
28 56
miRNA targeting (% sequences)b 15 30
protein level
translational rate (ribosomes/ORF) 0.5 0.37
protein abundance (proteins/cell) 2900 1860
protein half-life (min.) 45 37
% PEST sequences 19 42
ubiquitination sitesb,c 50 70
aData from S. cerevisae, adapted from ref 252, except, bentries obtained
from human tissues and cell lines, adapted from ref 253. cPercentage of
proteins with one or more predicted ubiquitination sites.
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families.257,258 Their analysis showed that disorder-rich regions
in otherwise ordered proteins evolve more rapidly. The authors
propose that these differences primarily arise because globular
proteins typically employ more residues to “construct” their
three-dimensional structures, leaving them fewer degrees of
freedom to accommodate substitutions. Because disordered
proteins exhibit fewer intramolecular contacts, their primary
amino acid structures tolerate mutational changes better. By the
same token, new interfaces arise without deleterious structural
consequences, which increases the functional repertoire of
IDPs. Dunker et al. use this evidence to convincingly argue that
the higher evolutionary rates of disordered proteins also lend
strong support to the notion that they exist freely in cells.13 If
they were always bound to interacting partners in vivo,
probably in folded conformations, their evolutionary rates are
expected to be comparable to those of ordered proteins, which
is not the case. We discuss additional aspects of IDP
evolvability and mutational tolerance in the section on post-
translational IDP modifications (see section 3.6).
3.2.2. Alternative Splicing. Alternative splicing constitutes
another process regulating IDP diversity.259 Interestingly,
alternative splicing occurs more frequently in mRNAs encoding
disordered than ordered proteins.260,261 Dunker and co-workers
analyzed 46 alternatively spliced human genes and found that
81% of all alternative splice sites occur in fully (57%) or
partially (24%) disordered protein domains. Only 19% occur in
ordered regions.261 More recently, the Tompa group analyzed
∼500 isoforms of spliced human proteins and found that
alternative splicing “avoids” folded domains and preferentially
“targets” disordered protein segments.260 The authors propose
that alternative splicing favors these regions to minimize
deleterious effects of truncated proteins that lead to loss of
function, misfolding, and aggregation. Alternative splice-site
selection can also entail the use of different exon combinations
to generate functionally distinct proteins or dual-coding regions
that are alternatively assembled into different open reading
frames. A sequence analysis of 62 dual-coding regions revealed
that their protein products are particularly rich in disordered
regions.262 For +1 frame shifts, the amount of disorder in the
resulting protein is comparable with that of the original frame,
whereas −1 frame shift proteins are more disordered. The
authors showed that this mechanism results in novel functions
and also protects mRNAs from nonsense-mediated decay.262
Alternative splicing is particularly versatile in controlling
protein diversity and abundance. Splice-isoforms of disordered
proteins can contain different sequences, different numbers of
linear motifs, or novel post-translational modification sites that
can affect functions by changing binding properties, stabilities
and/or subcellular localizations. Such changes can rewire
protein interaction networks and facilitate new phenotypes in
cell-, tissue-, organ- and organism-specific manners.244 One
example is p53 (TP53).263 Its central folded domain binds
DNA, while the disordered N- and C-termini act as regulatory
elements that interact with different effector proteins and
harbor numerous modification sites (see section 3.6).264 In
humans, 12 alternatively spliced p53 isoforms are known, and
splicing mostly occurs within the disordered N- and C-terminal
regions.265 In turn, these p53 isoforms display different
functional activities with regard to triggering cell-cycle arrest,
or apoptosis, they bind effector proteins such as Mdm2
differently, which affects their intracellular stability and
degradation, and they localize to different subcellular compart-
ments, i.e., the cytoplasm versus the cell nucleus.266
Similar to alternative splicing, isoforms of disordered proteins
are also generated on the protein level by targeted proteolysis.
We discuss examples for this regulatory mechanism in the
following section.
3.2.3. Proteolytic Processing. Disordered proteins
particularly amenable to functional and site-specific processing
events, such as targeted proteolysis. While some of these
cleavage reactions produce toxic fragments, including aggrega-
tion prone species (see section 4), others result in modified
proteins with novel functions. Proteolytic processing of the Bcl-
2 family of proteins is one example. These proteins contain
extended (∼50 residues) disordered loop regions that control
pro- and antiapoptotic cellular responses.267,268 Depending on
the extent of cell damage, opposing phosphorylation- and site-
specific caspase cleavage-reactions within these loops disrupt or
enforce existing interactions, and enable new binding events
that collectively determine whether cells commit to irreversible
cell death or reversible cell-cycle arrest and senescence.268 In a
similar fashion, site-specific cleavage within a disordered loop of
plasma membrane-bound sterol regulatory element-binding
protein (SREBP) by a subtilisin-related serine protease and a
Zn(II)-metalloprotease promotes membrane dissociation,
nuclear import and, in turn, transcriptional activity.269
Analogous endoproteolytic activation and translocation have
been reported for casein kinase I epsilon (CKIε), the NF-κB
associated factor Relish and other proteins.270,271
Other examples of productive proteolysis are the prion
protein and the amyloid precursor protein. The nontoxic form
of the prion protein (PrPc) is membrane-anchored and contains
a disordered N-terminus and an α-helical C-terminal
domain.272 Conversion of PrPc into toxic prion species
(PrPsc) causes Creutzfeld-Jakob’s disease (see section 4). In
cells, cleavage of PrPc by members of the desintegrin and
metalloproteinase family of proteases dissociates the disordered
N-terminus of PrPc from its membrane-bound C-terminus.273
Other proteases such as calpain and cathepsins target PrPsc at
different sites, generating longer and shorter N- and C-terminal
fragments, while autocatalytic PrPc cleavage also occurs in the
presence of reactive oxygen species.273 Whether these
proteolytic PrPc and PrPsc fragments execute biological
functions remains unclear, although some data suggest they
might be neuroprotective.274−276
The amyloid precursor protein (APP) is another ordered,
membrane-bound protein with well-defined heparin and Cu/
Zn binding domains.277 Along the amyloidogenic pathway, N-
terminal portions of APP are cleaved by β- and γ-secretase
releasing the disordered, aggregation-prone and highly neuro-
toxic Aβ peptides. Depositions of these peptides in the forms of
amyloid plaques are the pathological hallmarks of Alzheimer’s
disease (see section 4). By contrast, nonamyloidogenic
processing by α-secretase produces nontoxic Aβ species that
regulate gene expression and are considered neuroprotective.277
Together, these examples illustrate how site-specific protease
reactions regulate the cellular diversity of intrinsically
disordered proteins. Besides functional proteolytic processing,
IDPs are also targeted by general cellular proteolysis as a means
to maintain homeostasis. Next, we outline how the abundance,
stability and degradation of disordered proteins are regulated by
intracellular proteases.
3.3. Intracellular IDP Stability and Degradation
In vitro, disordered proteins are more susceptible to proteolysis
than ordered proteins. Historically, this property was used to
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identify and characterize IDPs.278,279 The simplest explanation
is that disordered proteins provide unrestricted access to
proteases over their entire lengths. Similarly, denaturation of
ordered proteins increases their susceptibility to cleavage280 and
surveys of crystal structures of substrate-bound proteases show
that their substrates are in extended conformations.281
Accordingly, conformational selection is thought to steer
proteolytic degradation of ordered and disordered proteins.281
In prokaryotes and eukaryotes, broadly acting proteases
degrade misfolded or otherwise damaged proteins. In addition,
complex proteolytic systems and processes, such as the
proteasome and autophagy regulate global protein homeostasis,
acting on a wide range of proteins.26 70−90% of all eukaryotic
proteins are cleared by the proteasome282,283 and 40% of all
cellular proteasomes exist as 20S proteasomal core units, with
poorly defined activities.284 Protein turnover is mainly achieved
via ubiquitin-mediated degradation, although 20S particles act
in an ubiquitin-independent manner.284 Both 20S and 26S
holo-proteasomes require disordered regions for initiating
proteolysis, however, catalytic activity is primarily governed
by proteasomal targeting motifs (20S) and poly ubiquitination
(26S).285−288
Some classes of cellular enzymes, such as the Lon family of
serine-specific proteases are tailored to target disordered
proteins. ATP-independent Lon isoforms exclusively degrade
unfolded substrates, whereas ATP-dependent isoforms require
ATP hydrolysis to degrade ordered substrates, but not
disordered ones.289,290 The three-dimensional structures of
Lon proteases reveal that individual degradation chamber entry
channels are too small for ordered proteins,290 suggesting that
disordered polypeptides are preferred Lon substrates, whereas
ordered proteins require ATP-dependent disassembly to be
degraded. Similar observations were made for the proteasome
system. Disordered proteins such as α-synuclein, p21 or c-Jun,
are efficiently degraded by the 20S core particle in vitro, while
ordered proteins are not under the same conditions.26
Interestingly, proteinase K-sensitive, molten-globule proteins
are also resistant to 20S degradation.279 As for Lon proteases,
these observations suggest that extended, flexible IDP
conformations facilitate proteasome entry. Support for this
hypothesis comes from experiments measuring 20S proteolysis
rates of disordered peptide chains coupled to bulky gold
particles.291 Without the gold labels, peptides are efficiently
degraded. When bound to gold particles, proteolytic cleavage is
severely impaired, likely because the substrates are unable to
enter the proteasome. In vitro, the 20S proteasome also
degrades folded proteins that contain extended disordered
regions at their termini, such as p53 for example. While
terminal disorder is required to initiate proteolysis, once
globular protein domains are encountered during the
degradation process they are actively unfolded in an ATP-
independent manner and further proteolyzed.292,293 Similarly, a
priming disordered region of ∼30 amino acids is required for
polyubiquitin-dependent proteolytic processing by the 26S
proteasome.294,295 Indeed, the 26S proteasome degrades fully
disordered proteins even in the absence of polyubiquitina-
tion,296 suggesting that ubiquitination is not absolutely required
for degradation.296,297
So far, we discussed in vitro aspects of proteolytic processing.
How do these considerations apply to the degradation of
ordered and disordered proteins in vivo? The Babu group used
different data sets reporting on protein half-life in a proteome-
wide fashion to investigate differences in abundance, stability
and degradation of ordered versus disordered proteins (Table
1).252 They concluded that, on average, the half-lives of IDPs
are slightly shorter than those of folded proteins. They focused
on two parameters known to modulate proteasome-dependent
degradation, namely the frequency and abundance of
disordered N-end residues and PEST motifs.298,299 The N-
end rule states that the half-life of a protein is determined by
the identity of its N-terminal residues. In E. coli bulky,
hydrophobic amino acids, such as Leu, Phe, Trp, and Tyr are
most destabilizing, followed by basic residues (Arg and Lys). In
eukaryotes, hydrophobic and basic amino acids act independ-
ently in determining the stability of a protein and its properties
as a proteolytic substrate.299 In eukaryotic proteins, PEST
sequences contain between 10 and 50 amino acids rich in Pro,
Glu, Ser, and Thr that cause rapid degradation. Indeed, PEST
sequences are overrepresented in proteins with high intra-
cellular turnover rates (<2 h).298,299 Although destabilizing N-
end residues are not more prevalent in disordered proteins,
PEST motifs are enriched.252 An independent study by Tompa
and co-workers using a yeast data set,300 concluded that
polypeptide length is the key determinant of in vivo
degradation rates, with longer proteins being degraded faster
than shorter ones, irrespective of whether they are ordered or
intrinsically disordered. Interestingly, when the authors
reanalyzed their data after normalizing to length, disordered
proteins displayed a weak, although probably significant
correlation with enhanced degradation rates.301 According to
their study, PEST motifs and other degradation sequences such
as the KEN box, only yielded weak correlations with the half-
lives of disordered proteins.301
Because polyubiquitination plays a pivotal role in cellular
protein degradation, Edwards et al. analyzed the occurrence of
predicted ubiquitination sites in disordered and ordered
proteins.253,302 They showed that ubiquitination sites are
more abundant in disordered proteins. Hagai et al investigated
a set of 482 in vivo ubiquitinated proteins and found a strong
correlation between confirmed degradation sites and regions of
structural disorder.303 In another study on protein turnover in
human cells, Yen et al. did not find a correlation between
disorder content and protein half-life.304 Given the technical
challenges in many of these studies, especially with regard to
annotating ubiquitination sites on a proteomic scale, it is
difficult to establish a conclusive link between protein disorder
and ubiquitin-mediated degradation.305 The Selbach group has
measured absolute mRNA and protein levels in mammalian
NIH3T3 cells, and their turnover rates and average stabilities,
thus providing a superior data set for a genome wide
comparison.306 This resource has not yet been interrogated
with respect to disorder.
Collectively, many in vivo studies suggest that disordered
proteins are not degraded appreciably faster than ordered ones,
which is contrasted by their in vitro behaviors. What causes
these discrepancies and do they accurately reflect high in vivo
stabilities of disordered proteins? One experimental short-
coming in measuring a protein’s half-life with fluorescently
labeled tags is the presence of bulky, folded entities at either the
N-, or the C-terminus of the investigated polypeptide.300,304 As
pointed out by Suskiewicz et al., given the importance of
disorder at protein ends in steering degradation (see above),
tagging is likely to affect these processes.26,307 In other cases,
partial degradation may preserve the globular tags and result in
incorrect scoring. Another issue may relate to the use of data
sets from different cellular systems and conditions.252 These
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variations might skew correlations between individual transcript
and protein levels.
While these considerations are valid and important, it is
unlikely that methodological shortcomings alone account for
the observed differences in in vitro and in vivo degradation
behaviors. It is plausible that additional cellular factors and
effectors synergistically modulate these processes.
3.4. Factors Affecting Intracellular IDP Degradation
Purely physical factors such as intracellular viscosity and
macromolecuar crowding are expected to increase, rather than
decrease, proteolytic activity. Limiting scenarios may be
encountered in cases of high molecular weight aggregates or
upon compaction, folding, and binding.308,309 In PEG-crowded
solutions for example, the affinity of α-chymotrypsin for its
substrates increases, whereas its proteolytic activity decreases.
Verma et al. showed that this is caused by crowding-induced
structural changes in the protease that favor an open
conformation of its substrate entry site, while sterically
restricting the exit path.310 A similar behavior was reported
for the HIV-1 protease, where crowding stabilizes the closed
conformation of the catalytic site.311 For SARS-CoV, protease
activity depends on the oligomerization state of the protein.
Under dilute in vitro conditions, the enzyme exists in a
monomer−dimer equilibrium, with only the dimer being
proteolytically active. In the presence of BSA or PEG, dimeric
SARS-CoV is stabilized, which leads to a 3-fold increase in
activity.312 Therefore, intracellular macromolecular crowding
cannot explain the observed differences between in vitro and in
vivo degradation behaviors of disordered proteins.
Another explanation may be afforded by intracellular
compartmentalization, separating disordered proteins from
the degradation machinery. Although organelles such as
lyzosomes, function as general destruction units, there are no
indications that disordered substrates are excluded from these
organelles in vivo. Several other factors may tune the stability of
disordered proteins in cells, especially because they interact
with diverse sets of biomolecules (see sections 3.6 and 3.7).
Accordingly, many disordered proteins are likely bound by
other biomolecules in cells, modulating their degradation. α-
synuclein for example, exists in a membrane-bound con-
formation that entails its first 100 residues.313,314 Hence, larger
portions of cytoplasmic α-synuclein can potentially be
proteolyzed when it is not bound to membranes. Indeed,
when free α-synuclein is treated with proteases such as
thermolysin, proteinase K, or the Glu-specific V8-protease it
is efficiently degraded into small peptide fragments that span its
entire sequence. When it is bound to SDS micelles, proteolysis
preferentially targets its free C-terminus.315 Similarly, disor-
dered regions in transcription factors may be protected from
proteolysis upon DNA binding.26,316 Recent data suggest that
many nonfunctional transcription factor-binding sites on
genomic DNA serve as proteolytic safe havens protecting
these proteins from degradation.317 Stabilizing effects can also
be mediated by interactions with other proteins318 such as
proteasome gatekeepers and nanny proteins.26 The proteasome
gatekeeper NQO1 for example, binds and protects many
disordered proteins,319,320 whereas nanny proteins interact with
newly synthesized polypeptides and counteract sporadic
degradation.293,321 Nanny proteins might also explain how
newly synthesized, disordered proteins escape the general
degradation machinery when they emerge from the ribosome.
It has been suggested that nascent disordered protein regions
transiently interact with ribosomal proteins until sequences
emerge that interact with nanny proteins.26 In that sense,
proteasome gatekeepers and nanny proteins function as
protective chaperones preserving the integrity of disordered
proteins (see section 3.5). Other cellular chaperones might also
influence the fate of IDPs, but their individual roles are less
clear. According to the prevalent view, disordered proteins are
not preferred chaperone targets.322 In fact, recent data on tau
and p53 suggest that IDP-chaperone interactions promote
degradation, rather than protection, either via the 26S
proteasome or the autophagy pathway.323,324
Post-translational modifications also determine intracellular
stability of disordered proteins and their degradation. As we
discuss in section 3.6, disordered regions are often post-
translationally modified which, in turn, leads to altered
structures and functions.252,302 In many cases, modifications
regulate protein−protein interactions, which may either protect
disordered proteins from degradation or signal their turnover.
In this manner, modifications can directly modulate intra-
cellular protein abundance and stability. One such example is
p27. Phosphorylation of Tyr88 results in its release from Cdk2
and further phosphorylation of Thr187, which serves as the p27
degradation signal.251 One example of a protective modification
effect is the MAP2 protein, which is rapidly degraded by calpain
in its unmodified form, whereas hyper-phosphorylation
prevents degradation.325 These results underscore the
importance of post-translational modifications in regulating
the intracellular stability of disordered proteins and their
turnover. Thus, several mechanisms influence abundance,
stability and degradation in cells, acting at the level of
transcription, mRNA stability and decay, synthesis and
homeostasis. Because intracellular protein clearance mainly
occurs via ubiquitin-dependent proteasomal degradation and
given that intrinsically disordered proteins are not targeted by
ubiquitination to an appreciable greater extent than ordered
proteins (see section 3.3), this may constitute the most
convincing argument for the comparable in vivo stabilities of
both classes of proteins.287,303,326
3.5. Molecular Chaperones
Protein quality control is an important aspect of cellular life. It
is executed by proteins called molecular chaperones, which
assist in protein folding, monitor and maintain structural
protein integrity, refold misfolded proteins, disentangle
aggregated proteins, and target proteins for degradation.327−329
For these reasons, interest in molecular chaperones and
disordered proteins is closely aligned. In the early days of IDP
research, disordered proteins were considered in vitro artifacts
and an indication of the absence of appropriate chaperones to
help them adopt their “native”, ordered conformations. We
now know that, in vitro, disordered proteins are equally stable
as ordered ones (see section 3.3), that they are not preferred
targets of cellular proteases (see section 3.4) and that many of
them maintain their disordered conformations inside the
crowded cytoplasms of prokaryotic and eukaryotic cells (see
section 2.3). When these notions became more widely
accepted, interest in cellular chaperone functions shifted toward
the prevention of spontaneous IDP aggregation. In fact, a large
portion of recent IDP/chaperone literature addresses the
functional roles of chaperones as cellular anti-aggregation
factors (see section 4). Here, we discuss chaperone functions
that target nonaggregated disordered proteins. We focus on
intrinsic disorder as an inherent structural property of
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chaperones, before we review the role of disordered proteins as
chaperone “substrates”.
3.5.1. Disordered Chaperones. As part of their
surveillance function, chaperones facilitate protein folding and
counteract interactions that result in misfolding.330 In response
to cell stress, chaperones prevent and reverse protein
aggregation and ameliorate refolding. The realization that
disordered protein regions constitute integral parts of
chaperones is largely based on in vitro studies of heat shock
proteins (Hsp). Within the ATP-dependent chaperones,
including the GroEL-GroES system, Hsp70 and Hsp90,
conformational flexibility of their “active sites” confers the
domain motions that comprise the chaperoning cycle.331−334
The disordered C-terminus of Hsp70 for example, functions as
an auxiliary domain in binding misfolded proteins, which
enhances chaperone activity in vitro and in vivo.335 In the
presence of ATP, hydrophobic segments of the disordered
linker domain dock onto the nucleotide-binding domain and
confer interdomain allostery.333,336−338
Extended disordered regions in ATP-independent chaper-
ones such as the small heat shock proteins (sHsp) mediate
interactions with different substrates.339,340 These regions
efficiently cross-link with many cellular proteins, suggesting
that they continuously sample and transiently interact with
folded and misfolded polypeptides in cells.339,340 HdeA and
Hsp33 for instance, undergo order-to-disorder transitions in
response to cellular stress, which concomitantly activates their
chaperoning functions.341,342 Promiscuous chaperone interac-
tions may further destabilize misfolded proteins and smoothen
energy landscapes to enable escapes from local minima, thereby
promoting refolding.343−345 These so-called entropy transfer
reactions transmit conformational entropy to misfolded
proteins.331,340,346−348 Indeed, weak chaperone activities were
reported for many “classical” IDPs such as α-synuclein349,350
and the plant LEA proteins, members of the dehydrin
family.340,348,351 Dehydrins such as ERD10 and ERD14 are
entirely disordered yet prevent temperature-induced aggrega-
tion of several substrates.352 Other LEA proteins, such as
nematode AavLEA1 and plant Em protect organisms from
desiccation-induced aggregation of citrate synthase.351 Surpris-
ingly, however, they fail to protect against temperature-induced
aggregation. These disordered proteins do not bind their
substrates as conventional chaperones, but, instead, act as
physical barriers against unfavorable interactions and are,
therefore, referred to as molecular shields.351,352 Hence,
molecular shielding via disordered regions is another
mechanism by which chaperones reduce unfavorable inter-
actions.
Another long-standing question in cellular homeostasis is
that of protein solubility. Molecular chaperones and disordered
proteins may represent one part of the answer.28 Because IDPs
constitute a significant proportion of the proteome, they might
add to an overall solubility increase by creating extended
hydrated and hydrophilic intracellular environments. A higher
proteome-wide content of disorder may also help to decrease
the load on cellular chaperone system(s), enabling cells to
better cope with different stress conditions. In that sense,
chaperones and IDPs may exert complementary functions and
thereby control cellular homeostasis on multiple levels.
Other classes of “protective” proteins with high contents of
disordered regions are cochaperones, i.e., proteins that interact
with, and activate chaperones.331 Although the role of disorder
in cochaperones is not yet fully understood, some data suggest
that it expands the ability of chaperones to interact with
substrate molecules.328 The chaperoning effect of disorder,
however, is not limited to proteins but also extends to the realm
of RNA and, in fact, is common in RNA chaperones.346,353
RNA chaperones such as the core proteins of flaviviruses
resolve misfolded RNA species, which critically depends on
their disordered regions.354 Upon binding to kinetically
entrapped RNA molecules, many of these chaperones undergo
disorder-to-order transitions. Some partially disordered riboso-
mal proteins, such as L16 and L18 exhibit dual protein and
RNA chaperoning activities, earning them the name Janus
chaperones.355
3.5.2. Disordered Chaperone Substrates. While the
importance of disordered protein contributions to the functions
of molecular chaperones is widely appreciated, considerably less
is known about IDPs as chaperone substrates. Importantly, a
computational study by Hegyi and Tompa concluded that they
do not constitute preferred chaperone targets.322 It is therefore
unlikely that disordered proteins spend more time in
chaperone-bound states than ordered ones.
Several specific chaperone/IDP interactions have been
reported. Aggregation-prone regions of human tau for example,
interact with Hsp72 and Hsc70, two homologous variants of
the Hsp70 family of proteins, as well as with Hsp90.356,357
These tau sites become available and accessible only when the
protein dissociates from microtubules.358 In the presence of
ATP, Hsp70 and Hsp90 bind tau with a dissociation-constant
in the low micromolar range (∼5 μM for Hsp90).357,359 In the
absence of ATP or ADP, the affinity between tau and Hsp70 is
likely to be weaker,356 wheras Hsp90 binding is unaffected.357
Reports of chaperone interactions with α-synuclein are more
controversial. Binding to αB-crystallin was not detected by
NMR spectroscopy, but dissociation constants in the ∼60 nM
range were delineated from surface plasmon resonance
experiments.360−362 The Dobson group reported no binding
of α-synuclein to Hsp70,363 although a later report postulated a
weak interaction.364 α-Synuclein does not bind Hsp70
according to fluorescence anisotropy and pull-down affinity
capture experiments,365 but chemical cross-linking was
confirmed by mass-spectrometry.366 Weak binding to
Hsp90365 and GroEL367 was reported in the absence of ATP
or ADP. Overall, it is difficult to assess whether such isolated in
vitro chaperone interactions with nonaggregated IDPs are
physiologically relevant in vivo.
Another level of complexity may involve cochaperone
interactions with both IDPs, and chaperones. The disordered
C-terminal region of measles virus nucleoprotein for example,
binds Hsp70 with ∼70 μM affinity.368 In the presence of
stoichiometric amounts of the cochaperone Hsp40, the
dissociation constant decreases to ∼50 nM. Thus, cochaper-
ones can modulate IDP-chaperone affinities, which may be
particularly important during translation, when multiple
chaperones and cochaperones line the ribosomal exit tunnel.369
Recent findings suggest that short, aggregation-prone, hydro-
phobic and disordered polypeptides are preferred substrates for
yeast ribosome-associated Hsp70,370 although cotranslational
ubiquitination was not found to be statistically different in
ordered and disordered proteins.371
3.6. IDPs and Post-Translational Modifications (PTMs)
The reversible nature of most PTMs enables eukaryotic
proteins to rapidly adopt different structural and functional
states in response to internal and external cues. These
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modifications greatly expand their repertoire of biological
activities. Based on a proteome-wide PTM analysis it was
suggested that, on average, all human proteins are modified on
at least three sites (Figure 5A).372 This number does not
include N-terminal acetylation, a constitutive chemical
modification in most mammalian proteins, which occurs
cotranslationally when nascent polypeptide chains exit the
ribosome.373 Hence, eukaryotic PTMs represent the single
most important means to dynamically regulate protein function
in a reversible manner.374,375 We often think of PTMs as binary
“switches” that toggle between “on” and “off” states. Such
notions assume that PTMs control all or nothing decisions,
which is not always the case, as we describe in the following
paragraphs. Here, we review the functional and structural
properties of post-translational modifications and show that
disordered proteins and protein regions are particularly well
suited to integrate cellular PTM activities.
3.6.1. IDPs as PTM Targets. Most eukaryotic PTMs occur
in disordered protein regions (Figure 5B), because disorder
provides unrestricted access for modifying and demodifying
enzymes and enables facile interactions with protein modules
that specifically recognize and interact with modified
residues.25,376−382 This property is reflected in the higher
abundance of disordered regions in eukaryotic proteomes and
correlates with the greater complexities of eukaryotic signaling
networks and regulatory pathways. Disorder is overrepresented
in signaling proteins and in proteins controlling gene activity,
such as transcription factors.12,15,383−385 Indeed, the occurrence
of PTMs in disordered proteins exceeds often the three to four
modifications per protein mentioned above.372
Among 50 proteins phosphorylated at 20 or more sites, most
are disordered or contain extended disordered regions.386
Prominent examples are the N-terminal “tails” of histones with
more than ∼40 chemically distinct modifications over a narrow
sequence range (∼35 residues for longest histone H3 tail, for
example).387,388 Histone tail modifications directly affect the
architecture of chromatin and regulate gene activity. Similarly,
the human transcription factor and oncoprotein p53 contains
∼20 annotated PTM sites in its disordered N- and C-terminal
transactivation domains.389,390 In p53, modifications modulate
protein stability, DNA binding and transcription. The
amyloidogenic tau protein represents another prominent
example with multiple modification sites. Intrinsically disor-
dered over its entire length (between ∼350 and 440 residues
depending on the splice isoform), tau contains 75 verified and
85 predicted phosphorylation sites, 45 of which are serines, 35
are threonines and 5 are tyrosines.391,392 Strikingly, only 7 of
these sites are annotated and known to affect microtubule
binding. The function(s) of the other sites are unknown. Given
the large number of tau phosphorylation sites, it remains to be
determined whether all of them are physiologically relevant.
Besides phosphorylation, 50 additional chemically distinct
modifications of tau have been reported.391,392
3.6.2. IDP Diversity and PTMs. By assessing phospho-site
conservation, a recent study suggested that 65% of these sites
might lack unique functional roles.393 This observation raises an
important question about the relative phosphorylation levels at
the individual modification sites. Indeed, most modifications are
present substoichiometrically (occupancy below 50%) (Figure
5C), meaning that roughly equal numbers of substrate
molecules lack the modification.386,394 Given the high
frequency of modifiable amino acids in disordered proteins,395
low “penetrance” can lead to substantial chemical hetero-
Figure 5. Post-translational modifications. (A) Experimental and
predicted phospho-serines (pS), -threonines (pT), -tyrosines (pY),
acetyl-lysines (acK), mono-, di-, or trimethyl-lysines (meK), symmetric
and asymmetric dimethyl-arginines (meR), and O-glycosylated serines
or threonines (O-Gly) according to ref 372. (B) Disorder scores for
pS, pT, pY, acK, meK, and meR (black), and nonmodified residues
(green), according to VSL2B, ref 382 and SwissProt, ref 380. Scores
above or below 0.5 predict disorder or order, respectively. Scores for
O-Gly (*) were calculated as the ratio of O-glycosylation sites in
predicted IDRs over the total number of O-glycosylation sites in 190
proteins. For nonmodified sites, the ratio of serines/threonines in
IDRs was determined over their numbers in the same set of proteins,
ref 379. (C) Left: Fraction of pS/pT sites in disordered and ordered S.
cerevisiae proteins and their relative phosphorylation levels (occu-
pancy), according to ref 386. Right: Average number of proteins per S.
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geneity, which may, in turn, have functional consequences. We
divide the following discussion into two parts. First, we describe
the functional and structural characteristics of modifications
that require dedicated enzymatic activities for their establish-
ment. Second, we outline nonenzymatic modifications.
3.6.2.1. Enzymatic PTMs. As mentioned above, modification
sites in disordered protein regions are easily accessible by
modifying and demodifying enzymes. Kinases and phosphatases
regulate serine, threonine, tyrosine and sometimes histidine
phosphorylation.77,396−398 Acetyltransferases and deacetylases
control lysine acetylation399,400 and methyltransferases and
demethylases mediate lysine and arginine methylation,401,402 to
mention just a few enzymes.
While protein phosphorylation constitutes the most
abundant modification in eukaryotes, the ∼500 kinases that
establish this modification in humans display moderate
substrate site specificities, typically governed by ∼9 residues
flanking the phosphorylatable amino acid.403 Site selection is
encoded and decoded by the kinase domains, whereas distant
docking sites, often in separate protein modules as in the case
of tyrosine kinases for example, create supplementary
recognition features.397 Conversely, Thr-Pro motifs represent
30% of all threonine phosphorylation sites in eukaryotic
proteins, whereas Ser-Pro constitutes ∼20% of all phosphory-
lated serine residues.404 Both motifs serve as minimal consensus
sequences for numerous kinases, including the large families of
cell cycle regulated, mitogen-activated protein kinases
(MAPKs) and the cyclin-dependent protein kinases
(CDKs).405,406 Dephosphorylating enzymes, i.e., protein
phosphatases are ten-times less abundant than kinases,407
which is also reflected in their weaker substrate site specificities,
compared to kinases. Importantly, however, kinase and
phosphatase activities and specificities are often modulated by
subunit interactions, which can either activate or deactivate
these enzymes depending on cellular conditions.397,398,407 In
cells, enzymes of both classes are further regulated by their
spatial context397,407,408 and kinases are often tethered to
subcellular structures such as membranes or occur as parts of
immobile scaffolding complexes.397
Other enzymes that establish post-translational modifica-
tions, such as acetyltransferases and deacetylases, display
similarly weak specificities. No consensus sequence has been
determined for the broadly acting transcriptional regulator and
acetyltransferase CBP/p300. Instead, in vitro studies suggest
that it follows the classical Theorell-Chance “hit and run”
model.409 In vivo, broad substrate specificity may be counter-
acted by localized enzyme action and dynamic subunit
interactions in different holo-enzyme complexes.409,410 Weak
substrate site specificities are also observed for many
deacetylases411 and the methyltransferases G9a and SET7/
9.412,413
Given these weak specificities, certain cellular modifications
may occur transiently on secondary target sites. In line with this
notion, abundant proteins, prone to random encounters with
kinases and phosphatases, are more frequently phosphorylated,
although their individual phospho-site “occupancies” are low.394
Within this group, 8% of all serines and threonines are
phosphorylated in disordered proteins, whereas the number is
only 2.5% in ordered ones. Hence, IDPs likely display greater
modification heterogeneities than ordered proteins.
3.6.2.2. PTM Recognition. As discussed above, disordered
proteins are frequently targeted by cellular modifications. Given
their disordered nature, they are also more versatile in their
capacities to interact with different modification recognition
domains. These domains are typically small, folded protein
motifs (∼120 or fewer amino acids) that bind, albeit weakly, to
modified residues (dissociation constants 10 to 100 μM414), in
a context independent manner,415 although some surrounding
residues confer low-level binding specificity.416 While they
specifically recognize specific modifications, their interactions
are context independent,415 although residues surrounding the
modification sites confer some specificity.416 Examples include
recognition domains that interact with phosphorylated residues,
such as WW-, 14−3−3-, and SH2-domains,417−419 as well as
protein modules that interact with methylated lysines and
arginines, i.e., chromo-, PHD- and Tudor-domains,420 or
acetylated lysines such as bromo-domains.421
Many of the ∼100 human SH2 domains, for example, bind
phospho-tyrosines with dissociation constants above 0.1 μM.422
Similarly, bromo-domains interact with acetylated lysines with
dissociation constants above ∼10 μM. Analogously, the 7
human phospho-serine and phospho-threonine specific 14−3−
3 domain isoforms (up to 15 in plants) are not specific and
interact with target sites within multiple kinase consensus
motifs, such as those of AuroraA/B/C, CaMKII, RSK, PKA and
PKCG.423 Finally, Tudor-, PHD-, and chromo-domains bind
methylated lysines irrespective of sequence context.424−426
3.6.2.3. Nonenzymatic PTMs. The intracellular milieu offers
several ways to establish non enzyme-catalyzed modifications.
Reactive oxygen- and reactive nitrogen-species (ROS and RNS,
respectively), for example, create multiple chemically distinct
modifications, such as oxidized cysteines, and methionines, or
nitrated tyrosines (Figure 5D).427,428 ROS and RNS are natural,
metabolic products of mitochondrial respiration.427−429 In
healthy cells, surveillance mechanisms and scavenging systems
control their cellular levels to protect proteins, and other
biomolecules, from oxidative damage.429,430 ROS and RNS
induced modifications accumulate during aging, as manifested
by higher numbers of oxidized cysteines and methionines, and
covalently cross-linked dityrosines.427,429,431−433 Cellular scav-
Figure 5. continued
cerevisiae cell and their relative phosphorylation levels, according
to ref 394. (D) Chemical structures of post-translational amino
acid modifications at increasing ROS/RNS levels. (E) Left:
Distances between phosphorylated serine/threonine residues in
eukaryotic proteins (black), versus average distances between
random (modified and nonmodified) serine and threonine
residues (green). Adapted with permission from ref 470.
Copyright 2010 Biomed Central Ltd., Springer Science
+Business media Right: Disorder and order at serine/threonine
phosphorylation sites (pS/pT), at pS/pT sites with neighboring
modification sites less than 4 residues apart (near pS/pT sites)
and at pS/pT sites with no other modification site less than 4
residues away (other pS/pT sites). Adapted with permission
from ref 470. Copyright 2010 Biomed Central Ltd., Springer
Science+Business media. Average serine/threonine/tyrosine
phosphorylation sites at oligomer interfaces and noninterface
regions (**). Adapted with permission from ref 469. Copyright
2013 Royal Society of Chemistry. (F) Left: Sensitivity and
robustness of single-, versus multiple-PTM signaling modes.
Right: Switch-like responses result from multiple modifications
in the presence of balanced kinase (Kin) and phosphatase
(Phos) activities.
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enging of ROS and RNS constitutes a process of fundamental
biological importance, and misregulation is often implicated in
human disorders, although it is difficult to determine whether
oxidative modifications are a cause or a consequence of the
disease.427,431,433 In other biological processes, inflammation for
example, ROS and RNS function as signaling molecules, and
modified proteins mediate cellular responses.430 Given the
solvent-exposed nature of most side-chains in IDPs, one may
assume that these proteins constitute preferred scavengers of
cellular oxidative PTMs. However, recent data suggest that this
is not always the case.
Cysteines are most sensitive to oxidation and oxidized
cysteines are often found in folded proteins, especially in
enzyme active sites.427,434 However, cysteine is the second least
abundant amino acid type in disordered proteins (less than
1%)395 and cysteine oxidation is rarely detected in these
proteins.376 The same is true for tyrosine nitration since the
overall abundance of hydrophobic and aromatic residues in
IDPs is low.395 Sequence proximity to charged residues, as well
as enhanced solvent accessibility favors tyrosine nitra-
tion,435−437 which should render tyrosines in IDPs preferred
nitration targets. Indeed, high levels of tyrosine nitration are
found in Lewy body aggregates of α-synuclein438 and the same
modification is detected in the soluble protein under conditions
of cellular oxidative stress.439 Similarly, tyrosine-nitrated tau is
found in brain plaques of Alzheimer’s disease patients and
nitration inhibits tau binding to microtubules.440 Although
nitrated tyrosines generally occur at low abundance and only
0.01% of all tyrosine are nitrated under inflammatory
conditions,435,437 they may serve as important disease factors.
Because postulated mechanisms of amyloid formation involve
nucleation and aggregation-prone seed structures, even low
quantities of potentially harmful IDP variants may trigger
aggregation.437,441 Alternatively, nitrated tyrosines may function
as immunogenic signals that activate inflammatory responses.
Interestingly, many of the tyrosine sites in IDPs that are readily
nitrated in vitro, do not correspond to residues modified in
vivo, indicating that intracellular conditions affect substrate site
selection and/or site-specific repair efficiencies.437,442
Little is known about methionine oxidation on a proteomic
scale. Studies of independent replicates of H2O2 exposed
mammalian Jurkat cells show that methionine oxidation does
not occur randomly, although no particular class of proteins,
nor subcellular compartment are preferentially affected.443
Methionine oxidation does not reach full penetrance and 85%
of the characterized modification sites show oxidation levels of
∼30%. However, a clear sequence bias is evident. Oxidation
does not occur on methionines that are flanked by aromatic or
cysteine residues and it is enriched at sites in the vicinity of
acidic-, basic- and glutamine residues,443 reflecting the bias in
amino-acid composition of IDPs.53 Levels of cellular
methionine oxidation appear to be balanced by endogenous
methionine reductase activities. In vitro, H2O2 mediated
methionine oxidation is less efficient when Lys, Arg, His, or
Pro precede the modifiable amino acid, and solvent exposed
methionines are modified faster than buried residues.443,444
Similarly, methionine sulfoxide reductases are less active when
acidic, or proline residues, enriched in IDPs, precede the
modified methionines and are more active in disordered
regions.443,444 Together, these in vitro and proteomic data
suggest that IDPs constitute preferred substrates for
methionine oxidation. Complete oxidation of all four α-
synuclein methionines results in a decompaction of the
protein,445 inhibits its fibrillization and promotes the generation
of off-pathway species. Given that methinione oxidation occurs
with rather low penetrance under physiological conditions,443
these effects may be mitigated in cells.
Several other oxidative modifications, such as tyrosine
halogenation, dityrosine formation, tryptophan nitration and
carbonylation of various amino acids427 are mediated by
reactive oxygen species that accumulate with aging, impairment
of oxidative stress response pathways and inflammation.
Because many neurodegenerative diseases are age-related and
associated with neuro-inflammation,446 functional roles of
oxidative modifications in these diseases were postulated early
on.440 Open questions remain with regard to timing, abundance
and effects of oxidative modifications and whether they are
causative or symptomatic.
3.6.3. PTMs and IDP-Mediated Signaling. Given the
complexity and heterogeneity of cellular modifications,
especially with regard to chemical diversity, specificity and
penetrance, the notion of global PTM “noise” emerges,
postulating that cellular proteins continuously experience
transient, chemically distinct modifications, many of which
with no biological function. From an analytical point of view,
this situation makes it difficult to discriminate between
meaningful, regulated modifications and coincidental “by-
standers”. In cells, differences in growth conditions and
intracellular environments may further embellish the hetero-
geneity of physiological modification patterns. Here, we discuss
the role of disordered proteins in processing PTM “noise”. We
entertain the idea that these proteins may be particularly well
suited to “buffer” noise and thereby regulate eukaryotic
signaling.
Intrinsic disorder is generally viewed as favoring rapid
association and dissociation,447 while maintaining a balance
between ligand binding specificity and affinity,448,449 and
greater binding partner promiscuity.450,451 Moreover, IDP
mutations have weaker impacts on general protein−protein
interactions.452 IDPs display higher mutation rates than folded
proteins453 (see section 3.2) and several studies suggest that
greater levels of genomic evolvability correlate with larger pools
of mutable IDPs.450,454 These properties are equally important
in cell signaling, which requires transient interactions with
multiple partners, while maintaining high levels of tolerance to
mutagenic alterations.12,383,448,455
A number of signaling pathways exhibit ultrasensitive
responses, meaning that switch-like functional changes occur
only above a threshold of stimulatory signals.456−458
Modification multiplicity on individual target proteins mediates
robust, ultrasensitive responses and low interference from
signaling noise (Figure 5F).459 Intramolecular substrate-site
competition, cooperativity, or stepwise modifications of multi-
ple substrate sites can amplify these responses.460−468 Protein
disorder favors cooperative mechanisms not only because PTM
sites are exposed and easily accessible to modifying and
demodifying enzymes, but also because modified residues can
rapidly engage in novel protein−protein or protein−membrane
interactions and directly alter local or global IDP conforma-
tions. Therefore, cumulative modifications on a single protein
can promote the establishment of additional modifications in a
stepwise manner or ramp up binding affinities to new partners,
once a certain threshold is surpassed. At the same time, such
behaviors may ensure that non biologically relevant mod-
ifications (i.e., noise) do not trigger aberrant signaling activities.
Phosphorylation sites in disordered proteins are often clustered,
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which can enhance multisite cooperativity (Figure 5E).469,470
Following this rationale, low-level PTM noise may actually
improve signaling sensitivity and robustness by allowing faster
responses, without the requirement for positional substrate site
conservation. The higher mutational tolerance of IDPs may
therefore provide an evolutionary advantage for such regulatory
mechanisms.
Substrates of cyclin-dependent kinase 1 (Cdk1), for example,
show low positional conservation of their substrate sites, but a
high degree of net conservation that preserves overall PTM
effects in fast evolving disordered regions.471 Among the many
Cdk1 substrates, one well-studied system, Cdk1 inhibitor Sic1
(the yeast ortolog of human p27), serves as a good example to
outline the concept of graded response behaviors upon
cooperative, multisite phosphorylation events. Sic1 is intrinsi-
cally disordered and contains seven Cdk1 phosphorylation
sites. Phosphorylation of these sites triggers binding to Cdc4, a
member of the ubiquitin ligase complex. Upon Cdc4 binding,
Sic1 is degraded and full Cdk1 activity required for entering S-
phase is established. While Sic1 phosphorylation by Cdk1
occurs cooperatively,472 high affinity Cdc4 binding also requires
double phosphorylation of at least one of three paired
modification sites on Sic1.464,473−475 Therefore, some phos-
phorylation events might occur at low abundance in the
absence of sustained Cdk1 activity, whereas full kinase
activation overcomes the signaling threshold that triggers the
robust biological response.
3.6.4. PTMs and IDP Structures. Another important
aspect of post-translational protein modifications concerns their
ability to modulate protein structure. Whereas PTM-induced
structural changes in folded proteins have been analyzed,476
comparable studies for intrinsically disordered proteins are not
available. Many IDPs undergo disorder-to-order transitions
upon binding to cognate partners and for equilibrium
thermodynamic reasons, binding conformations are often
transiently sampled in their free states, resulting in residual
secondary structure. These kinds of “motifs” have been termed
short linear motifs (SLiMs), molecular recognition features
(MoRFs), prestructured motifs (PreSMos) or anchor
sites.477−480 Given the structural plasticity of disordered
proteins, different modifications or sets of modifications may
modulate their structural propensities in either a positive or
negative way, similar to folded proteins, and thereby exert
important regulatory functions in cells.
3.6.4.1. PTM Effects on Secondary Structure. Several
studies investigated the influence of glycosylation and
phosphorylation on peptide secondary structures. Glycans for
example, can modulate conformations via the formation of new
hydrogen bonds or by steric restriction. These effects depend
on the nature of the glycan and the protein sequence context.
N-glycosylation promotes β-turn conformations,481 whereas O-
glycosylation can increase or decrease α-helix, β-strand, β-turn
or poly proline type II helix propensities.482−489 Phosphor-
ylation can also induce or stabilize α-helical structures via side-
chain salt bridges in cases where phosphorylated serines or
threonines at positions i are preceded or followed by lysines at
positions i−4 or i+4, respectively.490 In another example,
multiple phosphorylation of short peptides derived from the
proline-rich regions of human tau induces poly proline type II
helices,488,491 which is particularly intriguing given the large
number of proline-directed kinases and kinase consensus
sequences.492 Using short model peptides, Andrew et al. and
Elbaum and Zondlo showed that serine and threonine
phosphorylation at internal, or C-terminal helix positions
destabilizes the secondary structure, whereas N-terminal
phosphorylation stabilizes α-helices.489,493 These properties
are often mentioned in relation to secondary structure changes
in response to modifications occurring in vivo, although their
structural impact in physiological environments is less
clear.494−498 Phosphorylated Ser-Pro and Thr-Pro motifs are
further targeted by peptidyl-prolyl isomerases such as Pin1,
which collectively increase the rate of proline cis/trans
interconversion.499 In the absence of these enzymes, serine/
threonine phosphorylation N-terminal to prolines does not
affect cis/trans equilibria.500−503 However, in cells, proline cis/
trans isomers may be differently sequestered by binding
partners, which may, in turn, change equilibrium distribu-
tions.504
Other types of modifications may also affect the structural
properties of disordered proteins. N-terminal acetylation of α-
synuclein for example, increases transient helicity within its first
ten residues (from 10% to ∼30%).505−507 Although this
modification is not strictly speaking a PTM because it mostly
occurs cotranslationally,373 such findings confirm that cellular
modifications may have structural-, and ultimately functional-
consequences.505−508 Considering all possible PTM effects, it is
expected that they also impact the aggregation behavior of
disordered proteins (see section 4).392,509
3.6.4.2. PTM Effects on IDP Compaction. Besides altering
the conformations of IDPs, modifications can also affect their
global appearance. In general, levels of compaction decrease
with net charge.54,55 Therefore, PTMs that introduce charged
entities, such as phosphate groups or neutralize existing
charges, such as lysine acetylation, are likely to modulate the
shapes of disordered protein ensembles. Lower compaction has
been reported for a mutant version of tau that contained six
serine/threonine to glutamic acid substitutions, mimicking
multisite phosphorylation,510 although increased local compac-
tion was observed in the vicinity of the pseudophosphorylation
sites.510,511 Similarly, multisite phosphorylation of Sic1 leads to
compaction of this positively charged protein.512 A decrease of
compaction was observed for α-synuclein upon methionine
oxidation.513 Therefore, these effects often vary from protein to
protein. Similarly, ubiquitination and sumoylation introduce
new interaction surfaces that may mask, reveal, or modulate
IDP structures.514
In summary, we presented an exemplary overview of possible
PTM effects on disordered proteins in physiological environ-
ments. We showed that cellular modifications greatly expand
the chemical heterogeneity of these proteins, which, in turn,
may increase their structural and functional diversity. It is
important to keep in mind that in cells all the scenarios
discussed above occur in a much more complex environment
that offers many additional possibilities for modulatory effects.
3.7. Coupled Folding and Binding
Energy landscapes of disordered proteins are shallow and
contain many local minima,345 enabling them to adopt different
structures when they interact with other macromolecules.515,516
Indeed, many IDPs undergo disorder-to-order transitions upon
binding to proteins, nucleic acids, or lipids.53,347 Given the
abundance of disordered proteins in cells, the physiological
milieu offers ample opportunities for interactions that promote
disorder-to-order transitions, prompting researchers to ask
whether free disordered proteins ever exist in cells, or whether
they only occur as complex-bound, ordered entities.517 If that
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were the case, interacting molecules triggering these transitions
needed to be as abundant as disordered proteins, serving as the
prerequisite for an in vivo world without disorder. For folding
transitions that depend on cell membranes or other abundant
structures, such as the cytoskeleton, this might indeed be the
case. For folding transitions that require protein−protein
interactions the situation is less clear and relative intracellular
availabilities and concentrations come into play. Organelle
transport, intracellular localization and spatial confinement may
additionally impose restrictions onto intracellular binding
events and these spatial parameters may change in response
to different biological activities such as post-translational
protein modifications. Therefore, mixed populations of
disordered and ordered protein states likely reflect realistic in
vivo situations.
In this section, we discuss how different intracellular
environments may affect coupled folding and binding reactions.
We begin by introducing two prevalent models to explain the
thermodynamic and kinetic properties of these events, namely
the induced fit mechanism and conformational selection
(Figure 6A). In the following, we outline how disorder-to-
order transitions can be of biological advantage, and discuss
how coupled folding and binding may occur in cells.
3.7.1. Induced Fit. According to the induced fit model,
disordered proteins engage in initial encounter complexes
through weak interactions. Guided by these interactions, and
the surface properties of their binding partners, they mold into
their final conformations via disorder-to-order transitions
establishing the strong intermolecular contacts of their bound
states. One example to describe an induced fit interaction is the
binding of intrinsically disordered pKID to the folded CBP KIX
domain.518 In the initial encounter complex, the N-terminus of
pKID forms an α-helix (αA), while its C-terminus remains
flexible and disordered (30% transient helicity), and weakly
samples different hydrophobic surface areas on KIX. Eventually,
the C-terminal portion of pKID undergoes an induced fit
disorder-to-order transition and docks onto the KIX domain in
a second, α-helical conformation (αB) forming the final, high-
affinity complex. Transient helicity of the αB region in the
absence of KIX domain binding is only ∼10%, suggesting that
αA formation and binding also induces a substantial increase in
transient helicity of C-terminal pKID residues.
While the pKID-KIX interaction is often cited in reference to
coupled folding-upon-binding reactions, it is not without bias.
Strictly speaking, the helical conformations of pKID in the final
KIX complex mirror its structural tendencies in the free state.
pKID residues corresponding to αA exhibit ∼50% transient
helicity in their free form, arguing that some secondary
structure of the complex is already populated in the absence of
KIX binding.519−521 In fact, the presence of transient αA
features in free pKID may support the second reaction
mechanism of disorder-to-order transitions: conformational
selection.
3.7.2. Conformational Selection. Conformation selection
postulates that free disordered proteins sample the structures of
their bound states and that interacting partners scavenge these
prestructured populations to form complexes.522 Based on this
notion, and provided that interacting partners are abundant,
levels of transient secondary structure determine the rates of
disorder-to-order transitions, as well as the thermodynamic
properties of the respective binding processes. One often cited
example with regard to conformational selection is based on the
work of the late Flemming Poulsen.523 His group established
that the free nuclear coactivator binding domain (NCBD) of
CBP exists in a conformation resembling its structure in the
p160 coactivator (ACTR)-bound complex. They further
determined that NCBD adopts this conformation, described
as a molten globule, ∼90% of the time.524 To evoke an
exclusive conformational selection mechanism is not without
drawbacks. Dogan et al. showed that the NCBD-ACTR
interaction involves a transient priming state, whereas most of
the specific hydrophobic contacts are established after this rate-
limiting encounter, reminiscent of the nucleation-condensation
model in classical protein folding.525 Therefore, this interaction
too requires at least 2 steps, with the first encounter probably
driven by conformational selection, followed by a structural
rearrangement that could easily pass as an induced fit
mechanism.525,526
Figure 6. Coupled folding and binding. (A) Representations of
induced fit and conformational selection mechanisms of coupled
folding and binding reactions. The disordered and ordered ligand is
shown in red (D and O, respectively), the folded binding partner (P)
is shown in gray. (B) Schematic representations of possible differences
between in vitro and in cell free energy landscapes of coupled folding
and binding reactions. (C) Free energy/reaction coordinate profiles of
coupled folding and binding systems and possible in vivo modulations.
Resulting binding free energies (ΔGbinding) may be different.
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These two examples illustrate an important point in the
ongoing induced fit versus conformational selection debate:
The difficulty to clearly separate the two mechanisms. As we
discuss next, the physical boundaries between both scenarios
are diffuse and often depend on the experimental conditions
employed to characterize them. These considerations also set
the tone for the discussion about their physiological relevance
in the context of live cells.
3.7.3. Induced Fit versus Conformational Selection.
Cumulating experimental data conflict with mechanisms of
disorder-to-order transitions solely based on conformational
selection. Even for interactions between ordered proteins,
conformational rearrangements, at least on the side-chain level
are necessary to obtain high affinity complexes.527−529 In
disordered proteins, side-chains display high degrees of
flexibility and their time scales of motions (<10−8 s) are faster
than most diffusion controlled binding processes (>10−7 s).530
The same is true for nucleation-dependent α-helix formations
(<10−7 s).531 According to these considerations, binding via
conformational selection alone is unlikely to result in the
observed high affinity complexes and, as suggested by Zhou and
co-workers, fast conformational sampling appears to favor
interactions along the induced fit model.532 Although transient
preformed secondary structures are frequently observed for
regions that interact with cognate targets,477−479,533−540 IDP-
ligand complexes often contain additional structural features
that are not populated in their free states, exhibiting non
uniform levels of bound IDP flexibility.347,541 Exclusive induced
fit mechanisms have been proposed for some disorder-to-order
transitions,525,532,542−545 whereas mixed mechanisms have been
suggested for others.530,546−548 Given their high degree of
conformational plasticity, disordered proteins may be partic-
ularly prone to mixed binding behaviors exhibiting features of
b o t h i n d u c e d fi t a n d c o n f o rm a t i o n a l s e l e c -
tion.522,537,542,543,545,549−556 As pointed out by Hammes et al.,
solution conditions and protein concentrations additionally
affect the mechanistic properties of disorder-to-order tran-
sitions.557
3.7.4. Disorder-to-Order Transitions in Cells. We
mentioned earlier that intracellular environments contain
large numbers of biological interfaces that can potentially
catalyze disorder-to-order transitions. At the same time, the
physical properties of the intracellular space, including viscosity,
macromolecular crowding, excluded volumes and soft inter-
actions, contribute to the overall characteristics of cellular
binding events (see section 2). We discussed flexibility and
residual structural features as important determinants in
disorder-to-order transitions and both properties are likely
modulated in cells. Levels of transient secondary structure for
example, may increase (i.e., stabilizing) or decrease (i.e.,
destabilizing), either enhancing or reducing contributions to
interactions that involve conformational selection (Figure 6B).
Perhaps more important, these effects may enhance or reduce
binding free energies and thereby improve or weaken molecular
recognition (Figure 6C). These considerations illustrate how
intracellular contributions to disorder-to-order transitions can
have different effects based on the types of interacting species,
the nature of their interaction, and the physical and biological
properties of their surrounding environments. Therefore, it is
difficult to predict how these parameters modulate cellular
disorder-to-order transitions.
It has been suggested that disordered proteins enable faster
protein−protein interactions due to their extended hydro-
dynamic radii and enhanced ligand-capture efficiencies.558
However, this argument is contradicted by the fact that
extended hydrodynamic radii also lead to slower translational
diffusion.447 Moreover, such fly casting mechanisms may be
counterbalanced by in-cell compaction.447,449 Kriwacki and co-
workers provided important insights into how much disorder is
needed for the cellular functions of the cyclin-dependent kinase
(Cdk) regulators p21 and p27.559,560 These two disordered
proteins bind Cdk-cyclins via interactions of their D1 and D2
subdomains. p27 inhibits Cdk2-cyclin A activity and establishes
cell-cycle arrest in G1, whereas p21 broadly inhibits Cdk-cyclin
complexes and elicits arrest at various stages.561 In both p21
and p27, the LH linker domain between D1 and D2 exhibits
helical propensities in its free state559,560 and adopts a fully
helical conformation in the p27:Cdk2-cyclin A complex.561
Mutants of p27 with reduced levels of transient LH secondary
structure fail to elicit G1 cell-cycle arrest.562 Moreover, the
structural flexibility of the p21 LH domain is essential to
efficiently bind Cdk-cyclins and to initiate cell-cycle arrest.
Restrained LH domain mutants elicit partial arrest at the G1-to-
S transition, but no arrest at the G2-to-M transition. Mutants
with shorter LH domains fail to induce cell-cycle arrest, in line
with their inability to bind Cdks.561 Hence, the different
degrees of p21 and p27 disorder specifically tune their binding
affinities and specificities toward Cdk-cyclins in vitro and in
vivo.
Another example of coupled folding and binding is the α-
synuclein interaction with membranes.533 The protein is highly
abundant in the brain and its physiological role is linked to
synaptic vesicle trafficking and membrane fusion in dopami-
nergic neurons.314,563,564 In turn, lipid environments rather
than protein−protein interactions mediate folding transitions of
α-synuclein. In vitro, α-synuclein interacts with negatively
charged lipid vesicles and artificial membranes, such as SDS
micelles and unilamellar vesicles.313,533,565−572 These inter-
actions induce an α-helical conformation of its first ∼100
residues.533 Different membrane environments induce different
helical α-synuclein structures ranging from extended single
helices, to broken double-helical horseshoe conforma-
tions.313,533,565−571 These findings led to the conclusion that
membrane charge, composition and curvature determine the
global structural features of folded α-synuclein. How are these
disorder-to-order transitions mechanistically accomplished? We
can rationalize these coupled folding and binding reactions by
similar combinations of induced fit and conformational
selection mechanisms. In its free monomeric state, the N-
terminus of α-synuclein exhibits α-helical propensities (∼10%),
which it fully adopts in the different membrane-bound states.573
Despite the low abundance of non membrane-bound, helical α-
synuclein molecules, these species may initially interact with
membranes via conformational selection and trigger additional
helical transitions of more C-terminal α-synuclein residues in a
second induced fit step. The observation that α-synuclein binds
different membranes in different α-helical conformations
supports this hypothesis.
In cells, α-synuclein is enriched at presynaptic terminals and
colocalizes with synaptic vesicles, suggesting that the protein
also exists in helical membrane-bound conformations in
vivo.574−578 With respect to α-synuclein’s membrane-mediated
disorder-to-order transition, a recent study by the George
group is of particular interest. In their analysis the authors asked
whether differences in α-helicity affected the colocalization of
α-synuclein with physiological membranes.578 The authors
Chemical Reviews Review
dx.doi.org/10.1021/cr400695p | Chem. Rev. 2014, 114, 6661−67146682
studied the effects of N-terminal α-synuclein truncations and
point mutations in rat primary hippocampal neurons and found
that deletions of N-terminal α-helical residues disrupt
presynaptic localization and result in diffuse axon staining.
They also analyzed a prominent familial point mutation of α-
synuclein, A30P, exhibiting reduced levels of transient helicity
at residues surrounding the mutation site.573 In vitro, A30P
displays severely impaired membrane binding.579−581 They
found similarly reduced membrane colocalization of A30P α-
synuclein in hippocampal neurons, whereas another mutant
with unperturbed secondary structure, i.e., A53T, was not
affected.578 In support of these conclusions, other groups also
observed these effects in yeast cells.582,583
Recent evidence further suggests that N-terminal acetylation
of α-synuclein increases transient helicity from ∼10% to
∼30%.505,506 In agreement with conformational selection
driving the initial membrane encounter, N-terminally acetylated
α-synuclein binds membranes with higher affinity than the
nonacetylated form of the protein.505 Thus, arguing that this
enzyme-mediated cotranslational protein modification enhan-
ces the intrinsic propensity of α-synuclein to interact with
physiological membranes. Agreeing with this notion, α-
synuclein overexpressed in N-terminal acetylation competent
yeast cells, uniformly decorates the cytoplasmic side of the cell
membrane.582,583 By contrast, disrupting the N-acetyltransfer-
ase gene in yeast abolishes α-synuclein membrane staining and
results in diffuse cytoplasmic localization.583 Together, these
results provide compelling evidence for the existence of
membrane-bound pools of α-synuclein under physiological
conditions. Whereas a direct proof of an α-helical in vivo
conformation is missing, these indirect observations support
the notion that membrane-bound α-synuclein exists in helical
conformations in cells.
3.7.5. Fuzzy Complexes. Challenging the exclusiveness of
coupled folding and binding reactions, Fuxreiter et al. proposed
the concept of fuzzy complexes.584 In fuzzy complexes, IDPs
exhibit different extents of disorder in their bound states, and
display dynamic properties in between fully disordered, and
ordered structures. One often cited example of a fuzzy complex
is the interaction between the regulatory region and the
nucleotide-binding domain (NBD) of the cystic fibrosis trans-
membrane conductance regulator (CFTR).585 In this case,
multiple sites of the regulatory region contribute to binding,
each exhibiting transient helical features in their free states.
Even upon binding, these regions remain dynamic and
frequently exchange in the NBD binding site.
Forman-Kay and co-workers studied another example of a
fuzzy complex, the interaction between phosphorylated Sic1, an
inhibitor of Cdk kinases, and the ubiquitin ligase Cdc4.512 Sic1
is degraded in response to multisite phosphorylation,
prompting binding to Cdc4.586 Cdc4 recognizes six different
phosphorylation sites of Sic1 and engages the protein in
transient, disordered interactions. The concept of fuzzy
complexes also offers a means of describing modulatory cellular
effects along a continuum of stabilizing and destabilizing
interactions. In this sense, coupled folding and binding
reactions, disorder-to-order transitions and folded conforma-
tions of disordered proteins and protein regions in complex-
bound states likely exhibit higher degrees of fuzziness in vivo.
4. IDP AGGREGATION
Aggregation of ordered proteins requires initial unfolding.587,588
Because disordered proteins exist as dynamic ensembles of
interconverting monomers, they do not have to unfold to
aggregate.1−3 Therefore, IDPs have long been considered
particularly prone to aggregation. However, not all IDPs
aggregate, and those that do only represent a small fraction of
the disordered proteome. Within this portion, some IDPs
aggregate spontaneously, while others require additional
factors, or defined solution conditions, highlighting the
importance of contextual contributions from native in vivo
environments. In the following paragraphs, we outline cellular
aspects of IDP aggregation and discuss possible roles in
physiology and pathology.
4.1. Aggregation and Disease
Early interest in IDPs was spurred by observations that post
mortem brains of neurodegenerative disease patients contained
high levels of intra- or extra-cellular IDP deposits that were later
shown to be representative of the different pathologies.589,590
Intracellular aggregates of α-synuclein for example, are
hallmarks of Parkinson’s disease (PD), extracellular deposits
of Aβ peptides and intracellular inclusions of the tau protein are
found in Alzheimer’s disease (AD). Insoluble aggregates of the
prion protein are synonymous with Creutzfeld-Jacob’s disease
(CJD), while insoluble fibrils of Huntingtin are characteristic of
Huntington’s disease (HD). In their native states, these
proteins are either fully or largely disordered, whereas they
adopt extended β-sheet structures in their aggregated forms.
Moreover, these aggregates, as well as their deposits in post
mortem tissues, can be stained with iodine, which led to their
initial, wrongful identification as starch deposits (amylum in
Latin) and the creation of the term “amyloid”. Our knowledge
about disordered proteins and amyloids has increased
considerably since those days, but how ordered aggregates
form in complex intra- and extra-cellular environments remains
enigmatic. In the following, we describe how aggregation of
disordered proteins results in cell damage and pathology. We
further discuss how different intracellular environments may
affect aggregation and thereby contribute to disease progression
and prevalence.
Alzheimer’s disease is the most common neurodegenerative
disorder. It is characterized by progressive memory loss and
dementia that arises from tissue damage in the cortex and
hippocampus.591 Cell death coincides with extracellular
aggregation of Aβ peptides and intracellular deposition of the
microtubule-binding protein tau into insoluble amyloid plaques
and neurofibrillar tangles, respectively.592,593 Aβ peptides occur
as 40- to 42-residue proteolytic fragments of the amyloid
precursor protein, which functions in synaptic stabilization and
plasticity. Tau is a 55−62 kDa protein with a role in
microtubule-dependent transport in the nervous system. Both
proteins readily form amyloid fibrils in vitro and in vivo, and
several lines of evidence support their roles in AD.594
Parkinson’s disease is the second most common, age-related
neurodegenerative disorder. It is accompanied by the
progressive loss of dopaminergic neurons of the substantia
nigra pars compacta, which translates into severe motor
problems.595 Pathologically, the disease is characterized by
proteinaceus cytoplasmic inclusions known as Lewy
bodies,595,596 which primarily contain α-synuclein amyloid
fibrils. Aggregation of α-synuclein is one of the underlying
causes of PD,597 and other neurodegenerative disorders such as
multiple system atrophy, and dementia with Lewy bodies, all of
which are characterized by intracellular amyloid inclusions of α-
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synuclein. Accordingly, these diseases are called synucleino-
pathies.16
Creutzfeld-Jakob’s disease, also known as “mad cow” or prion
disease, is a neurological disorder manifested by insoluble
deposits of the prion protein (PrP).598 Prion aggregates are
transmissible and can be passed on similar to an infectious
agent.599 Native PrP (PrPC) is bound to the outer plasma
membrane. The N-terminus of PrP constitutes the intrinsic
disordered part of the protein, whereas the C-terminus is folded
and adopts an α-helical structure.600,601 PrP aggregation
constitutes the key determinant of CJD and a conformational
rearrangement of its C-terminus into β-sheet structures is
responsible for the pathological conversion of PrPc into PrPSc,
the toxic form of the protein. PrPSc is self-propagating and
catalyzes further conversions of PrPC into PrPSc. This process is
strongly influenced by the N-terminal disordered region of
PrPc.602
Expansions of poly glutamine repeats (polyQ) are encoun-
tered in many human disorders, including in Huntington’s
disease. Huntington’s disease is characterized by the formation
of granular and fibrous deposits of the Huntingtin protein in
the nuclei and cytoplasm of several neuronal cell types, leading
to pervasive cell death. Aggregating IDPs that cause this
disorder contain different lengths of polyQ expansions with a
direct correlation between numbers of polyQ repeats and
aggregation propensities.16,603
Type II diabetes is another related amyloid disease that arises
from the loss of pancreatic β-cells and results in an insufficient
insulin response.604 Cell death is thought to occur due to
aggregation of the 37-residue amylin peptide into amyloid
fibrils.605
Many of these pathologies are of neuronal origin and it is
likely that certain biological activities in brain cells contribute to
the prevalence of amyloid phenotypes in this organ. Cellular
oxidative stress and oxidative protein modifications for example,
are risk factors in many neurodegenerative disorders.392,606,607
Indeed, the brain is particularly vulnerable to oxidative stress,
because it consumes approximately one-fifth of the inspired
oxygen and metabolizes ATP at high rates.608,609 Considering
that 5% of all oxygen consumed by cells is converted into
reactive oxygen species (ROS), levels in the brain are higher
than in other tissues. In response, the brain has evolved several
mechanisms to deal with elevated amounts of ROS, but
whenever an imbalance between ROS production and clearance
exists, oxidative damage may lead to protein oligomerization
and/or the impairment of protein homeostasis. Many of the
age-related characteristics of these diseases underscore the
plausibility of such scenarios. Here, we discuss cellular aspects
of disordered protein aggregation using α-synuclein as an
example.
Whereas α-synuclein is abundantly expressed in various parts
of the brain,610 intracellular aggregation and neuronal damage is
primarily, and first manifested in dopaminergic neurons.597
These observations suggest that the biological makeup of these
cells contributes to aggregation. Additionally, most sporadic
cases of PD occur late in life, enforcing the notion that age, and
age-related cellular processes constitute important disease
factors. Abnormal accumulations of cytosolic dopamine for
instance, produce highly reactive intracellular radicals and
quinone derivatives with great oxidative potential that can
readily oxidize α-synuclein in vitro and in vivo.611−614 At the
same time, systems that protect cells against oxidative damage,
such as glycogen synthase kinase 3β (Gsk3β), mitogen-
activated protein kinases (MAPKs), superoxide dismutase
(SOD) and catalases display age-related declines of their
activities.615 In turn, co-occurrence of both effects may render
an abundant, intrinsically disordered protein such as α-
synuclein particularly prone to oxidative damage, and increase
intracellular accumulations of toxic species forming amyloid
fibrils. Experimental evidence supports such multifactorial
scenarios for PD and many other neurodegenerative disor-
ders.616
4.2. Functional IDP Aggregates
IDP aggregation and amyloid formation are usually linked to
pathological conditions. However, recent evidence suggests that
IDP amyloids can have physiological roles in prokaryotic and
eukaryotic cells.617 The E. coli protein curlin forms amyloids in
vivo, which enable bacteria to colonize epithelial surfaces and
develop biofilms, two properties that provide survival
benefits.618 In the yeast S. cerevisae, functional amyloid
aggregates of the prion-like partially disordered proteins
Ure2p and Sup35p have been reported.619 Ure2p binds
Gln3p and prevents transcription of genes that regulate cell
growth under low nitrogen conditions. Aggregation of Ure2p
disrupts its interaction with Gln3p and enables cell growth and
adaptation to nitrogen deprivation. The unrelated protein
Sup35p acts as a release factor during translation termination,
and its activity is lost upon amyloid formation.620 Once Sup35p
aggregates, RNA polymerase reads through stop codons, which
results in greater protein diversity and the generation of new
protein activities that are beneficial for survival. Aggregation of
Ure2p and Sup35p are mediated by their disordered,
asparagine- and glutamine-rich N-termini.621 Related functional
amyloids have also been reported in mammalian cells.
Disordered Pmel17 forms amyloid-like fibrils in specialized
organelles of epithelial cells called melanosomes. These
structures act as polymerization seeds for small molecules
forming melanin fibers that protect cells from UV and oxidative
damage.622 Pmel17 aggregation also prevents melanin-asso-
ciated toxicity by sequestering intermediate on-pathway species
in the course of polymer formation. A disordered repeat
domain that is rich in proline, threonine and glutamic acid
residues drives aggregation,623,624 in a tightly controlled
manner.622 These examples underscore the functional
importance of disordered protein amlyoids in providing
organisms with benefits for certain growth, and metabolic
conditions.
So far, we outlined disease-related aggregation of disordered
proteins and introduced the concept of functional amyloids. In
the following paragraphs, we describe molecular mechanisms
leading to aggregation in vitro, and outline factors that likely
influence aggregation in cells. Specifically, we discuss how
physical and biological properties such as macromolecular
crowding, intracellular viscosity, post-translational protein
modifications and ligand binding affect aggregation in vivo.
4.3. Mechanisms of IDP Aggregation
Despite their great divergence in sequence, size and native
conformations, certain aggregation characteristics of disordered
proteins are surprisingly similar. Most mechanisms entail initial
steps of native ensemble perturbations that produce partially
folded intermediates with higher aggregation propensities
(Figure 7A).16 Intermolecular associations then lead to early
oligomeric species, often rich in β-sheet structures that rapidly
convert into proto-fibrils. Eventually, proto-fibrils assemble into
elongated structures of mature amyloids.625−627 The rate-
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limiting step in many of these processes is the formation of
early oligomeric species acting as aggregation seeds, out of
which proto-fibrils and fibrils grow in a nucleation-dependent
fashion.625,627 Equations 1 and 2 provide simplified representa-













P denotes the protein, i is the number of protein molecules
that assemble in the aggregation seed and knuc, kpol and kdpol are
the nucleation, polymerization and depolymerization rate
constants, respectively. Accordingly, monomeric proteins are
continuously consumed by initial oligomeric species that
eventually extend into mature amyloid fibrils. More detailed
mechanisms have been reported, some of which depend on the
nature of the aggregating protein or on specific aggregation
conditions.602,628−630 Several studies aimed at characterizing
on-pathway species in vitro and the structural properties of
early Aβ, α-synuclein and amylin oligomers have been analyzed
to great detail.631−637 Typically, they display spherical shapes
and contain 10−50 monomers that interact in chain-like proto-
fibril conformations, often arranging into annular, pore-like
structures (Figure 7A-G).637−644 Higher-order fibrils are
insoluble and stain positive for dyes such as Congo red and
Thioflavin T.645 They typically comprise 2 to 6 proto-filaments,
with diameters of 2−5 nm and continue to form rope-like
structures with diameters of 10−30 nm. Individual proto-
filaments are rich in β-sheets that mostly align perpendicular to
the extended fibril axis.646,647 Different factors increase or
decrease the in vitro aggregation rates of disordered proteins,
some by stabilizing early oligomeric or prefibrillar species.
Interactions with binding partners, post-translational protein
modifications and intracellular macromolecular crowding
conditions exert additional effects. In the following paragraphs,
we analyze these contributions with respect to aggregation and
fibrillation in cells and tissues.
4.4. Aggregation and Macromolecular Crowding
As outlined in section 2.1, intracellular environments and
extracellular fluids contain large amounts of macromolecules,
reaching concentrations of up to 300−500 g/L, including
proteins, nucleic acids, lipids, glycans, metabolites, and solvated
ions.114,648 Together, these species occupy a defined fraction of
the intracellular space and make it unavailable to other
molecules.649−651 They also determine intracellular viscosity
(see section 2.3).652−654 One general conclusion from several
studies is that macromolecular crowding stabilizes compact
protein structures.650,655 Because partially folded intermediates
constitute key aggregation species,588,656−659 macromolecular
crowding is thought to enhance aggregation. Viscosity, by
contrast, is expected to exert the opposite effect, because it
mainly interferes with diffusion-controlled processes, such as
the addition of monomers to preexisting proto-fi-
brils.649−651,655,660−662 Accordingly, net in vivo effects of
these opposing contributions are difficult to predict, because
they depend on the geometries, concentrations, and surface
properties of both the aggregating species and the macro-
molecules that define the crowded environment.
Several studies dissected the individual contributions of
crowding and viscosity to IDP aggregation. Enhanced
aggregation of α-synuclein for example, was observed under
crowded in vitro conditions at PEG, BSA, lysozyme, Ficoll, and
dextran concentrations ranging from 100 to 150 mg/mL (Table
2).660,661,663 In these studies, aggregation-enhancing effects
were attributed to a selective decreases in the lag-phases of the
respective aggregation processes, indicating that the formation
of early oligomers is favored under crowded conditions. At
higher concentrations of crowding agents, these effects were
less pronounced, supporting the notion that higher viscosity
slows down diffusion-controlled additions of monomers to
preexisting oligomers and proto-fibrils. This hypothesis was
independently confirmed in solutions of 40% glycerol, which
severely impaired α-synuclein aggregation.661 Crowding has
also been shown to modulate the aggregation behavior of Tau
and the human prion protein.664,665 Increasing amounts of
Ficoll and dextran enhanced aggregation in a concentration
dependent manner (4-fold and higher at 200 g/L). In vitro,
crowding further prompted fibrillation of GSK3-phosphory-
lated Tau, which does not normally occur under comparable
dilute conditions. Similar aggregation-promoting effects in
crowded in vitro solutions were also reported for Aβ peptides,
amylin, tau and the prion protein,666,667 and for folded proteins
under denaturing conditions, such as core histones, S-
carboxymethyl-α-lactalbumin, β-lactoalbumin and human apo-
lipoprotein CII.660,668,669 Crowding can also affect the
morphologies of mature amyloid fibrils. In some intances,
identical fibrils are formed under dilute and crowded
conditions,664,665,670 whereas different shapes and structures
such as shorter fibril lengths,664,665 or higher numbers of
branching sites are observed in other cases.661 These results
indicate that cellular conditions and activities, including post-
Figure 7. Amyloid cascade. (A) Stages of amyloid formation. In the
nucleation phase, IDP monomers aggregate via partially folded
intermediates into soluble oligomers. During the exponential growth
phase, oligomers assemble into high-molecular weight proto-fibrils,
into which monomers are incorporated. In the stationary phase, proto-
fibrils mature into amyloids. (B−D) Transmission electron microscopy
(TEM) and (E−G) atomic force microscopy (AFM) images of Aβ
aggregates. Structures of mature amyloid fibrils (B and E) and
coexistence of linear (yellow) and annular (white) proto-fibrils (C).
AFM of linear and annular proto-fibrils (F and G) and TEM of
annular oligomers (D). Panels B-G adapted with permission from refs
641−644. Panels B−D, Copyright 2003 Elsevier; Panel E, Copyright
2005 FASEB; Panel F, Copyright 2003 American Chemical Society
and Panel G, Copyright 2005 US National Academy of Sciences.
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translational protein modifications and biological interactions,
likely modulate in vivo aggregation kinetics and aggregate
morphologies.
4.5. PTMs and Aggregation
We outlined how unrelated disordered proteins can form
amyloid fibrils of strikingly similar morphologies. However, not
all IDPs aggregate into amyloids and even for those that do,
their rates of fibrillation vary greatly. An IDP’s sequence, its
amino acid composition and the positional clustering of
individual amino acids affect its aggregation, because these
factors influence the global and local physicochemical proper-
ties, including hydrophobicity, net charge, dynamic character-
istics and the propensities to populate transient states of
secondary structure.589,671 As we discuss in section 3.6, IDPs
constitute preferred in vivo targets for post-translational
modifications and these may, in turn, modulate aggregation.
We use α-synuclein, Tau and other disease related IDPs as
examples to discuss some of these aspects.
Early analyses of α-synuclein deposits in PD patients’ brains
showed that ∼90% of the protein is phosphorylated at Ser129,
whereas only 4% of cytosolic α-synuclein is modified.672−674 It
was established later that phosphorylated Ser87 constitutes
another pathological hallmark of intracellular α-synuclein
inclusions.675 These results led to the hypothesis that
phosphorylation promotes aggregation in vivo. In vitro studies
of Ser129 and Ser87 phosphorylated α-synuclein revealed that
the protein adopts a more extended structure, which supports
the notion that phosphorylation may expose the aggregation-
prone, hydrophobic nonamyloid component (NAC) region to
intermolecular interactions.675−679 Surprisingly, in vitro aggre-
gation of Ser129, and Ser87 phosphorylated α-synuclein is




kineticsb main species refs
macromolecular crowding and viscosity:
PEG (150 g/L) enhancement
(∼10-fold)
amyloid fibrils 661, 663
dextran (150 g/L) enhancement
(∼2-fold)
amyloid fibrils 661, 663
Ficoll 70 (150 g/L) enhancement
(∼5-fold)
amyloid fibrils 661, 663
Ficoll 400 (150 g/L) enhancement
(∼5-fold)
amyloid fibrils 661, 663
BSA (60 g/L) enhancement
(∼7-fold)
amyloid fibrils 661, 663
lysozyme (50 g/L) enhancement
(∼5-fold)
amyloid fibrils 661, 663
glycerol (40%) enhancement
(∼3-fold)
amyloid fibrils 661, 663
glycerol (50%) enhancement
(∼1-fold)
amyloid fibrils 661, 663
glycerol (60%) no fibrillation n.d.h 661, 663
post-translational modifications:








Tyr125 phosphorylation no change amyloid fibrils 679
Met-oxidation no fibrillation soluble oligomers 700
Tyr-nitration no fibrillation spherical aggregates 696, 697
monoubiquitination: 694
Lys10 no change amyloid fibrils








Tetra-Ub- Lys12 no fibrillation large, nonfibrillar
aggregates
692
Sumoylationd no fibrillation amorphous
aggregates
693
4-hydroxy-2-nonenale no fibrillation monomers/soluble
oligomers
695
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amyloid fibrils 687, 722
Mn(II), Fe(II), Zn(II)
(1:1)
no change amyloid fibrils 721
Ca(II) (10:1) n.d.h spherical oligomers 730




















EGCG (1:1)g no fibrillation spherical aggregates 746
theaflavins no fibrillation spherical aggregates 753

















HspB8 (1:1) no fibrillation spherical aggregates
Hsp 70 (1:10) no fibrillation monomers
Hsp104 (1:400 -ATP) no change amyloid fibrils 758
Hsp104 (1:400 +ATP) inhibition
(∼2-fold)
amyloid fibrils
Hsp104 (1:40 + ATP) no fibrillation amorphous
aggregates
757
aAggregation is defined as the formation of Thioflavin-T (ThT)
positive amyloid fibrils. bQuantification based on the half-time (t1/2) of
in vitro aggregation. Each condition was compared to the aggregation
rates of α-synuclein control samples. cLonger incubations produced
ThT positive aggregates that were morphologically different from non
phosphorylated control samples. dComplete sumoylation at Lys96 and
Lys102. eAddition of up to six 4-hydroxy-nonenal molecules.
fMetal:protein ratios are given in parentheses. g(−)-Epigallocatechin-
gallate. hn.d. = not determined
Chemical Reviews Review
dx.doi.org/10.1021/cr400695p | Chem. Rev. 2014, 114, 6661−67146686
severely impaired (Table 2). The increased net charge and
electrostatic repulsions between α-synuclein monomers were
put forward as explanations for these inhibitory effects.675,678 In
line with these arguments, a Ser129-to-alanine mutant of α-
synuclein displays enhanced aggregation tendencies in vitro and
in vivo.680,681 This example illustrates the difficulties to
correlation with changes in in vitro aggregation behaviors to
effects observed in vivo. Do higher levels of Ser129
phosphorylation in α-synuclein deposits reflect higher intra-
cellular aggregation tendencies? Maybe aggregated α-synuclein
constitutes a better kinase substrate than the monomeric
protein and phosphorylation occurs after aggregation? Perhaps
aggregated and nonaggregated species are equally good kinase
substrates, but only nonaggregated α-synuclein is efficiently
dephosphorylated by cellular phosphatases? Maybe phosphor-
ylation of α-synuclein increases its affinity to Cu and Fe,682
which are known to promote aggregation?625,659,683
Unlike phosphorylation, truncations of α-synuclein correlate
with enhanced aggregation in vitro and in vivo. C-terminal
truncations are found in intracellular α-synuclein depos-
its672,684−686 and they aggregate more readily in vitro (Table
2).52,687−690 Indeed, removing C-terminal parts of the protein
produces aggregation prone species with a decrease in net
charge and an increase in hydrophobicity, as well as critical
perturbations of autoinhibitory conformations that counteract
aggregation of full-length α-synuclein.676,677 Aggregated α-
synuclein isolated from post-mortem PD patients’ brains,
exhibits a number of nonenzymatic and oxidative stress-
associated modifications, such as tyrosine nitration, methionine
oxidation and lipidation.689 Many of these modifications were
carefully investigated given their prominence in the dis-
ease.607,609,691−695 Nitration of monomeric α-synuclein, for
example, produces partially folded species that readily aggregate
into off-pathway oligomers, inhibiting amyloid formation
(Table 2).696,697 However, when nitrated protein is added to
unmodified α-synuclein, it triggers aggregation and amyloid
formation, even at substoichiometric concentrations.698 By
contrast, higher amounts of nitrated α-synuclein inhibit
fibrillation. Based on these results, Uversky et al. proposed
that seed formation and growth comprises two independent
events.696 Similarly, α-synuclein methionine oxidation induces
soluble oligomers that do not aggregate into amyloid fibrils in
vitro, acting as effective fibrillation inhibitors (Table
2).607,699,700 Similar to the reported phosphorylation effects,
these in vitro studies must be considered with caution because
different outcomes may be observed in vivo in the presence of
other synergistically or antagonistically acting factors.701 Serine
phosphorylation, tyrosine nitration and methionine oxidation
also decrease the avidity of α-synuclein membrane interactions,
which may result in abnormally high concentrations of cytosolic
protein and enhanced aggregation.702−704
Tau hyperphosphorylation inhibits microtubule binding and
thereby contributes to the formation of neurofibrillar tangles in
the course of Alzheimer’s disease.705,706 In turn, overexpression
of Asp/Glu-phosphomimetic Tau mutants in PC12 cells
recapitulates some of the phosphorylation-dependent neuro-
toxic phenotypes.707 In vitro experiments also showed that
phosphomimetics had opposing effects on Tau aggregation,
which depended on the targeted protein region. While N-
terminal Asp/Glu replacements suppressed aggregation, C-
terminal substitutions enhanced aggregation.392,708,709 Other
modifications, such as tyrosine nitration and proteolytic Tau
processing, often observed in post mortem AD patients’ brains,
also promote aggregation.392,710−713 Similarly, Aβ-oxidation
enhances fibrillation.714
In the case of the Huntingtin protein, N-terminal Ser to Asp
substitutions at positions 13 and 16 reduce aggregate formation
in vitro and in vivo, and result in neuroprotective phenotypes in
mouse models of HD.715,716 In line with these findings, in vitro
experiments revealed diminished aggregation propensities of
Thr3-, Ser13-, and Ser16-phosphorylated protein.716,717 In turn,
Mishra et al. hypothesized that phosphorylated or mutant forms
of Huntingtin failed to form α-helical oligomers, critically
required as seed structures for aggregation to occur.509,716
Together, these results underscore the importance of cellular
post-translational modifications in defining the aggregation
behaviors of IDPs in cellular environments.
4.6. Ligand Interactions and Aggregation
Ligand interactions can similarly affect the aggregation
properties of disordered proteins. A myriad of IDP-ligand
interactions have been described that promote or inhibit
aggregation. Among them, physiological IDP-metal interactions
are of particular interest, because of the strong link between
cellular metal homeostasis and neurodegenerative disor-
ders.609,625,718−720 Cu for instance, was identified as a potent
enhancer of α-synuclein, Aβ and tau oligomerization and/or
fibrillation.718,721−724 Fe, Zn, Mn, and Ca are additional risk
factors in several neurodegenerative disorders and they
promote aggregation (Table 2).62,659,725−730 The mechanisms
by which these metals act often involve alterations in the
structures of disordered proteins, either by direct binding or via
oxidation.625,724,731 Metal binding affects the net charges of
IDPs, which may, in turn, promote structural changes that
expose hydrophobic regions and lead to aggregation.659,724
Metals may also induce secondary modifications such as
methionine oxidation or dityrosine cross-linking and thereby
trigger oligomerization.625,699,724 Besides metals, other physio-
logical ligands such as polyamines, dopamine, or other oxidized
cathechols, glycosaminoglycanes, nucleic acids, lipids and
membranes may additionally promote aggregation.75,732−743
On the other hand, ligands may also inhibit aggregation (Table
2).744−753 Many of these studies provided important insights
into different aggregation processes. Collectively, they
reemphasize the notion that exposed, hydrophobic IDP
residues function as key aggregation determinants and that
aromatic π−π stacking interactions are instrumental for fibril
formation, thereby offering clues for therapeutic interven-
tion.748,749,751,754,755
IDP interactions with proteins are worth noting. Cellular
chaperones for example, often protect cells from deleterious
effects of spontaneous aggregation (see section 3.5)331 and
their roles in aggregation have been studied extensively.
Chaperones such as the heat shock proteins Hsp20, Hsp70,
Hsp90 and Hsp104, as well as TRAP1 prevent α-synuclein
aggregation and exert neuro-protective effects in several cell and
animal models of PD (Table 2).362,756−758 Hsp70 inhibits Tau
aggregation in vitro and decreases neurotoxicity in live
cells.759,760 Indeed, elevated levels of intracellular Hsp70 and
Hsp90 diminish Tau deposits and enhance microtubule
binding.761 Cellular Hsp40 and Hsp70 modulate the
aggregation behavior of Huntingtin.762 Atomic force micros-
copy experiments revealed that these chaperones impair the
formation of spherical and annular oligomers of expanded
polyQ-tract Huntingtin, which correlates well with their generic
roles in repressing intracellular potein aggregation and
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cytotoxicity.763 Besides ATP-dependent chaperones, members
of ATP-independent chaperones, such as αB-Crystallin and
clusterin, were shown to inhibit fibrillation of Aβ pepti-
des.764,765 In most of these cases, chaperone-mediated
antiaggregation activities result from direct interactions with
target IDPs or via sequestration of early oligomeric species and
the prevention of amyloid maturation.362,762,764,765 In cells,
chaperones likely also function to clear aggregated species via
chaperone-assisted autophagy or by proteasomal trafficking and
degradation.761,762 These interactions exemplify the diversity of
biological processes that affect protein aggregation in
physiological environments.
4.7. Aggregation in Cells
As discussed above, macromolecular crowding, cellular post-
translational modifications and ligand interactions affect
aggregation in vitro. Given the numerous specific and
unspecific interactions that disordered proteins experience in
intra- and extra-cellular environments, aggregation processes
are modulated in ways that in vitro experiments cannot fully
recapitulate. Early transmission electron-microscopy studies on
amyloids extracted from post-mortem tissues revealed that their
overall β-rich structures are similar to fibrils grown in
vitro.766−771 High-resolution methods such as electron para-
magnetic resonance (EPR)-, and solid-state nuclear magnetic
resonance (NMR)-spectroscopy later showed that despite these
overall similarities, in vitro and in vivo aggregates display
different morphologies.24,772,773 When recombinant Aβ (1−40)
was seeded with proto-fibrils from AD patients, different
structural arrangements of monomers in the amyloid core and
novel side-chain interactions within the strand-bend-strand
motifs emerged.774 The Tycko group further showed that
amyloid fibrils grown in vitro from physiological Aβ seeds
display polymorphisms that are AD patient-specific (Figure
8).775 These findings indicate that native Aβ amyloids have
structural and/or biochemical features that modulate the
outcomes of in vitro aggregation processes. Different fibril
polymorphisms were also observed for Huntingtin aggre-
gates.776−778 In situ Fourier-transform (FT)- and synchrotron
infrared (FTIR) microspectroscopy experiments on mice and
human brain slices confirmed the presence of alternate
Huntingtin conformations containing different extents of
secondary structure (see section 5.4). They also showed that
aggregate morphologies depended on the lengths of polyQ-
tract motifs, subcellular aggregate localization and the affected
brain regions.776
Ignatova and Gierasch et al. investigated how different
cellular conditions modulated the aggregation kinetics and
amyloid structures of a Huntingtin-53 exon 1 fusion protein in
E. coli (53 polyQ-repeats).779,780 Their data showed that
nonamyloidogenic, amorphous aggregates formed in the
presence of osmolytes, such as TMAO and proline. By contrast,
glycerol and glycine-betaine prompted the formation of classical
amyloid structures.779 In another study, Morimoto et al.
followed the aggregation of a Huntingtin-78 exon 1 fusion
construct in HeLa cells.781 Their results indicated that fibril
formation occurred via compact polyQ-cores onto which
monomers were progressively added, thus confirming previous
models of in vitro aggregation.
Fluorescence imaging is often used to study cellular
aggregation of disordered proteins (see section 5.3). A recent
application analyzed the behaviors of Aβ (1−40) and Aβ (1−
42) peptides in HeLa and SH-SY5Y cells (Figure 9).782
Although Aβ aggregates typically form in the extracellular
space, new evidence suggests that intracellular deposits are also
involved in pathogenesis.783,784 Indeed, exogenously added
oligomeric and fibrillar Aβ (1−42) peptides were detected in
the cytoplasm within 1 h of incubation.782 While most of these
fibrils displayed in vitro-like lengths and diameters, ∼10%
exhibited curvatures and distortion angles similar to amyloid
fibrils from Alzheimer’s disease patients.774 In the case of Aβ
(1−40) peptides, only small oligomeric species were detected,
in agreement with the reduced aggregation propensities of
these species.609
Similar fluorescence imaging techniques were employed to
study intracellular aggregation of α-synuclein.785 Biarsenic
fluorescence labels were coupled onto the protein to enable
spatially resolved, real-time aggregation monitoring in neuronal
and non-neuronal SH-SY5Y and HeLa cells, respectively. In situ
measurements revealed that α-synuclein distributed evenly
throughout the cells at early time points, whereas it
Figure 8. Amyloid polymorphisms. (A and B) TEM images of Aβ
fibrils grown in vitro from pathological seeds of two Alzheimer’s
disease patients. Yellow arrows point to fibrils with reduced diameters
and periodic twists, not observed when grown from seeds of patient 1.
(C) Superposition of two-dimensional, 13C−13C solid-state NMR
spectra of patient 1 (red) and patient 2 fibrils (blue). Labels indicate
cross-peak assignments for patient 2 fibrils. Reprinted with permission
from ref 775. Copyright 2013 Elsevier.
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accumulated in cytoplasmic inclusions after 48 h. ThioS-
staining subsequently confirmed that these deposits contained
amyloid signatures. Förster resonance energy transfer (FRET)
experiments further showed that aggregates displayed greater
degrees of heterogeneity than in vitro samples and a more
compact architecture, which was attributed to steric intra-
cellular confinement. A detailed investigation of these cellular
α-synuclein aggregates revealed that they contained diameters
ranging from 40 to 200 nm, resembling those of large
prefibrillar species observed in vitro (Figure 9B).786−788 Similar
experiments in the presence of FeCl3 revealed larger numbers
of intracellular deposits.785 In-cell aggregation of α-synuclein
was also studied with novel FRET-based sensors that exploit
the intrinsic fluorescence properties of amyloid-protein
cores.789 Using such tools, these authors reported that α-
synuclein aggregation occurred faster in SH-SY5Y cells than in
vitro (Figure 9C,D),782 which they interpreted as an indication
for ce l l type-spec ific contr ibut ions to aggrega -
tion.660,661,734,790,791 No intracellular aggregation of β-synuclein
was observed in SH-SY5Y cells. In C. elegans, α-synuclein
displays reduced aggregation propensities and forms oligomeric
structures rather than characteristic amyloid fibrils (Figure
9E,F).789
Having discussed several lines of evidence supporting the
notion that IDP aggregation in vitro and in vivo follows similar
nucleation-dependent pathways that populate intermediate
proto-fibrillar states, we note that the final outcomes of these
reactions, especially with regard to their kinetics and the
morphologies of the resulting species, may be strongly
influenced by specific cellular contributions. Following, it is
critically important to choose suitable cell and animal models to
study these processes in physiologically relevant environments.
The advent of technologies to generate such appropriate
cellular systems for studying IDP aggregation, such as induced
pluripotent stem cells (iPSC), offers exciting new possibilities
in this direction.792−794
5. THEORETICAL AND EXPERIMENTAL METHODS TO
STUDY IDPS
In this section we discuss methods to study the structural and
functional properties of disordered proteins in cellular environ-
ments. These include in silico molecular simulations (section
5.1), high-resolution in-cell NMR spectroscopy (section 5.2),
fluorescence imaging methods (section 5.3) and Fourier-
transform infrared (FTIR) microspectroscopy (section 5.4).
5.1. Molecular Simulations
Molecular simulations are an integral part of IDP investigations
and they have been used extensively to simulate the structural
properties of disordered proteins (for reviews see refs 20, 56,
544, and 795). While molecular simulations are always subject
to concerns about how well they reflect reality, the following
features make them attractive vehicles both for exploring the
behavior of disordered proteins and for modeling biomolecules
in general. First, in simulations, all molecules are directly
visualizable and there is no need to modify them to observe
their behavior. Second, factors that might govern particular
types of behaviors can often be adjusted directly without
affecting other aspects of the system. For example, to
unambiguously assess the contributions made by electrostatic
interactions, a simulation can be carried out with all
electrostatic interactions switched off (i.e., by setting all partial
charges to zero) and compared with identical simulations in
which electrostatic interactions are present. Moreover, since
such adjustments can be made at the discretion of the
simulator, i.e., switching some electrostatic interactions off
while leaving others on, it becomes possible to dissect the
contributions of individual molecules, residues, or atoms in a
way that is not achievable in experiments. Third, and of direct
relevance to modeling intracellular environments, the simulator
can choose which molecules to include in the system and in
what concentrations. Hence, there are no unknown compo-
nents or quantities complicating the understanding of the
resulting behaviors.
All of these advantages are to be weighted against two
principal disadvantages of molecular simulations. The first one
Figure 9. Intracellular morphology and aggregation kinetics of
example IDPs. Super-resolution microscopy images of in vitro and
in HeLa cell aggregates of Aβ peptides (A) and α-synuclein (B).
Arrows and arrowheads denote fibrillar and small oligomeric species.
Insets show intracellular peptide/protein localization. Aggregation
kinetics of yellow-fluorescence protein (YFP)-coupled α-synuclein in
vitro (C), in SH-SY5Y cells (D) and in C. elegans (E), as determined
by single photon counting fluorescence lifetime microscopy. Shorter
fluorescence lifetimes indicate more aggregated α-synuclein. (F) Time
evolution of α-synuclein YFP fluorescence in the three systems.
Reprinted with permissions from refs 782, 787, and 789. Panel A,
Copyright 2011 American Chemical Society; panel B, Copyright 2012
Elsevier; panels C−E Copyright 2011 WILEY-VCH Verlag GmbH &
Co.
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concerns the accuracy of the energy functions used to describe
intra- and intermolecular interactions.544 When these are
inaccurate or imbalanced, it is possible that simulated behaviors
have little relation to reality. The second one is the problem of
“sampling”. Since biomolecular systems are capable of assuming
many different configurations it is critical to sample them in a
meaningful way. In many cases, this issue can be addressed by
“brute force”, i.e., by running a single simulation for a very long
period of time or by running many short simulations in parallel.
Good examples of the power of brute force approaches are
provided by recent molecular dynamics simulations of protein
folding carried out with the revolutionary Anton super-
computer developed by Shaw and co-workers.796−799 In other
cases, more efficient ways of sampling might be required, i.e.,
replica-exchange techniques.800−802 Because we discuss cellular
aspects of intrinsically disordered proteins, we focus on
simulations of intracellular environments. Readers interested
in simulations of IDPs alone are referred to recent re-
views.20,56,544
5.1.1. Molecular Simulations of the Prokaryotic
Cytoplasm. A number of groups have devised computational
strategies to recapitulate the physical properties of the E. coli
cytoplasm in silico. In 1996, Bicout and Field performed the
first dynamic simulation of this kind.803 They assumed a
mixture of three different types of macromolecules: ribosomes,
tRNA, and proteins, all of which were modeled as spheres.
Using Langevin dynamics simulations, coupled with simple
descriptions of intermolecular interactions, they showed that
translational diffusion is approximately 2-fold slower in their
model than in dilute solution. In 2008, the Ellison group
reported a conceptually similar, but substantially expanded
model of the E. coli cytoplasm.804 Their model included a more
diverse set of macromolecules and added concentrations
according to quantitative proteomics studies.805 Although all
molecules were modeled as spherical particles, and simplified
approaches were used to calculate their interactions and
diffusive behaviors, this work provided several additional
insights into the effects of macromolecular crowding on
translational diffusion and a prototypical protein−protein
association reaction. Confirming the results by Bicout and
Field,803 they determined that the average diffusion coefficients
of GFP-sized molecules are decreased 2-fold relative to dilute
solutions. By then, its was known that this decrease was smaller
than what had been observed experimentally (see section
2.3.3.2).164,166,652,806 The authors duly noted that factors
additional to steric repulsion needed to be considered to
quantitatively reproduce macromolecular diffusion in vivo.
The next advance in dynamically modeling the bacterial
cytoplasm was reported by McGuffee and Elcock.807 Their
model was also based on quantitative proteomics data241 but
included the atomically detailed models of 50 types of
macromolecules. Interatomic interactions were treated as a
combination of electrostatic and Lennard-Jones potentials, the
latter to mimic hydrophobic interactions. The authors were
able to adjust the simulated diffusion behavior of GFP until it
corresponded to its measured in vivo properties by altering the
strengths of these hydrophobic contributions. Hydrophobic
intracellular encounters are consistent with “soft” interactions
exerting important modulatory effects on translational diffusion
(see section 2.3.4). Importantly, these soft interactions also
recapitulated the destabilizing effects of the cytoplasm on the
apparent folding thermodynamics of the CRABP protein, as
determined experimentally by the Gierasch group.808,809
The Skolnick group reported the most recent dynamic
simulation of the bacterial cytoplasm.810 In their study,
hydrodynamic contributions to macromolecular translational
diffusion were modeled for the first time. By using the
sophisticated technique of Stokesian dynamics, together with
spherical representations of all macromolecules, they showed
that the inclusion of intermolecular hydrodynamic interactions
explains the ∼10-fold decrease in intracellular GFP mobility
observed in vivo, even in the absence of attractive hydrophobic
interactions. Together, these combined modeling results
suggest that macroscopic in vivo properties such as translational
diffusion are shaped by macromolecular crowding, intermo-
lecular hydrodynamic-, and weak attractive electrostatic-, and
hydrophobic-interactions although their individual contribu-
tions remain to be determined quantitatively.
5.1.2. Outlook for IDP Simulations. At the time of
writing, all of the published cytoplasm simulations treated
intracellular macromolecules as rigid bodies. However, the only
meaningful way to model IDPs is to include internal protein
dynamics and conformational motions. One major challenge to
simulating flexible proteins is that both inter- and intra-
molecular hydrodynamic interactions must be treated appro-
priately to derive meaningful in vivo diffusion behaviors. In
particular, omitting the latter can lead to drastic under-
estimations of cellular diffusion coefficients.811 Owing to the
expense involved in calculating hydrodynamic interactions,
efforts are ongoing to develop alternative tools to treat them in
simulations of large numbers of molecules.812,813 These
methods will likely enable accurate modeling of intracellular
IDP diffusion in the future.
5.2. In-Cell Nuclear Magnetic Resonance (NMR)
Spectroscopy
One particularly appealing method to study the structural
characteristics of disordered proteins inside live cells is high-
resolution in-cell NMR spectroscopy. It exploits the atomic
resolution properties of solution state NMR in the context of
individual isotope-labeled proteins that are selectively enriched
in non isotope-containing eukaryotic or prokaryotic cells.814,815
In bacteria, intracellular enrichment is achieved via the
induction of recombinant protein expression in the presence
of isotope-labeled metabolic precursors. Because most ex-
pression plasmids make use of strong promoters, recombinant
protein production typically outperforms endogenous protein
synthesis. By switching to isotope-labeled growth media during
the induction process, labeled recombinant proteins are
selectively enriched in the cytoplasm or periplasm of E.
coli.816 Similar routines can be employed to produce in-cell
NMR samples in yeast,817 insect,818 and mammalian cells.819,820
For the preparation of in-cell NMR samples in large
eukaryotic cells, such as Xenopus laevis oocytes, isotope-labeled
proteins can be directly delivered by microinjection.149,821,822
Mammalian cells can be targeted with isotope-labeled, cell
penetrating peptide-tagged cargo proteins for active intra-
cellular transport.823,824 Alternatively, cells can be permeabi-
lized with pore-forming bacterial toxins to enable passive
infusion of isotope-labeled proteins.824,825 By directly using
such protein-loaded cells in in-cell NMR experiments, the
isotope-effect is exploited as a selective visualization filter to
detect the protein of interest against the backdrop of all other
non isotope-labeled cellular components. In doing so, the
structural and functional properties of individual disordered
proteins can be analyzed in truly physiological environments
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that display native degrees of intracellular viscosity (see section
2.2), macromolecular crowding (see section 2.3), and biological
activities, such as post-translational protein modifications
(eukaryotic cells) (see section 3.6). Importantly, high-
resolution in-cell NMR spectroscopy does not yield spatial
information about intracellular protein localizations and must
not be confused with magnetic resonance imaging (MRI).
Instead, it provides ensemble descriptions of the combined
effects that the cellular environment exerts on the isotope-
labeled protein under investigation.
To obtain high-quality in-cell NMR signals of ordered and
disordered proteins, the respective targets need to “tumble
freely” in the cytoplasm (which determines their overall NMR
relaxation behavior). In NMR terms, “tumbling” equates to
rotational diffusion, i.e., the rates with which local reorienta-
tions occur and, hence, directly reports on intracellular viscosity
and crowding in the absence of intracellular interactions (see
section 2.3.3). “Tumbling” of ordered proteins is primarily
governed by their molecular size. Small proteins tumble faster
and their NMR signals relax slower, whereas large proteins
tumble slower and their NMR signals relax faster. Slow relaxing
NMR signals give rise to sharp resonance cross peaks, which is
favorable, whereas fast relaxing NMR signals give rise to broad
resonances, which is unfavorable. The “tumbling” behavior of
disordered proteins is different to that of ordered ones. IDPs
exhibit much higher intrinsic flexibilities on the per-residue
scale and do not adopt compact globular shapes. Therefore,
backbone and side-chain motions, rather than protein size
determine their “tumbling” rates. On average, these are ∼2−3
times greater than for ordered proteins of the same size. High
intracellular viscosity slows down rotational diffusion or
“tumbling” and, accordingly, leads to faster relaxation character-
istics and broadening of in-cell NMR signals of ordered and
disordered proteins. Because of their favorable dynamic
properties, disordered proteins often display superior in-cell
NMR qualities. Nevertheless, given the nature of NMR as an
ensemble method, IDP properties are similarly averaged over
all intracellular molecules and it is not possible to dissect
contributions from inhomogeneous intracellular microenviron-
ments.
The validity of these statements critically depends on one
sentence: “In the absence of intracellular interactions”. As we
discuss in section 2.3.4, intracellular binding events are
manifold and ubiquitous. However, they affect folded and
disordered proteins differently. When folded proteins engage in
transient intracellular interactions they often respond as single
entities and display uniform degrees of signal attenua-
tions.177,182,183,826 By contrast, transient interactions of
disordered proteins often elicit line broadening of few residues
only.151,184,185 In many instances, these effects identify weakly
interacting proteins regions. It is important to note, however,
that other scenarios can also lead to broadening of NMR
signals. The intracellular environment often affects dynamic
processes such as chemical reactions or conformational
exchange on the μs to ms time scale, and exchange rates can
experience modulations toward slower, more unfavorable NMR
time-scales (i.e., intermediate exchange). Such effects are
particularly abundant in disordered protein regions exhibiting
features of transient secondary structure or for protein
segments that adopt multiple conformations.
While most in-cell NMR studies investigated ordered
proteins, some were geared toward deciphering the structural
in vivo properties of disordered proteins.149,827−829 Out of
these, some were primarily concerned with understanding post-
translational protein modifications in intact cells,149,827,829 or
cell extracts,830−834 whereas others were more specifically
geared toward structural and dynamic analyses.835 Among the
latter, in-cell NMR studies on α-synuclein feature most
prominently.148,150,151,185,507,508,653,836−838 Two of the likely
reasons for α-synuclein’s rise to fame in the in-cell NMR
community are recent reports that relieved the protein of its
disordered status by postulating a folded helical tetramer as
representing the relevant in vivo structure in cells.839,840 Both
papers stirred considerable interest in the α-synuclein and
larger IDP community and prompted several follow up studies.
Among them, proponents of the tetramer hypothesis argued
that in vivo cross-linking in bacteria, primary neurons and
human erythroleukemia cells confirmed the presence of
tetrameric, although labile α-synuclein species,841 similar to in
vitro experiments with N-terminally acetylated protein in the
presence of membranes.842 Opponents contested the existence
of a tetramer with results from similar experimental
approaches.507,508,843 One argument that lay at the heart of
the original discussion was in reference to a boiling step in the
purification protocol of bacterially expressed, recombinant α-
synuclein.844 In their papers, the groups of Selkoe and Petsko
argue that the use of denaturing agents or boiling of bacterial
cell lysates during initial purification steps of the recombinant
protein destroys the alleged tetramer conformation and results
in the accumulation of monomeric species.839,840 While
reasonable in its own right, although oblivious to the original
paper by Weinreb et al., both groups stated that this constitutes
the main reason for why the α-synuclein tretramer evaded
detection for so many years. However, these statements also
ignore earlier in-cell NMR reports on α-synuclein showing that
the protein is monomeric and disordered in intact E. coli
cells.148,150,653,836 Several follow-up in-cell NMR studies
reinvestigated the structural properties of α-synuclein in intact
bacteria151,185,507,837,838 and concluded-, in agreement with
earlier reports-, that α-synuclein is intrinsically disordered and
monomeric when overexpressed in bacteria.
Another in-cell NMR analysis investigated the disordered
bacterial protein FlgM.828 FlgM is a 97-residue polypeptide
from Salmonella typhimurium, which regulates flagellar synthesis
by binding to the transcription factor Δ28.845 Free FlgM is
mostly unstructured in dilute solution, but its C-terminal half
can form a transient α-helix.846 Upon binding to Δ28 in vitro
this portion of FlgM undergoes a disorder-to-order transition,
which is manifested by the disappearance of a set of C-terminal
resonance signals.847 In their study, Dedmon et al. exploited
this behavior to investigate the conformational properties of
FlgM in different in vitro and in vivo environments. In E. coli,
the same NMR resonances that disappear upon Δ28 binding are
not detected. The authors reasoned that this indicates a similar
structural rearrangement in bacteria. Binding to an endogenous
homologue of Δ28 cannot account the observed effect, because
neither Δ28, nor homologous proteins are present in E. coli.
Further NMR analyses in glucose- (450g/L), BSA- (400 g/L),
or ovalbumin-crowded (450 g/L) in vitro solutions revealed
that the observed transition depends on the absolute amount of
the respective crowding agent. This suggested that the
intracellular environment modulates the structural in vivo
properties of this disorderd protein, although transient weak
interactions can similarly explain the disappearance of FlgM
NMR signals.
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With regard to eukaryotic in-cell IDP studies, Bodart et al.
investigated the structural in vivo properties of tau in Xenopus
laevis oocytes. Being one of the largest IDPs, with disordered
features over its entire length (441 residues, ∼45 kDa), in-cell
NMR experiments represented a veritable challenge. Tau
exhibits only weak propensities for transient secondary
structure and binds to microtubules, i.e., one of the largest
macromolecular structures in cells, present at high natural
abundance (∼10 μM). At intracellular concentrations of ∼5
μM, in-cell NMR spectra revealed that the predominantly
unfolded conformation of tau was similarly populated in
oocytes. Due to intracellular viscosity and sample inhomoge-
neity, line broadening and increased spectral overlap made it
difficult to assess whether some portions of the protein adopted
structural features not populated in vitro. No substantial
conformational rearrangements or overall protein folding were
observed. Additional characteristics of the in-cell NMR spectra
indicated that tau existed in a microtubule-bound conforma-
tion, based on striking similarities with in vitro NMR spectra of
tubulin-bound tau.848 Given the high endogenous abundance of
microtubules in Xenopus oocytes, such scenarios are perfectly
plausible. In-cell NMR spectra of tau also revealed several NMR
signals indicative of phosphorylated amino acids. By comparing
these signals with in vitro phosphorylated tau,849 the authors
confirmed that in-cell phosphorylation by endogenous kinases
occurred.
Together, these in-cell NMR results underscore several
important points. Foremost, they indicate the overall feasibility
of high-resolution IDP studies in prokaryotic and eukaryotic
cells. They further prove that in vivo conformations of
disordered proteins can be assessed with simple NMR
experiments and that changes in protein structures can be
readily detected. Given the abundance of cellular post-
translational modifications, and their various effects on the
structures and functions of disordered proteins (see section
3.6), paired with the unique ability of NMR spectroscopy to
detect PTMs and their structural consequences,850 in-cell NMR
methods are well-suited to report on the in vivo characteristics
of IDPs in a fully integrated manner.
5.3. Fluorescence Microscopy and Spectroscopy
Fluorescence microscopy methods provide relatively simple
ways to monitor localization, oligomerization, and diffusion of
IDPs in cells and on cell surfaces thereby offering a window
into IDP function and dysfunction in cells. For the simplest
studies, the diffuse, dim fluorescence of fast moving monomers
and oligomers can easily be distinguished from the punctate,
bright fluorescence intensity of larger, less mobile aggregates.
More complicated imaging and data analysis modalities
primarily aimed at monitoring molecular motion include
fluorescence recovery after photobleaching (FRAP), fluores-
cence loss in photobleaching (FLIP), fluorescence correlation
and image correlation techniques, and single particle tracking.
With the exception of FLIP,851 in-cell implementations of these
techniques were recently reviewed.852 The basis of these and
other fluorescence microscopy techniques that have been used
to monitor mobility, function, conformations, oligomeric
state(s), and/or localization of IDPs in cells are discussed
briefly below.
FRAP and FLIP exploit photobleaching to monitor
molecular diffusion. In FRAP, an intense laser pulse is used
to bleach a small region of the cell and illumination is then
returned to lower levels.852,853 If fluorescently labeled protein
can diffuse into the bleached region within the experimental
time scale fluorescence intensity in this region recovers, but
little or no recovery is observed when the fluorescently labeled
protein is immobile. FLIP uses a similar principle, but in this
case the photobleaching beam is constantly on.851 In FLIP
experiments, mobile fluorescent species move into the
photobleaching region and are photobleached, leading to a
loss of fluorescence intensity in the entire cell. By contrast, cells
containing large proportions of immobile fluorescent species
retain their fluorescence outside the volume illuminated by the
photobleaching beam. Both FRAP and FLIP provide
quantitative data on translational diffusion and whether IDP
populations contain both mobile and immobile species.
Diffusion in cells can also be measured by fluorescence
correlation spectroscopy (FCS) and related image correlation
spectroscopy methods, recently reviewed by Digman and
Gratton854 and by Fitzpatrick and Lillemeier.855 These take
advantage of fluorescence intensity fluctuations, the time scales
of which depend on how fast the fluorescent molecules diffuse
in and out of the observation volume, as a function of molecular
mass and shape. Correlating the fluorescence signal over time
and/or space thus provides data on molecular mobility,
oligomeric distributions, and binding of small fluorescent
moieties to larger molecular assemblies or vesicles.854,855
Correlation methods also provide information on the cellular
environment, including the local viscosity, barriers to diffusion
and directed motion
If the probability of detecting multiple oligomers in the same
region of an image (referred to as a region of interest) is low,
photobleaching measurements can be employed to count the
number of fluorescent subunits (i.e., monomers) in oligomers
(for a recent review see ref 856). This method is particularly
powerful in cases where oligomers move relatively slow, i.e.,
when proteins bind to DNA857 or to cell membranes.858−860 In
these experiments, the number of photobleaching steps (steps
in fluorescence intensity before the fluorescence baseline is
reached) report on the number of monomers in a single region
of interest and thereby provide information on the
stoichiometry of oligomers. Data from multiple regions of
interest reveal the distribution of oligomeric species.
For molecules that diffuse quickly or as an adjunct to
photobleaching experiments, fluorescence brightness analysis,
such as fluorescence distribution analysis and photon counting
histograms are used to determine oligomeric distribu-
tions.861,862 These techniques directly take advantage of the
increase in fluorescence intensity that occurs when fluorescently
labeled molecules oligomerize. Protein oligomerization can also
be monitored using protein-fragment complementation meth-
ods where interacting proteins of interest are tagged with
complementary pieces of a fluorescent protein, such as GFP or
a luminescent protein, such as luciferase.863 Dimerization of the
tagged proteins reconstitutes the full-length, folded fluorescent
or luminescent entity and leads to an optical readout. See below
for a more detailed discussion on labeling IDPs.
Distance sensitive Förster resonance energy transfer (FRET)
spectroscopy provides a way to monitor protein−protein
interactions or conformational changes, in cells. FRET utilizes
the steep (1/r6) distance dependence of nonradiative dipole−
dipole energy transfer from a donor molecule to an acceptor
and is most sensitive for donor−acceptor distances between
∼0.5 and ∼1.5 times the Förster distance (Ro),
864 where Ro,
often ∼5 nm, is the donor−acceptor distance at which there is a
50% probability of energy transfer. The most common
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applications of FRET involve two labels with spectrally distinct
fluorescence emissions, i.e., a donor that emits in the green and
an acceptor that emits in the red. In vitro174 and in cells,134
FRET can be used to monitor conformational changes and
conformational distributions when an IDP is labeled with both
a donor and acceptor. FRET can also be used to monitor
protein−protein interactions, oligomer formation and con-
formational changes within oligomers by labeling one pool of
IDPs with a donor and another pool with an acceptor,865 or by
energy transfer between labeled IDPs and dyes, such as
thioflavin T, that bind to specific oligomeric species.215
Alternatively, energy migration Förster resonance energy
transfer (emFRET, also called homoFRET) uses two identical
fluorophores.866 In emFRET, energy transfer from the donor to
the acceptor changes the polarization of the emitted
fluorescence and reduces the rotational correlation time.
Fluorescence anisotropy methods can thus report on
oligomerization and, via emFRET, conformational changes of
IDPs.867
Recent developments in super-resolution fluorescence
imaging methods provide even more information on intra-
cellular protein localization and motion, as highlighted in a
number of recent reviews.868−870 In these techniques, single
fluorophores are localized with a spatial resolution of tens of
nm. Super-resolution methods have been used to probe
oligomerization and localization of at least three different
IDPs in cells providing valuable data on the formation and
morphology of oligomers, inclusion bodies and fibrils.782,787,871
Advances in illumination procedures, such as light-sheet
illumination that allows 3-D imaging of cells and tissues while
reducing photodamage,872,873 will likely make super-resolution
techniques even more powerful.
While steady-state methods provide valuable insights into
intracellular behaviors of IDPs, the ability to quickly manipulate
the cellular environment and monitor relaxation kinetics
provides important additional information on protein stability
and the conformations accessible to IDPs and folded proteins.
Gruebele and co-workers have recently adapted in-cell
temperature jump methods (up to 4 °C in milliseconds),
which they call Fast Relaxation Imaging (FReI).874 For FReI,
the protein of interest is tagged with a donor fluorescent
protein, usually AcGFP, at the N-terminus and an acceptor
fluorescent protein, usually mCherry, at the C-terminus. Two-
color fluorescence is monitored with millisecond resolution,
and FRET between the donor and acceptor reports on protein
conformations, protein stability and protein folding/unfolding
kinetics. In-cell FReI experiments on the globular protein
phosphoglycerate kinase (PGK) have revealed that GFP-
mCherry tagged PGK is more compact and more stable in
vivo relative to dilute solutions.134,874 These studies also
showed that PGK exhibited substantial differences in protein
stability and folding within individual cells and in different
cellular compartments.134 PGK was more stable, folding was
faster and the PGK population was more homogeneous in the
nucleus of U2OS bone cancer cells than in the endoplasmic
reticulum or the cytoplasm. However, PGK folding displayed a
two-state, rather than multistate, character in the ER. These
results, attributed to differences in viscosity and macro-
molecular crowding effects in different microenvironments
even within the same subcellular compartment, demonstrate
the richness of these cellular data.
FReI has since been applied to α-synuclein875 and has the
potential to reveal both the stability of the proteins in cells and
the dynamics of conformational changes in response to
temperature jumps. FReI may thus provide a measure of the
conformational space accessible to IDPs in cells, the dynamics
of in-cell conformational changes and how these properties vary
between organelles in the same cell, and from cell to cell. Such
new and improved technologies along with continuing
advancements in fluorescence microscopy methods, including
both single molecule fluorescence microscopy and ensemble
methods such as fluorescence lifetime imaging,876 are likely to
increase the utility of fluorescence microscopy for studying
IDPs in cells.
5.3.1. Fluorescence Labeling. In-cell fluorescence mi-
croscopy and spectroscopy requires labeling of IDPs with
fluorescent molecules. This is most easily accomplished
genetically by fusing IDPs to a fluorescent protein (FP). FPs
are quite large (∼27 kDa) compared to many IDPs and FP
fusions can lead to experimental artifacts. Conjugation to FPs
can result in mislocalization,877 and many FPs can dimerize or
form higher order oligomers. Monomeric FP variants should be
used for all experiments. For green fluorescent protein from the
Aequorea victoria jellyfish and its variants, monomers can be
obtained by mutating of Ala206 to Lys.878,879 But, there is no
established method for ensuring that FPs derived from other
organisms are monomeric, although an in-cell membrane
protein based assay was recently suggested880 and FPs reported
to be monomeric have, in some cases, been found to promote
dimerization.881 Finally, FPs may affect the conformational
behaviors of IDPs via weak intra- or intermolecular interactions.
For a detailed description of how to choose an appropriate FP,
see ref 878.
In addition to labeling with FPs, IDPs may be tagged with
small organic fluorophores, such as the biarsenical dyes FlAsH
and ReAsH that bind to tetra-Cys motifs not found in naturally
occurring proteins.882,883 FlAsH and ReAsH are membrane
permeable and allow facile in-cell labeling. They also show
significant increases in fluorescence quantum yield when
conjugated to specific sequence/structural motifs in proteins,
enabling the detection of tagged proteins in the presence of
unbound fluorophores.882 IDPs labeled with other fluoro-
phores, such as rhodamines may be injected into cells or
applied to cell surfaces to study IDP-membrane interactions
and/or internalization. Even small organic fluorophores can be
perturbing and care must be taken when implementing any of
these labeling techniques. When possible, in vitro measure-
ments of structures, i.e., by NMR,785 aggregation propensities,
aggregate structures,867,884 as well as in-cell measurements of
IDP behaviors and localizations should be performed with
native and fluorescently labeled IDPs.
Pioneering studies by Ignatova and Gierasch demonstrated
the utility of engineered tetra-Cys motifs and biarsenical dyes to
study protein synthesis, stability and aggregation in E. coli cells
(reviewed in ref 809). In these experiments, the authors
introduced a tetra-Cys motif into a loop region of the folded
cellular retinoic acid binding protein (CRABP) and expressed it
in E. coli. In the absence of tetra-Cys CRABP, FlAsH has a low
quantum yield882 and the cells showed little fluorescence signal.
FlAsH binding to tetra-Cys CRABP increased the FlAsH
quantum yield and resulted in diffuse cellular fluorescence, as
expected for a fast diffusing, monomeric species. By contrast,
production of the aggregation prone Pro39Ala (P39A) tetra-
Cys CRABP mutant resulted in bright fluorescent puncta due
to inclusion body formation, which increased the total
fluorescence intensity per cell. Similarly, denaturing tetra-Cys
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CRABP by incubating E. coli cells with increasing concen-
trations of urea led to aggregation and formation of
fluorescence puncta at the cell poles. Inclusion body formation
could be followed over time or as a function of urea
concentration and revealed that tetra-Cys CRABP was
destabilized in E. coli relative to in vitro experiments in dilute
solutions. Further experiments on P39A tetra-Cys CRABP
showed that the addition of the osmolyte proline to the cellular
medium cleared inclusion bodies and led to the loss of
fluorescence puncta and increases in diffuse fluorescence. Thus,
tetra-Cys motifs and biarsenical probes provide a powerful tool
for in-cell measurements of protein stability, protein
aggregation and the screening of small molecules that prevent
or break up aggregates.
Biarsenic dyes bind to the linear sequence Cys-Cys-X-Y-Cys-
Cys where X and Y are usually Gly-Pro to yield the preferred
beta turn motif.885 This sequence and structural specificity
allowed the design of split-tetra-Cys motifs on adjacent beta
strands that bind FlAsH only when the sheets are properly
oriented, reporting on structure formation.886 Similarly, the
tetra-Cys motif may be split between two proteins, allowing
FlAsH binding to report on protein−protein interactions.887
Lee and co-workers used the split tetra-Cys motif to monitor
Aβ (1−40) aggregation in vitro by appending Cys-Cys to the
N-terminus of Aβ (1−40).215 FlAsH binding was reversible and
the aggregation kinetics were not significantly altered by the N-
terminal tetra-Cys motif or by FlAsH binding. Two processes
with two different time scales were evident from increases in
FlAsH fluorescence intensity: (i) an almost immediate fast
increase that plateaued after 3 h and (ii) a second increase after
∼12 h that coincided with the increase in ThT fluorescence
intensity, which reports on fibril formation. ThT binding also
resulted in FRET from FlAsH to ThT. The early and swift
increase in fluorescence intensity indicated that oligomers
formed quickly, and the later, coincident increase in ThT and
FlAsH fluorescence intensity as well as FRET suggested that
oligomers were on-pathway for fibril formation, and that fibrils
formed more slowly than smaller oligomers. Soluble oligomers
are quite difficult to detect and these results suggested that split
tetra-Cys motifs are suitable for monitoring IDP oligomer
formation in cells.
5.3.2. Fluorescence Studies of IDP Aggregation.
5.3.2.1. polyQ-Repeat Proteins. By appending polyglutamine
(polyQ) repeats from the Huntingtin exon 1 to the C-terminus
of tetra-Cys CRABP, Ignatova et al. investigated IDP aggregate
formation in E. coli.809,888 As expected, in-cell aggregation of
tetra-Cys CRABP-Huntingtin constructs depended on the
length of the polyQ tracts. Tetra-Cys CRABP-Huntingtin-40
(where 40 is the length of the polyQ repeat) displayed both
soluble and aggregated populations, while tetra-Cys CRABP
constructs with longer polyQ tracts, Huntingtin-53 and
Huntingtin-64, formed detergent insoluble aggregates over
time. Long polyQ tracts also resulted in long, filamentous
bacteria indicating that the detergent insoluble fibrils interfered
with E. coli cell division.
The use of a flanking sequence can influence IDP
aggregation. Both in vitro and in E. coli the aggregation
prone P39A CRABP variant seeds early oligomer formation
while polyQ tracts with lengths above the pathological
threshold seeded the formation of later, detergent resistant
aggregates.888,889 Thus, as observed for polyQs appended to
other folded proteins,890−893 the context of the polyQ sequence
is key. Aggregation of polyQ repeats tagged with an FP, (often
cerulean fluorescent protein (CFP), GFP, or yellow fluorescent
protein (YFP) at the C-terminal end) or complementary GFP
fragments has been studied in yeast cells, in mammalian cells
and in the transparent nematode C. elegans (for reviews and
methods see refs 852, 894, and 895). As expected, polyQ
monomers and small oligomers in cells show dim, diffuse
fluorescence throughout the cytoplasm while larger, less mobile
inclusion bodies result in intense, punctate fluorescence.896 The
translational diffusion of fluorescently labeled polyQ constructs
directly report on how long it takes for inclusion bodies to
form. In C. elegans, FRAP experiments revealed that short
polyQ tracts containing 35, or fewer repeats were mobile in 3 to
4 day old nematodes, tracts with 40 repeats were polydisperse
with mobile and immobile fractions, and constructs with 82
repeats were essentially immobile.897 Inclusion body formation
was age dependent and polyQ constructs with 33 repeats,
which were mobile in young nematodes displayed punctate
fluorescence in 5 day, or older nematodes. Inclusion body
formation by polyQ-FP constructs, in both mammalian cells
and C. elegans, has proven to be an extremely effective sensor
for monitoring changes in protein homeostasis due to
aging,897,898 osmotic899 and other stresses, and for testing
whether and how protein homeostasis can be re-
stored.895,898,900,901 The high fluorescence intensity from
inclusion bodies obscures lower intensity fluorescence signals
from smaller, more mobile aggregates. By combining specific
photobleaching of inclusion bodies with super-resolution
microscopy, Frydman and co-workers were able to visualize
smaller oligomers formed by Huntingtin polyQ-eYFP repeats in
mammalian cells.871 Such super-resolution imaging is likely to
provide more detailed data on the polyQ oligomeric
distribution in cells, how larger oligomers form and how
changes in the cellular environment affect the oligomeric
distribution.
Specific fluorescent sensors for oligomerization can be
constructed by combining labeling modalities. Onodera and
co-workers have built an in-cell FRET sensor for oligomeriza-
tion by expressing mixtures of polyQ constructs labeled with
different FPs, i.e., polyQ-CFP and polyQ-YFP, where energy
transfer only occurred if the polyQ-FP constructs adopted
particular orientations in oligomers and large aggregates.865
FRET in mobile oligomers and large aggregates were only
observed when the FPs were on the same termini of the polyQ
construct (polyQ-CFP plus polyQ-YFP, or CFP-polyQ plus
YFP-polyQ) and not on different termini (i.e., polyQ-CFP plus
YFP-polyQ).865 Alternatively, Hatters and colleagues combined
tetra-Cys tags and FPs in the same monomers.892,902 In these
experiments, monomers displayed a high ratio of biarsenical
dye fluorescence intensity to fluorescent protein intensity.
Occlusion of the tetra-Cys binding sites due to inclusion body
formation for example, reduced this ratio. When the polyQ
repeat length was above the pathogenic threshold, the ratio was
also reduced in the mobile population, but only for some
locations of the tetra-Cys tag. While attention must be paid to
how the location and presence of the fluorophores affects
aggregation, the sensitivity of both of these methods to the
location of the fluorescent tag should be helpful in modeling
the molecular structure of in-cell oligomers. Already, the
similarity of FRET signals for soluble oligomers and inclusion
bodies provide limits on the conformational distributions of
these species.
Identification of cytotoxic species is key to understanding
how polyQ repeats and other aggregation prone species kill
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cells. Fluorescently labeled polyQ repeats can be monitored
over time as cells or animals age and die providing data on
cytotoxic species.894,895,903,904 Experiments in cells and in C.
elegans showed that individual cells that accumulate inclusion
bodies often live longer than cells with diffuse, mobile
oligomers865,900,905,906 supporting models in which inclusion
body formation is a cytoprotective mechanism.895,907−909 In
addition, in C. elegans, some gene knockdowns that reduced
inclusion body formation of a polyQ with 35 repeats (Q35)
resulted in increased toxicity, again arguing that soluble
oligomers can be cytotoxic.900 Identification of toxic oligomeric
species is, however, more difficult and FCS experiments in
which mobile Q35 was monitored in C. elegans cell lysates, or
after being purified from C. elegans revealed a heterogeneous
oligomeric population where the population shifted to slower
moving species as the animals aged.910 Interestingly there was
no correlation between changes in the oligomer distributions
and gene knockdowns that enhanced cytotoxicity. While in-cell
fluorescent techniques provide clues as to which polyQ species
or sets of species may be toxic, truly deciphering the
conformational distributions in cells will likely require creative
applications of and innovations in fluorescence techniques
combined with other techniques including NMR and ion-
mobility mass spectrometry.
5.3.2.2. IDP Aggregation and Neurodegeneration. Re-
search on other IDP containing proteins, or peptides associated
with neurodegeneration have focused on the localization and
function of native conformers, identifying and localizing
cytotoxic species as well as how interactions with membranes
alter IDP conformation and oligomerization. The techniques
used are similar to those described above for polyQ repeats
with an added emphasis on labeling with small fluorophores,
particularly for the short Aβ peptides, and a number of studies
using luciferase,911 or FP complementation912 to study
oligomerization and aggregation. These experiments, discussed
below, have mainly focused on the Parkinson’s disease
associated protein α-synuclein and the Aβ peptides associated
with Alzheimer’s disease. In cell culture, animal models and
humans, conformational changes and oligomerization of
proteins associated with neurodegenerative diseases appears
to propagate from cell to cell (for recent reviews see refs 913
and 914). Fluorescently labeled IDPs have been used to
monitor cell−cell spread of oligomers and oligomerization in
real time, to determine the conformational distributions of the
species involved and to test interventions.784,915,916
To elucidate the cellular localization and function of α-
synuclein, a number of groups have constructed α-synuclein-
eGFP fusions with the enhanced GFP at the C-terminus.917−920
Imaging of neurons containing this construct has shown that α-
synuclein is enriched at the synapse where it dynamically binds
to synaptic vesicles.574,918,920 More recently, α-synuclein has
been localized at the presynaptic terminals, in intraluminar
vesicles of multivesicular bodies and in lysosomes in neuronal
cell bodies by combining fluorescence imaging of α-synuclein-
eGFP in cells with 3D electron tomography of cells containing
α-synuclein-miniSOG constructs, where the miniSOG provides
contrast.917 These studies suggest that α-synuclein remains
bound to synaptic vesicles until they fuse with plasma
membranes,918 and that overexpression of the protein may
perturb intracellular membrane architecture.917
In C. elegans expressing human α-synuclein-YFP fusions,
inclusion body formation increased as a function of age and this
system has been used to test methods for ameliorating
cytotoxicity.921 Like the polyQ model systems where molecular
chaperones helped protect against cytotoxicity, overexpression
of the molecular chaperone Hsp70 reduced cytotoxicity in C.
elegans.921 In neuronal cultures, overexpression of α-synuclein-
FP constructs resulted in secretion into the extracellular
medium and, as shown using α-synuclein fused to fragments
of luciferase, the secreted protein was often oligomeric915 and
associated with Hsp70 altering its size distribution. Nonethe-
less, RNA interference screens in C. elegans designed to identify
proteins that reduced α-synuclein pathology did not pull up
Hsp70, or other molecular chaperones, but rather identified a
number of proteins involved in vesicular trafficking and lipid
transport as key to reducing toxicity.921 These results are
consistent with α-synuclein’s role in synaptic vesicle traffick-
ing,918 lysosomal abnormalities observed in the nervous system
of transgenic mice expressing human α-synuclein-eGFP,922 α-
synuclein associated fragmentation of mitochondrial mem-
branes in neuronal cells923 and membrane abnormalities in
yeast.924 α-synuclein membrane interactions were reviewed by
Lindquist and colleagues.924
While α-synuclein-FP fusions provided important informa-
tion on cellular localization and function, FPs (∼27 kDa) are
much larger than the protein and there is some evidence that α-
synuclein-FP species can be mislocalized in cells.920 Therefore,
a number of groups have pursued alternative labeling strategies
using smaller organic fluorophores. The biarsenical dye, FlAsH,
was employed to monitor the aggregation of α-synuclein
modified with a C-terminal tetra-Cys tag in mammalian
cells.785,788 Super-resolution fluorescence microscopy was
used to monitor α-synuclein aggregates by labeling the protein
with a rhodmaine spiroamide derivative, an organic fluoro-
phore, in vitro and then microinjecting the protein into cells.787
Further super-resolution fluorescence microscopy experiments
either using microinjected, or photoactivatable-, photoswitch-
able FP-tagged protein may help elucidate how α-synuclein is
trafficked in cells providing more data on the physiological
function and dysfunction of this important IDP.
Intrinsically disordered Aβ peptides derived from amyloid
precursor protein are the main component of extracellular
plaques in the brains of Alzheimer patients (for a recent review
see ref 925). The N-termini of Aβ peptides are easily labeled
with small, organic fluorophores including fluorescein,926−930
rhodamine928,930−932 and HiLyte930,933,934 based dyes, and
these N-terminal labels do not significantly perturb the
peptides.931,933,935,936 Because these peptides are extracellular,
incubation of cells with fluorescently labeled peptides can
provide valuable, physiologically relevant data on how Aβ
peptides interact with the extracellular leaflet of plasma
membranes.
Renner et al. showed that preformed oligomers of
fluorescently labeled Aβ peptides localize to synapses and
cluster glutamate receptors when incubated with live hippo-
campal neurons.930 Similar synaptic localization of oligomers
was observed by immunofluorescence for hippocampal neurons
incubated with unlabeled oligomers937 and for Aβ oligomers
found near plaques in a mouse model of Alzheimer disease.938
Fluorescently labeled oligomers, but not fibrils can also be
internalized by cells.931 Cellular incubation with low concen-
trations (250−500 nM) of fluorescently labeled Aβ peptides
results in internalization and formation of intracellular
aggregates.782,928 Super-resolution imaging of such in-cell
aggregates revealed fibril formation by internalized, fluores-
cence-labeled Aβ (see section 4.7).782
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Physiological Aβ peptide concentrations range from sub-nM
to low nM.939−941 At these concentrations in aqueous solution,
fluorescent Aβ (1−40) and Aβ (1−42) peptides are mainly
monomeric, with small populations of dimers and
trimers.860,934,942 Single molecule fluorescence photobleach-
ing,860,943 or multicolor934 experiments, as well as fluorescence
correlation methods929,932 provide a way to monitor Aβ
peptides-cell interactions at these physiologically relevant
concentrations. In photobleaching experiments, both the
fluorescence intensity and number of photobleaching steps
were used to determine the number of labeled monomers in a
single fluorescent spot.860,943 While in multicolor experiments,
Aβ peptides labeled with two different color dyes were mixed at
equimolar concentrations before incubation with cells and both
fluorescence intensities and the colocalization of multiple colors
were used to identify and characterize oligomers. The exact
characteristics of cell bound species depended on which cell-
types and Aβ peptides, i.e., Aβ (1−40) or Aβ (1−42)934 were
used, or on the combination of peptides that was applied to
cells.943 Nonetheless, in all of these experiments, as well as in
experiments using higher peptide concentrations,926,927 the
distribution of oligomeric states shifted from mainly mono-
meric in solution to dimers and higher-order oligomers on the
surface of cells and a large portion of these oligomers showed
restricted motions on cell membranes.860,929,934,943 Thus, these
experiments demonstrate the utility of single molecule
fluorescence and fluorescence correlation methods for
determining the oligomeric states of membrane bound IDPs
and their motions on cells. Taken together with the results
from super-resolution fluorescence microscopy, these data
suggest that by combining fluorescence microscopy modalities
it may be possible to monitor Aβ on-cell aggregation on the
single molecule level in real time.
Fluorescence labeling of IDPs and fluorescence microscopy
in cells continues to provide facile methods for monitoring IDP
conformations, interactions with other biomolecules including
membranes, oligomerization, motion and localization in real
time. With the continuing advances in fluorescence labeling
modalities and the recent revolution in super-resolution
methods, fluorescence microscopy in cells and whole organisms
will likely continue to be important for understanding IDP
localization, function and dysfunction.
5.4. Fourier Transform Infrared (FTIR) Microspectroscopy
Fourier transform infrared (FTIR) spectroscopy exploits bond
vibrations in molecules to yield spectra with unique absorption
patterns. Besides providing specific molecular fingerprints of
investigated molecules, these patterns also contain structural
information.944 Proteins, nucleic acids, lipids and carbohydrates
have unique chemical features giving rise to distinct FTIR
spectra. Protein FTIR spectra for example, contain different
regions characteristic for the different modes of vibration. The
amide I band in particular (∼1655 cm−1) is sensitive to protein
secondary structure, because its spectral features are affected by
the different hydrogen-bond patterns in α-helices, β-sheets, and
disordered structures.944−947 FTIR additionally provides unique
information about protein aggregates based on characteristic IR
signatures of intermolecular β-sheets with absorption peaks at
1630−1620 cm−1.948,949 For these reasons, FTIR is extensively
used to study the conformational properties of aggregated
disordered proteins.950,951
Early FTIR studies were carried out on isolated, purified
proteins, or aggregates. However, the recent combination of
FTIR spectroscopy with light microscopy, i.e., FTIR micro-
spectroscopy, made it possible to also study aggregated IDPs in
intact cells and tissues, which is particularly attractive because is
does not rely on exogenous protein labeling, or the use of
contrast agents.777 Despite these advantages, FTIR micro-
spectroscopy also bears several drawbacks, some of which are
directly linked to the physical nature of the technique. First, IR
wavelengths are long and, hence, achievable spatial resolution is
restricted to the specific diffraction limit (∼2−10 μm for the
mid-IR region, ∼4000−500 cm−1). In practice, however, spatial
resolution is primarily limited by the low intensity of IR rays. In
turn, large microscope apertures are needed, which further
decreases spatial resolution. For these reasons, modern FTIR
microspectrometers are installed at synchrotrons, providing a
100−1000 times brighter source of IR illumination.952
Synchrotron IR beams also offer the possibility to implement
fast data collection and readout schemes, which enable time-
resolved recordings of biological processes.952 Another impedi-
ment to FTIR microspectroscopy is water. Present at high
endogenous concentrations in most biological samples, the
water absorption band in the mid-IR region pollutes IR spectra
of cells and tissues. Different strategies to reduce these water
effects have been devised and are excellently reviewed in.944,952
IDP-based FTIR microspectroscopy applications in cells and
tissues have focused almost entirely on intracellular aggregation
of Aβ, Huntingtin and the Prion protein.776,953−955 In these
approaches, IR spectra of different sample areas are spatially
matched with immuno-electron, or -fluorescence microscopy.
Thereby, intracellular regions of high secondary structure
content, characteristic of β-rich amyloid aggregates for example,
are correlated with areas of bright antibody-, or thioflavin S-
fluorescence. In one such study, Andre et al. investigated the
structures of Huntingtin fibrils in brain slices of control
individuals and Huntington’s disease patients.776 By measuring
IR signatures of different protein deposits that had been
spatially localized by immuno-fluorescence microscopy, the
authors established that the structural features of intracellular
Huntingtin inclusions are nonuniform and display localized
degrees of polymorphisms and β-sheet contents.
Similarly, FTIR microspectroscopy of amyloid fibrils of
Alzheimer’s disease patients displays varying degrees of β-sheet
content in different brain regions.953 However, IR detection of
the amide I band at ∼1632 cm−1 conflicted with earlier reports
of in vitro aggregated Aβ and IR absorption bands at 1620−
1628 cm−1.956,957 The authors attributed this discrepancy to the
presence of nonfibrillar amyloid-associated proteins, such as
apolipoprotein E and ubiquitin, which are known components
of native neuritic plaques.953 When Miller et al. investigated
thioflavin S-positive inclusions in brain slices of AD patients
they detected β-aggregate characteristic absorption bands at
∼1625 cm−1.958 However, they also noted that the β-sheet
contents of these species are lower than those of in vitro
aggregated Aβ fibrils. In a next step, they used synchroton X-ray
fluorescence to probe for local accumulations of Cu and Zn and
found that regions of high metal content correspond to areas
with localized amyloid deposits. These results provided first-
time experimental evidence for a spatial correlation between Aβ
plaques and enhanced intracellular concentrations of Cu and
Zn, in support of the postulated link between defects in metal
homeostasis and the onset of AD.724
Diomede et al. used FTIR microspectroscopy to monitor Aβ
aggregation in the presence of tetracyclines in C. elegans.954
Tetracyclines inhibit Aβ amyloid formation and are considered
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possible AD drugs.959 Induction of Aβ overexpression resulted
in a time dependent increase of the 1623 cm−1 IR absorption
signal. When Diomede et al. cultured worms in tetracycline-
containing media they did not detect aggregate-indicative IR
absorption signals and consistently found fewer intracellular
amyloid aggregates.
Kneipp et al. used FTIR microspectroscopy to study cellular
inclusions of the Prion protein in scrapie-infected hamster
neurons.960 When the authors compared IR spectra of brain
slices from control and infected animals, they noted prominent
absorption bands in diseased animals only. Further PrP
immuno-stainings revealed a strong colocalization with brain
areas of high β-sheet contents. Wang et al. independently
confirmed these results in a larger animal cohort and in
different neuronal cells.961 They also probed for the
accumulation of metals using X-ray fluorescence spectroscopy
and found elevated levels of intracellular Fe in PrP-positive
cells. When they prepared brain slices of infected hamsters at
different postinfection time points, they discovered that local
increases in β-sheet contents correlate with the abundance of
insoluble PrP deposits. However, regions that were void of PrP
deposits also featured high β-contents, which suggested that
either β-aggregate formation precedes precipitation, or that
other non-PrP aggregates are additionally present. Together,
these FTIR microspectroscopy studies conveyed several
important points. First, they indicate that intracellular IDP
aggregates are structurally inhomogeneous, which contrasts
with results obtained in vitro. Second, they show that IDP
aggregation scavenges bystanders, either actively, or passively,
including other intracellular proteins and/or metals. Third, they
indicate that aggregate accumulation correlates with disease
progression.
6. SUMMARY AND OUTLOOK
With this work, we attempted to provide a comprehensive
overview of factors influencing the structural and functional
properties of intrinsically disordered proteins in different
cellular environments. We discussed the elementary composi-
tion of prokaryotic and eukaryotic cells in terms of ions,
metabolites and biological macromolecules such as proteins,
RNA, DNA, lipids, and glycans and delineated how they
contribute to general physical parameters such as viscosity and
macromolecular crowding. We outlined how these properties
affect micro- and macroscopic intracellular behaviors such as
diffusion and association. We described biological activities
encountered in cells, such as post-translational protein
modifications, and how they influence in vivo properties of
intrinsically disordered proteins, especially also with regard to
protein association and aggregation, and vice versa. Finally, we
presented methods to study IDPs in silico and in intact cells.
Some general conclusions can be drawn from these
discussions. Ordered and disordered proteins experience the
intracellular milieu in a similar manner and they are subject to
the same types of physical and biological forces acting upon
them. Given their unique structural features, disordered
proteins may respond to these factors differently, especially in
terms of compaction and aggregation. With regard to their
cellular stability and lifetimes, ordered and disordered proteins
behave similarly. IDPs are not preferred targets for proteolytic
degradation or for chaperone interactions, and given their
roughly equal abundance in proteomes of higher organisms,
most of their cellular properties are indistinguishable from
ordered proteins. IDPs are more prone to post-translational
modifications and therefore likely to exist as chemically
heterogeneous intracellular populations. They may interact
with multiple physiological ligands and display ordered
properties in their bound states.
By using complexity-reduced experimental setups such as
artificially crowded in vitro solutions, or cell extracts, we can
learn a great deal about the in vivo properties of disordered
proteins. However, we must acknowledge that these environ-
ments only partially reflect the physical and biological
contributions experienced in cells. Especially cell extracts fall
short in recapitulating the effects exerted by cellular compart-
ments and localized biological activities. Therefore, we must
strive to develop and employ tools to analyze disordered
proteins in intact physiological settings. While this presents a
veritable challenge for the future, it also offers exciting new
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